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CHAPTER 1 INTRODUCTION 
The mitochondrion is one of the most important membrane-bound structures in 
eukaryotic cells. Mitochondria play a pivotal role in cellular energy production as well as 
metabolism. Mitochondria consist of outer and inner bilayer membranes, which 
constitute a unique composition of phospholipids and proteins. The lipid composition of 
the inner membrane determines its shape, which confers a functional role in anchoring 
proteins, modulating protein activity and signal transduction. The signature lipid of 
mitochondria is cardiolipin (CL), which is primarily localized in the inner membrane. In 
the presence of reactive oxygen species (ROS), which are known to accumulate in the 
mitochondria when the cells respire, CL acyl chains are peroxidized (Petrosillo et al., 
2001). The activity of peroxidized CL, and products generated downstream, are intrinsic 
to mitochondrial signal transduction. The results of this dissertation research identify 
novel functions of CL remodeling in peroxidized CL removal and myotube differentiation.  
1. Structure and cellular functions of CL 
CL (1,3 diphosphatidyl-sn-glycerol) was first isolated from bovine cardiac tissue, 
in which it is most abundant (Pangborn, 1948; Shen et al., 2017). Unlike other 
phospholipids that have two fatty acyl chains and one phosphatidyl group, CL contains 
two phosphatidyl moieties, contributing two negative charges, and four acyl chains 
(Lecocq and Ballou, 1964) (Figure 1-1).  
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PE 
Figure 1-1 Cardiolipin (CL) has a unique structure 
Unlike PE and other membrane phospholipids, CL has a dimeric structure in which 
two phosphatidyl moieties are linked by a glycerol. Consequently, it is hydrophobic 
and negatively charged due to the presence of four fatty acyl chains and two 
phosphate groups respectively. CL interacts with diverse mitochondrial proteins by 
hydrophobic and electrostatic interactions. The asymmetry of CL molecules, 
resulting from the diversity of fatty acyl chains, leads to a variety of CL species, 
which confer distinct functions of CL in different tissues. Symmetric CL molecules, in 
which all four fatty acid chains are linoleic acid, are common in heart and muscle. 
However, asymmetric CL molecules, with highly diversified acyl chains, are found in 
mammalian brain (Cheng et al., 2008; Kagan et al., 2014; Schlame et al., 2005). 
CL 
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Figure 1-2 Various cellular functions of CL have been identified in yeast. 
CL-protein interactions stabilize respiratory chain supercomplexes (Pfeiffer et al., 
2003; Zhang et al., 2002), which is pivital to mitochondrial bioenergetics. 
Interestingly, CL is essential in cellular functions not generally associated with 
bioenergetics. Although the vacuolar concentration of CL is low, CL deficiency has 
been linked to vacuolar morphology and acidification defects at elevated temperature 
(Chen et al., 2008). The importance of CL to protein import is underscored by the 
finding that the absence of CL leads to a reduced membrane potential and 
decreased protein import (Jiang et al., 2000). Furthermore, CL is also required for 
assembly of outer membrane protein translocases (Gebert et al., 2009). Increasing 
evidence supports a  role for CL in cellular signaling pathways, including PKC and 
HOG, which affact cell wall biogenesis, aging, and mitophagy (Zhong and Greenberg, 
2005; Zhou et al., 2009). Additionally, functions of CL in life span/stress response 
(Gonzalvez and Gottlieb, 2007; Schug and Gottlieb, 2009), cell division (Chen et al., 
2010), iron homeostasis (Patil et al., 2013), and mitochondrial fusion (Joshi et al., 
2016) are now established. 
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CL comprises approximately 15% of total mitochondrial phospholipids (Jakovcic 
et al., 1971). CL interacts with a variety of mitochondrial proteins through both 
hydrophobic and electrostatic interactions (Schlame et al., 2000a), including the 
ADP/ATP carrier (Beyer and Klingenberg, 1985; Claypool et al., 2008b) and respiratory 
complexes (Eble et al., 1990; Lange et al., 2001; Palsdottir et al., 2003). CL-protein 
interactions stabilize and promote supramolecular associations such as respiratory 
chain supercomplexes and ADP/ATP carrier (Claypool et al., 2008b; Pfeiffer et al., 2003; 
Zhang et al., 2002). Additionally, CL deficiency leads to functional defects in diverse 
biochemical pathways other than mitochondrial bioenergetics, including mitochondrial 
dynamics (DeVay et al., 2009; Joshi et al., 2012); cell wall biogenesis (Zhong et al., 
2005; Zhong et al., 2007); mitochondrial protein import (Gebert et al., 2009; Jiang et al., 
2000); vacuolar function and morphology (Chen et al., 2008); aging (Zhou et al., 2009); 
cell cycle (Chen et al., 2010); mitophagy (Shen et al., 2017); iron homeostasis (Patil et 
al., 2013); and apoptosis (Gonzalvez and Gottlieb, 2007; Schug and Gottlieb, 2009). It 
is likely that this list will grow in the future (Figure1-2). The regulation of CL synthesis 
and remodeling is crucially important to the physiological state of an organism, as 
different CL species are engaged in diverse, yet significant cellular pathways (Kagan et 
al., 2014; Kagan et al., 2015). 
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Figure 1-3 CL biosynthesis synthesis.  
Prior to CL synthesis, CDP-DAG synthase (Tam41) catalyzes the transfer and 
conversion of phosphatidic acid (PA) from the outer membrane to the matrix face of 
inner mitochondrial membrane. To initiate CL synthesis, PGP synthase (Pgs1) 
catalyzes conversion of CDP-diacylglycerol (CDP-DAG) to 
phosphatidylglycerolphosphate (PGP). In the second step, PGP phosphatase (Gep4) 
dephosphorylate PGP to generate phosphatidylglycerol (PG). Lastly, CL synthase 
(Crd1) converts PG to nascent CL that contains saturated and unsaturated fatty acyl 
chains. 
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2. CL biosynthesis 
According to current literature, “the life of a CL molecule can be divided into 
several discreet phases: biosynthesis, remodeling, peroxidation modification, 
translocation, and degradation” (Schlame and Greenberg, 2017). TAM41-encoded 
CDP-DAG synthase, located on the matrix side of the mitochondrial inner membrane, 
initiates CL biosynthesis through the conversion of phosphatidic acid (PA) to CDP-
diacylglycerol (CDP-DAG)  (Kutik et al., 2008; Tamura et al., 2013).  PA is synthesized 
on the mitochondrial outer membrane and translocated to the inner membrane via the 
UPS1-encoded PA transfer protein (Athenstaedt and Daum, 1999). Secondly, CDP-
DAG is converted to  phosphatidylglycerol phosphate (PGP) by PGS1-encoded PGP 
synthase (Chang et al., 1998a), which is then dephosphorylated to phosphatidylglycerol 
(PG) by GEP4-encoded PGP phosphatase (Osman et al., 2010). CL synthase (Crd1) 
catalyzes the last step of CL synthesis by condensing CDP-DAG and PG to form CL 
(Figure 1-3) (Chang et al., 1998b; Jiang et al., 1997; Tamai and Greenberg, 1990; Tuller 
et al., 1998). Following de novo synthesis, CL undergoes a remodeling process in which 
saturated acyl chains are exchanged for unsaturated acyl chains. 
3. CL remodeling 
CL remodeling is a structural modification that follows de novo biosynthesis. This 
process facilitates fatty acyl chain transfer. The remodeled CL acyl chain species are 
organism and tissue specific. In the mammalian brain, the CL species are very diverse 
(Kiebish et al., 2008). However, in tissues with high energy turnover, such as the heart, 
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CL species are typically dominated by acyl groups with one or two double bonds 
(Schlame et al., 2005). 
In yeast, a CL-specific phospholipase (Cld1) initiates CL remodeling as it 
deacylates CL to monolysocardiolipin (MLCL) on the matrix side of the inner 
mitochondrial membrane (Baile et al., 2013; Beranek et al., 2009). The CL transacylase, 
Taz1, utilizes donor phospholipids, particularly PC and PE, to reacylate MLCL and 
produce remodeled CL in the mitochondrial periphery (Figure 1-4) (Brandner et al., 
2005; Gu et al., 2004; Testet et al., 2005). Remodeled CL contains more unsaturated 
acyl chains than CL synthesized de novo (Beranek et al., 2009; Gu et al., 2004; Vaz et 
al., 2003). Presently, the scientific community debates whether tafazzin transfers fatty 
acyl-chains from PE and PC to MLCL specifically. Although Abe et al. purport that 
purified yeast tafazzin catalyzes acyl-specific transacylation in bilayers, Schlame and 
Greenberg contend that tafazzin is simply a vehicle to facilitate fatty acid exchange 
between phospholipid molecules. Specifically, they argue that in order to generate 
specific CL species, the free energy of remodeled CL must be lower than the free 
energy of other molecular species (Abe et al., 2016; Schlame and Greenberg, 2017). 
These theories attempt to elucidate the mechanistic functions of Taz1 to further our 
understanding of the cellular role of CL remodeling. However, focus of my study was to 
elucidate the link between the cellular functions of Cld1 and CL remodeling.  
The experiments described in Chapter 3 demonstrate that yeast Cld1 exhibits 
specificity for different CL molecular species. The observed molecular specificity 
suggests that the functional role of Cld1, with respect to CL remodeling, is to maintain 
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the levels of various molecular species within the CL pool. The study described in 
Chapter 2 identifies CL deacylation, catalyzed by Cld1, as the only step of CL 
remodeling significantly upregulated at the mRNA level. Taken together, my findings 
support this as a third possible explanation for the observed specificity of CL 
composition generated by CL deacylation. However, maintaining a CL pool of specified 
fatty acyl composition is not the only function of CL remodeling. My work also suggests 
that CL deacylation serves to specifically remove peroxidized acyl chains in response to 
oxidative stress. 
4. CL peroxidation and translocation 
In normally functioning mitochondria, the CL concentration is highest on the inner 
leaflet of the mitochondrial inner membrane (Hovius et al., 1990; Krebs et al., 1979). A 
Figure 1-4 CL remodeling.  
Unremodeled CL contains both saturated and unsaturated fatty acyl chains. 
Remodeling occurs in the outer leaflet of the inner membrane. CLD1-encoded 
phospholipase catalyzes the conversion of CL to monolyso-CL (MLCL). The 
transacylase, Taz1, utilizes donor phospholipids, particularly PC and PE, to 
reacylate MLCL to CL. Remodeled CL contains primarily unsaturated fatty acyl 
chains. 
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significant portion of CL is translocated to the mitochondrial outer membrane during 
mitochondrial injury and depolarization, which distorts the highly asymmetric distribution 
of CL between the outer and inner membranes (Baile et al., 2013; Garcia Fernandez et 
al., 2002; Gonzalvez and Gottlieb, 2007). Externalized CL signals autophagy machinery 
to remove damaged mitochondria (Chu et al., 2013). The translocation of CL from the 
inner to outer mitochondrial membrane, along with oxidative modification of CL acyl 
chains, leads to apoptotic death (Kagan et al., 2005b). 
CL containing polyunsaturated fatty acyl chains are susceptible to oxidative 
modifications. This process is, under certain conditions, enzymatically catalyzed by the 
peroxidase function of an intermembrane space hemoprotein, cytochrome c (cyt c) 
(Atkinson et al., 2011; Kagan et al., 2009). In the absence of CL, cyt c peroxidase 
activity is negligible (Basova et al., 2007). Upon binding CL, cyt c undergoes a 
conformational change facilitating CL-specific peroxidation. Cyt c tyrosyl radicals are 
likely reactive intermediates of the peroxidase cycle, leading to CL peroxidation 
(Kapralov et al., 2011). Recent studies reveal that acute reperfusion injury, such as the 
massive apoptotic response observed during acute brain injury, is accompanied by the 
generation of multiple peroxidized CL (CLox) species (Chan and Di Paolo, 2012; Ji et al., 
2012). The study also emphasizes that attenuating CL peroxidation confers a significant 
countermeasure against the biochemical and physiological effects of oxidative stress. 
Mammalian cells possess a similar mechanism to mitigate damage resulting from CL 
peroxidation. Liu’s 2017 study reveals iPLA2γ, a gene product whose function is 
analogous to Cld1, as the major enzyme responsible for deacylation of oxidized 
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aliphatic chains from CL (Liu et al., 2017). Deletion of iPLA2γ results in the 
accumulation of peroxidized CL in mouse mitochondria when subjected to oxidative 
stress. There is mounting evidence to support CLs/CLox as necessitative signaling 
molecules for immune responses, cell death, and coordination of metabolism (Kagan et 
al., 2014; Maguire et al., 2017).  
The physiological consequences and molecular mechanism of CL peroxidation 
remain poorly understood, and represent a significant gap in the field. My work, in part, 
focuses on the link between CL remodeling and peroxidation. Using the powerful yeast 
model, in which well-characterized mutants for every step of CL synthesis and 
remodeling are available, we are trying to elucidate the molecular mechanism of CL 
peroxidation. 
5. CL and Barth Syndrome 
The importance of CL remodeling is underscored by the X-linked mitochondrial 
disorder Barth syndrome (BTHS) (Figure 1-4). In 1983, Barth et al. identified a 
mitochondrial disease that negatively impacts bioenergetics of the heart, muscle and 
neutrophil leukocytes (Barth et al., 1983). Many abnormalities are well established in 
BTHS patients, including cardiomyopathy (Kelley et al., 1991; Spencer et al., 2006a); 
neutropenia (Kelley et al., 1991); underdeveloped skeletal musculature and weakness 
(Barth et al., 1983); growth delay (Kelley et al., 1991); exercise intolerance; and 
elevated urinary excretion of 3-methylglutaconic acid. Untreated BTHS patients die in 
infancy, or during early childhood, due to defective development of heart and skeletal 
muscle. Moreover, surviving BTHS patients are known to have a distinct cognitive 
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phenotype (Mazzocco et al., 2007a).  After a decade, investigators mapped the mutant 
locus (Bolhuis et al., 1991), and the functional loss of tafazzin (TAZ) was identified as 
the genetic basis for clinical BTHS (Bione et al., 1996). Schlame and Ren showed that 
tafazzin reacylates monolyso-CL (MLCL) to CL (Schlame and Ren, 2006). The yeast 
and human tafazzin sequences are highly conserved, and encode a transacylase that 
catalyzes CL reacylation. Approximately 28 different TAZ mutations, resulting in single 
amino acid substitution, have been identified in BTHS patients (Schlame and Ren, 
2006). These tafazzin mutations lead to either a complete loss of function, or expression 
of a severely truncated protein resulting in decreased total CL, accumulation of MLCL 
and  aberrant CL acyl species (Schlame et al., 2002).  
Figure 1-5 The cause of BTHS is not clear. 
Mutations in tafazzin lead to perturbed CL remodeling resulting in decreased total CL, 
accumulation of MLCL, and aberrant CL acyl species that is associated with 
cardiomyopathy, skeletal myopathy, growth retardation and exercise intolerance. 
However, the link between CL deficiencies and the BTHS symptoms is not clear.  
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6. Yeast and mammalian BTHS models 
The budding yeast, Saccharomyces cerevisiae, is an excellent eukaryotic model 
system (Botstein et al., 1997) because it is nonpathogenic, grows rapidly, and can be 
easily used for genetic analysis. More specifically, yeast is an excellent model for CL-
focused research because deletion mutants for all CL biosynthetic genes are readily 
available and viable. Although the yeast model has clarified the role of CL in cell 
function and links the deficiency of CL to bioenergetic defects, a mammalian model 
organism is essential to test and confirm hypotheses regarding CL function in humans.  
BTHS lymphoblasts, generated by EBV transformation, exhibit decreased 
mitochondrial membrane potential and abnormal mitochondrial proliferation (Xu et al., 
2005). These cells exhibit phospholipid deficiencies similar to those seen in BTHS 
patients, namely impaired CL levels, increased MLCL, and aberrant acyl species. 
Lymphoblasts are relatively inexpensive and simply grown, which make them an easy 
model to work with. However, the disease phenotype may only manifest with a 
substantial metabolic demand beyond cell growth and division. BTHS lymphoblasts do 
not exhibit the same metabolic demand as cardiac and skeletal muscle cells. Most 
importantly, a congenic control cell line is not available for BTHS lymphoblasts. 
Induced pluripotent stem cells (iPSCs) generated from BTHS patients exhibit 
mitochondrial defects similar to BTHS lymphoblasts (Dudek et al., 2013b). These cells 
can readily differentiate into muscle cells that exhibit the same metabolic demand as 
muscle cells. Unfortunately, they share the same disadvantage with BTHS lymphoblasts: 
the lack of a congenic control cell line. 
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Inducible short hairpin RNA (shRNA)-mediated tafazzin knockdown mice, and 
tafazzin knockout mouse embryonic stem cells are very powerful models for BTHS 
research (Acehan et al., 2009; Acehan et al., 2011; Soustek et al., 2011). Murine 
tafazzin knockdown resulted in a dramatic decrease of tetralinoleoyl CL and 
accumulation of MLCL. When tafazzin is knocked down, mitochondria, myofibrils, and 
mitochondrial-associated membranes of murine skeletal and cardiac muscles exhibit 
pathological changes similar to BTHS patients. Additionally, the congenic control is 
available for both of these models. However, mice and stem cells are relatively 
expensive and laborious to handle. 
To circumvent the drawbacks of current mammalian models, I constructed a 
stable mammalian cell line using C2C12 mouse myoblasts, which will be described in 
Chapter 6. The C2C12 mouse skeletal muscle cell line is maintained as myoblasts 
under high serum conditions, and is easily differentiated into myotubules under low 
serum conditions. It is often employed in studies of mitochondrial bioenergetics (Leary 
et al., 1998; Liu and Brooks, 2012; Nicholls et al., 2010). The TAZ-KO C2C12 cells 
exhibit similar mitochondrial defects observed in other BTHS models such as decreased 
membrane potential and respiration. Additionally, the TAZ-KO C2C12 cells exhibit the 
same metabolic demand as skeletal muscle cells, have a congenic control cell line, and 
are relatively inexpensive and easy to handle. 
7. Project outline  
The objectives of the studies described in this thesis were to elucidate functions 
of CLD1 and CL remodeling in the yeast S. cerevisiae and murine myoblasts. 
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In the studies summarized in Chapter 2, we assayed the regulation of yeast CL 
phospholipase, Cld1. Our data indicated that an increased MLCL/CL ratio, but not 
decreased CL unsaturation, is likely the primary cause of decreased respiratory growth 
and chronological life span observed in taz1. This suggests that the physiological 
defects of BTHS patients is possibly due to increased MLCL/CL rather than decreased 
unsaturated CL, and that attenuation of CL phospholipases may potentially treat BTHS. 
If unsaturated CL is not essential, as suggested by our finding, what is the 
function of CL remodeling? Our finding that CLD1 expression was upregulated under 
respiratory conditions suggests the possibility that CLD1 expression is upregulated in 
response to oxidative stress. CL peroxidation, resulting from oxidative stress, has been 
described in mammalian cells (Bayir et al., 2007; Kriska et al., 2005; Petrosillo et al., 
2001). Based on this, one of the physiological roles of CL remodeling may be to remove 
peroxidized CL. To address this possibility, it was necessary to determine whether CL 
species can be altered by nutritional supplementation of PUFA, because yeast does not 
synthesize oxidizable CL (Chapter 3). Liquid chromatography−mass-spectrometry-
based phospholipidomics was combined with genetic and nutritional manipulations to 
assay CL incorporation of PUFA during the CL biosynthetic and post-synthetic 
remodeling processes in yeast. Our results demonstrated that yeast readily 
incorporated PUFA to synthesize oxidizable CL. To genetically manipulate CL species, 
the H. brasiliensis Δ12-desaturase gene was expressed in yeast (Chapter 4). Lipidomic 
analysis of this strain confirmed the presence of PUFA within molecular species of CL. 
Although multiple CL-hydroperoxides and CL-dihydroperoxides were readily detected in 
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these cells, cell growth and life span were not impacted. Using this novel yeast model, 
in which cells expressed ∆12-desaturase, the specificity of Cld1 for peroxidized CL, and 
its role in deacylating peroxidized CL, was determined (Chapter 5). cld1Δ cells 
expressing ∆12-desaturase were utilized to determine the effect of peroxidation on CL 
remodeling. In cells expressing desaturase, loss of CLD1 led to increased peroxidized 
CL species, as well as decreased cell growth and life span. The findings from this study 
may help to clarify the role of CL remodeling and its mechanistic roles in mitigating 
oxidative stress. 
To probe defects resulting from CL deficiency in mammalian cells (Chapter 6), I 
constructed a tafazzin knockout C2C12 cell line, which exhibits an increased MLCL/CL 
ratio, decreased respiration capacity, increased ROS generation and decreased 
membrane potential. Although WT and TAZ-KO C2C12 cells can differentiate into 
myotubes, differentiation was significantly decreased in TAZ-KO C2C12 cells under 
certain conditions. Taken together, these findings indicate that CL remodeling plays a 
role in myotube differentiation. 
While the studies described here identify various functions of CL, many questions 
remain unanswered. Future studies to elucidate functions of CL are suggested in 
Chapter 7. 
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CHAPTER 2 DELETION OF THE CARDIOLIPIN-SPECIFIC 
PHOSPHOLIPASE CLD1 RESCUES GROWTH AND LIFESPAN 
DEFECTS IN THE TAFAZZIN MUTANT: IMPLICATIONS FOR BARTH 
SYNDROME 
 
The work described in this chapter has been published in Ye*, C., W. Lou*, Y. Li, 
I.A. Chatzispyrou, M. Huttemann, I. Lee, R.H. Houtkooper, F.M. Vaz, S. Chen, and M.L. 
Greenberg. 2014. Deletion of the cardiolipin-specific phospholipase Cld1 rescues 
growth and life span defects in the tafazzin mutant: implications for Barth syndrome. 
The Journal of biological chemistry. 289:3114-3125. *Equal contributors 
http://www.ncbi.nlm.nih.gov/pubmed/24318983 
It has also been published in Ye, Cunqi, "Characterization And Identification Of 
Novel Regulators Of The Synthesis Of Phospholipids" (2014). Wayne State University 
Dissertations. Paper 1036. 
INTRODUCTION 
Cardiolipin (CL) is a unique phospholipid that is predominant in mitochondrial 
membranes (Hostetler et al., 1972; Joshi et al., 2009a). Unlike other membrane 
phospholipids, it contains two phosphatidyl moieties, four acyl chains and two negative 
charges (Lecocq and Ballou, 1964; Pangborn, 1947). As the signature lipid of 
mitochondria, it comprises about 15% of total mitochondrial phospholipids (Jakovcic et 
al., 1971) and interacts with a wide range of mitochondrial proteins (Claypool, 2009; 
Klingenberg, 2009; Schlame and Ren, 2009; Schlame et al., 2000a), including the 
ADP/ATP carrier (Beyer and Klingenberg, 1985; Claypool et al., 2008b) and respiratory 
complexes (Eble et al., 1990; Lange et al., 2001; Palsdottir et al., 2003; Shinzawa-Itoh 
et al., 2007). CL-protein interactions stabilize respiratory chain supercomplexes (Pfeiffer 
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et al., 2003; Zhang et al., 2002) and promote supramolecular associations between the 
ADP/ATP carrier and respiratory supercomplexes (Claypool et al., 2008b). Therefore, it 
is not surprising that mitochondrial respiration and energy production are highly 
correlated with CL biosynthesis (Claypool et al., 2008b; Gohil et al., 2004; Jiang et al., 
2000). Interestingly, CL deficiency also leads to deficiencies in diverse cellular functions 
other than mitochondrial bioenergetics, including mitochondrial dynamics (DeVay et al., 
2009; Joshi et al., 2012), mitochondrial protein import (Gebert et al., 2009; Jiang et al., 
2000), cell wall biogenesis (Zhong et al., 2005; Zhong et al., 2007), vacuolar function 
and morphology (Chen et al., 2008), cell cycle (Chen et al., 2010), aging (Zhou et al., 
2009), and apoptosis (Gonzalvez and Gottlieb, 2007; Houtkooper and Vaz, 2008; Schug 
and Gottlieb, 2009). As CL is engaged in a plethora of cellular activities, the regulation 
of CL synthesis is crucially important. 
The synthesis of CL is well-characterized in Saccharomyces cerevisiae. As seen 
in Figure 2-1, Pgs1 catalyzes the committed step of CL synthesis by converting CDP-
DAG and glyerol-3-phosphate to phosphatidylglycerolphosphate (PGP) (Chang et al., 
1998a), which is dephosphorylated to phosphatidylglycerol (PG) by the PGP 
phosphatase Gep4 (Kelly and Greenberg, 1990; Osman et al., 2010). CL synthase 
(Crd1) catalyzes the final step of de novo CL synthesis by condensing PG and CDP-
DAG to form CL with primarily saturated acyl chains (Chang et al., 1998b; Jiang et al., 
1997; Tamai and Greenberg, 1990; Tuller et al., 1998). Following the de novo synthesis 
of CL on the matrix side of the inner mitochondrial membrane, CL undergoes 
remodeling in which acyl chains are exchanged. In this process, CL is deacylated to 
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monolysocardiolipin (MLCL) by the CL-specific lipase Cld1 on the matrix side of the 
inner mitochondrial membrane (Baile et al., 2013; Beranek et al., 2009). MLCL is 
reacylated by the transacylase Taz1 in the mitochondrial periphery (Brandner et al., 
2005; Claypool et al., 2008a; Gu et al., 2004; Testet et al., 2005). Remodeled CL has 
more unsaturated acyl chains than CL synthesized de novo (Beranek et al., 2009; Gu et 
al., 2004; Vaz et al., 2003; Xu et al., 2003). Although the CL remodeling genes and 
enzymes have been identified in yeast, the function of CL remodeling and mechanisms 
underlying its regulation are not understood.  
The importance of CL remodeling is underscored by the X-linked mitochondrial 
disorder Barth syndrome (BTHS), a cardioskeletal myopathy that results from mutations 
in the tafazzin gene (the homologue of yeast TAZ1) (Barth et al., 1983; Barth et al., 
2004; Barth et al., 1999a). Tafazzin deficiency leads to a decrease in the CL/MLCL ratio 
and a decrease in CL species containing unsaturated fatty acids (Acehan et al., 2011; 
Gu et al., 2004; Houtkooper et al., 2009; Schlame et al., 2003; Valianpour et al., 2002; 
Vreken et al., 2000; Xu et al., 2006a). Which of these biochemical outcomes leads to 
the pathology in BTHS is not understood. Genetic inactivation of the CL-specific 
phospholipase iPLA2-GVIA rescued sterility defects associated with tafazzin deficiency 
in Drosophila (Malhotra et al., 2009). The mechanism underlying this rescue is not 
known. In mammals, CL-specific phospholipases have not been identified, and multiple 
phospholipases supposedly catalyze the deacylation of CL (Hsu et al., 2013), 
complicating experiments to elucidate the role of deacylation in mammalian cells. In  
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contrast, CLD1 is the only CL-specific phospholipase in S. cerevisiae (Beranek et al., 
2009).  The yeast cld1Δ mutant has decreased unsaturated CL compared to wild type 
cells, but the CL/MLCL ratio is not altered. In this study, we demonstrated for the first 
time that deletion of CLD1 rescued both respiratory and fermentative growth defects as  
well as decreased chronological life span in yeast taz1Δ cells. This suggests that 
deacylation of CL in the absence of tafazzin is deleterious because it leads to a 
decrease in the CL/MLCL ratio.  These findings argue against the current thought that 
defects in tafazzin deficient cells result from decreased unsaturated CL.  We further 
show that expression of CLD1 is regulated in response to conditions affecting 
mitochondrial respiration and controlled by the HAP transcriptional activator. 
   
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Invitrogen 
BY4742 MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 Invitrogen 
crd1Δ MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 crd1Δ::KanMX6 Invitrogen 
cld1Δ MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cld1Δ::KanMX6 Invitrogen 
taz1Δ MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 taz1Δ::KanMX6 this study 
cld1Δtaz1 Δ 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cld1Δ::KanMX6 
taz1Δ::KanMX6 this study 
mig1Δ MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 mig1Δ::KanMX6  Invitrogen 
hap2Δ MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 hap2Δ::KanMX6 Invitrogen 
hap3Δ MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 hap3Δ::KanMX6 Invitrogen 
hap4Δ MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hap4Δ::KanMX6 Invitrogen 
hap5Δ MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 hap5Δ::KanMX6 Invitrogen 
BY4741 ρ° ρ° mutant derived from BY4741 this study 
crd1Δ ρ° ρ° mutant derived from BY4741 crd1Δ this study 
cld1Δ ρ° ρ° mutant derived from BY4741 cld1Δ this study 
taz1Δ ρ° ρ° mutant derived from BY4741 taz1Δ this study 
cld1Δtaz1Δ 
ρ° 
ρ° mutant derived from BY4741 cld1Δtaz1Δ this study 
pYPGK18 2μm, LEU2 
(Vaz et 
al., 2003) 
pYPGK18CL
D1 
derived from pYPGK18, expression CLD1 from PGK1 
promoter 
this study 
  
  
Table 2-1 Strains and plasmids used in this study 
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Overexpression of CLD1 leads to decreased ATP production from mitochondrial 
respiration that is compensated by increased glycolysis. Based on these findings, we 
proposed that transcriptional regulation of CLD1 controls deacylation of CL, and the 
regulation of this process modulates cellular energy production 
METHODS AND MATERIALS 
Yeast strains, plasmids and growth media—The yeast S. cerevisiae strains and 
plasmids used in this study are listed in Table 2-1 and Table 2-2. Single deletion 
mutants were obtained from the yeast knock-out deletion collection (Invitrogen). Double 
mutants were obtained by tetrad dissection. Parental ρ+ cells were used to generate ρ° 
derivatives by growing in yeast extract peptone dextrose (YPD) medium containing 20 
μg/ml ethidium bromide to the early stationary phase. ρ° strains were confirmed by 
inability to grow on yeast extract peptone glycerol ethanol (YPGE) medium, the absence 
of mitochondrial DNA by DAPI staining, and the failure to complement ρ− tester strains 
for growth on YPGE medium. To construct a CLD1-overexpression plasmid, a 1338-bp 
sequence containing the entire open reading frame of CLD1 was amplified from yeast 
genomic DNA using an EcoRI-tagged forward primer CLD1_EcoRI_F (5’-
TATAGAACATGAATTCAAAAGTGAGCTGCAATGAGCA) and an XbaI-tagged reverse 
primer CLD1_XbaI_R (5′- ATTTTGAGATTCTAGAAAGAAGAAAAATAGCGGCGA -3′). 
The PCR products were purified using the Wizard SV Gel and PCR Clean-up System 
(Promega). The purified DNA fragments were ligated into pYPGK18 cut with EcoRI and 
XbaI, downstream of the PGK1 promoter. All the plasmids were amplified and extracted 
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using standard protocols. The plasmids were transformed into yeast strains using a 
one-step transformation protocol. 
Synthetic complete (SC) medium contained adenine (20.25 mg/L), arginine (20 
mg/L), histidine (20 mg/L), leucine (60 mg/L), lysine (200 mg/L), methionine (20 mg/L), 
threonine (300 mg/L), tryptophan (20 mg/L), uracil (20 mg/L), yeast nitrogen base 
without amino acids (Difco), all the essential components of DIFCO vitamin (inositol-
free), 0.2% ammonium sulfate, and glucose (2%). Inositol (75 μM) was supplemented in 
all media used in this study. Synthetic dropout media contained all ingredients 
mentioned above except for the amino acid used as a selectable marker, and were 
used to culture strains containing a plasmid.  
Chronological life span—Yeast chronological life span is determined by survival of 
non-dividing cells in a prolonged stationary culture (Fabrizio and Longo, 2003). A 
standard protocol previously described was followed (Hu et al., 2013) to assess 
chronological life span. In brief, individual colonies were inoculated in 10 ml of SC 
glucose medium and incubated overnight. The cultures were then diluted in 50 ml of SC 
medium, and cells were allowed to grow until saturation. Viable cells were measured 
every 2 or 3 days by counting colonies that were serially diluted and plated on YPD 
plates and represented as percentage of cells at day 2. The viability is considered to be 
100% at or before day 2.  
Spotting assay—Cells were pre-cultured in SC medium to the early stationary growth 
phase at 30°C and washed with sterile water. Three μL aliquots of a series of 10-fold 
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dilutions of 0.5 units of A550 cells were spotted onto indicated plates and incubated at 
30°C.  
Real-Time quantitative PCR (RT-qPCR) analysis—Cells were grown to the indicated 
growth phase and harvested at 4°C. Total RNA was extracted using hot phenol (Kohrer 
and Domdey, 1991) and purified using the RNeasy Mini Plus kit (QIAGEN, Valencia, 
CA). Complementary DNA (cDNA) was synthesized using the First Strand cDNA 
Synthesis Kit (Roche Applied Science, Indianapolis, IN) according to the manufacturer’s 
manuals. RT-qPCR reactions were performed in a 20 μL volume using Brilliant III Ultra-
Faster SYBR Green QPCR Master Mix (Agilent Technologies, Santa Clara, CA).  
Triplicates were included for each reaction. The primers for RT-qPCR are listed in Table 
2-2. RNA levels were normalized to ACT1. Relative values of mRNA transcripts are 
shown as fold change relative to indicated controls. Primer sets were validated 
according to Methods and Applications Guide from Agilent Technologies. Optimal 
primer concentrations were determined, and primer specificity of a single product 
monitored by a melt curve following the amplification reaction. All the primers were 
validated by measurement of PCR reaction efficiency and have calculated reaction 
efficiencies between 95-105%. 
Measurement of respiration—Cell respiration was analyzed in a closed 500 L 
chamber equipped with a micro Clark-type oxygen electrode (Oxygraph plus system, 
Hansatech) at 30°C. Cells grown to the logarithmic phase were mixed in fresh growing 
media using a  
3 
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protein concentration of 2 mg/mL following measurements of basal respiration. State 4 
and 3 respiration was determined in the presence of 4 M oligomycin and 5 μM FCCP, 
respectively.  KCN (0.2 mM) was added at the end of the experiment to inhibit 
cytochrome c oxidase to normalize for (subtract) cytochrome c oxidase independent 
oxygen consumption. Oxygen consumption was recorded on a computer and analyzed 
with the Oxygraph plus software. Respiration rates are defined as consumed O2 
(nmol)/min∙total protein (mg). 
Table 2-2. Real-time PCR primers used in this study.   
    
Gene Primers Sequence (5' to 3')  
ACT1 Forward TCCGGTGATGGTGTTACTCA 
this study 
  Reverse GGCCAAATCGATTCTCAAAA 
PGS1 Forward TTTGCTCCAACTCACTCGTCCTCA 
this study 
  Reverse ATTGCCAAATGGAGAAGGGTTCGC 
GEP4 Forward AAAGGCCGTGGTCTTGGATAAGGA 
this study 
  Reverse ATTGGAACCGGCGGTATTGCTAA 
CRD1 Forward TGCGGCGATAATTCTGGGTAGAGA 
this study 
  Reverse ATTCCATGCCACACGACCAGGATA 
CLD1 Forward ACTGGCTTTGGCTTTATGGCGAT 
this study 
  Reverse TCCAGGTACAAGTGATGCCCTGA 
TAZ1 Forward CGAAGCCATCTTGGGTCCATGTT 
this study 
  Reverse CAATGGGCGGCTTTGTTGCTTCT 
ADH1 Forward GGTCTAGGTTCTTTGGCTGTT 
this study 
  Reverse CACCACCGATGGATCTGAATAA 
ADH2 Forward GTACTGTTGTCTTGGTTGGTTTG 
this study 
  Reverse GTAAGAGCCGACAATGGAGATAG 
PGK1 Forward AGGCTTCTGCCCCAGGTTC (Szijgyarto et 
al., 2011)   Reverse CAGCACGTTGTGGCAAGTC 
GAPDH Forward AGTCTTTTGGGTGGCGGTCA (Szijgyarto et 
al., 2011)   Reverse ACATTGACGCTGGTGCCAAG 
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Determination of ATP concentrations—Yeast cells were cultured to the logarithmic 
phase and flash-frozen with liquid nitrogen. ATP levels were determined by the 
bioluminescence method described previously (Lee et al., 2010).  
Determination of ethanol concentrations—Yeast cells were cultured in 10-mL growth 
medium for the indicated times to the logarithmic phase after inoculation at A550 of 0.05, 
and cells were pelleted by a 5-min centrifugation at 3,000 rpm. Supernatants were used 
to determine ethanol concentrations in the media. An ethanol colorimetric assay kit from 
BioVision was used to assay ethanol concentrations according to the manufacturer’s 
manual.  
Mitochondrial aconitase activity—Cultures (2L) of yeast cells in the mid-logarithmic 
phase were harvested for isolation of mitochondria. Mitochondria were isolated as 
described previously (Diekert et al., 2001). Briefly, spheroplasts generated by 
zymolyase treatment were ruptured by Dounce homogenization, and mitochondria were 
obtained by differential centrifugation. Total mitochondrial protein concentration was 
determined using the BCA protein assay (Pierce Protein). Mitochondrial aconitase 
activity was determined in mitochondrial extracts (50-μg protein) using an aconitase-
isocitrate dehydrogenase-coupled assay, in which NADPH formation was monitored at 
A340 for 1 h (Gardner, 2002). 
Determination of CL by mass spectrometry —Total lipid extracts from 10 mg of cells 
(dry weight) were analyzed by HPLC-MS as described previously (Houtkooper et al., 
2006). 
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RESULTS 
Deletion of CLD1 rescues growth and life span defects of the taz1Δ mutant.  
Deacylation of CL in the absence of tafazzin leads to a decreased ratio of 
CL/MLCL and decreased unsaturated CL (Acehan et al., 2011; Gu et al., 2004; 
Valianpour et al., 2002; Xu et al., 2006a), either of which may be responsible for cellular 
defects in tafazzin-deficient cells. We wished to distinguish between decreased 
CL/MLCL ratio vs. decreased unsaturated CL as the mechanism underlying the defects 
in the taz1Δ mutant. Blocking CL deacylation by deletion of CLD1 prevents the 
decrease in CL/MLCL ratio (Beranek et al., 2009). However, the CL that is synthesized 
de novo but not remodeled is mostly saturated, in contrast to remodeled CL in wild type 
(WT) cells, which is mostly unsaturated (Beranek et al., 2009). To determine if the 
decreased CL/MLCL ratio is responsible for taz1Δ defects, we determined the effects of 
CLD1 deletion in taz1Δ mutants. Interestingly, deletion of CLD1 rescued the respiratory 
growth defect of the taz1Δ mutant (Figure 2-2A). Because mitochondrial respiration 
varies in strains with different genetic backgrounds (Ocampo et al., 2012) and the 
presence of polymorphic mitochondrial DNA can contribute to differences in 
mitochondrial respiration (Dimitrov et al., 2009), we assayed the effects of CLD1 
deletion independent of mitochondrial respiration.  To do so, we constructed ρ0 strains 
(which lack mitochondrial DNA) of the WT and CL mutants. While CL deficient cells 
grow normally on glucose (Figure 2-2A), which can be fermented, 
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Figure 2-1. Deletion of CLD1 rescues growth and chronological life span 
defects in taz1Δ. 
(A) Serial 10-fold dilutions of WT, crd1Δ, cld1Δ, taz1Δ, and crd1Δtaz1Δ cells were 
spotted on synthetic complete medium with 2% glucose or 2% ethanol as carbon 
sources. Plates were incubated at 30°C for 3 days. (B) Serial 10-fold dilutions of 
respiration-incompetent (ρ
0
) cells of the above mutants were spotted on synthetic 
complete medium with 2% glucose. (C) Chronological life span of WT, crd1Δ, cld1Δ, 
taz1Δ, and crd1Δtaz1Δ cells was determined as described under “Experimental 
Procedures.” The data depicted in the figure is a representative of three experiments. 
B 
C 
A 
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 growth on glucose is compromised in the mutants if they lack mitochondrial DNA 
(Figure 2-2B). Deletion of CLD1 rescued this growth defect (Figure 2-2B). We predicted 
that CL deficient cells would exhibit a decreased chronological life span similar to the 
decreased replicative life span observed in these cells (Zhou et al., 2009). As shown in 
Figure 2-2C, both crd1Δ and taz1Δ mutants exhibited a dramatic decrease in 
chronological life span. Deletion of CLD1 partially rescued the decrease in taz1Δ life 
span, as the life span of taz1Δcld1Δ was almost similar to that of WT (Figure 2-2C). The 
observation that deletion of CLD1 suppresses the defects in taz1Δ indicates that 
deacylation of CL is deleterious in the absence of tafazzin, and that the decreased 
CL/MLCL ratio but not decreased CL unsaturation is likely the primary cause of taz1Δ 
defects. 
CLD1 expression is highly regulated in response to growth phase, glucose 
availability and respiratory activity. 
The finding that cld1Δ rescued respiratory defects in taz1Δ suggested that CLD1 
expression plays a role in respiration.  We first compared expression of CL biosynthetic 
genes, including PGS1, GEP4, CRD1, CLD1, and TAZ1, in logarithmically growing cells 
(in which energy is generated primarily from glycolysis) and in cells in the stationary 
phase (during which energy is generated from respiration). Expression of all the CL 
biosynthetic genes was increased in the stationary phase (Figure 2-3A). However, while 
PGS1, GEP4, CRD1, and TAZ1 were increased about 3-5 fold, CLD1 was increased by 
about 10-fold in the early stationary phase and more than 30-fold in the later stationary 
phase (Figure2-3A). The large increase in CLD1 expression suggests that levels of 
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unsaturated CL may be increased during stationary phase. This was in fact observed 
(Figure 2-3B). Specifically, in the C68 cluster, the most unsaturated CL (C68:4, m/z 
699.5) was abundant, while a more saturated species (C68:2, m/z 701.5) was less 
abundant in stationary phase cells. Conversely, the C68:4 CL was much less abundant 
than C68:2 in logarithmically growing cells. This is also evident in the C60 cluster as the 
most saturated CL (C60:0, m/z 647.4) was absent from stationary cells but clearly 
present in logarithmically growing cells. Deletion of CLD1 prevents CL remodeling and 
leads to decreased unsaturated CL (Beranek et al., 2009). As expected, cld1Δ exhibited 
a decreased degree of unsaturated CL compared to WT regardless of growth phase 
(Figure 2-3C). Interestingly, unsaturated CL levels were greater in stationary phase than 
in log phase cld1Δ cells. This finding suggests that an as yet unidentified mechanism 
regulates CL saturation in the absence of Cld1. 
Increased CLD1 expression in the stationary phase, during which glucose is 
exhausted and cells shift from fermentation to oxidative phosphorylation, suggested that 
CLD1 may be transcriptionally regulated in response to glucose availability and the 
Figure 2-2. Increased CLD1 expression in the stationary phase is concomitant 
with increased CL unsaturation.  
(A) WT cells were grown in SC medium to the early-logarithmic (EL), mid-logarithmic 
(ML), early-stationary (ES), and stationary (S) growth phases, and PGS1, GEP4, 
CRD1, CLD1, and TAZ1 expression was quantified by RT-PCR as described under 
“Experimental Procedures.” Values of each gene were normalized to the internal 
control ACT1 and are represented as fold change relative to those in EL. Data shown 
are mean ± S.E. (n = 3). (B) Cells grown in YPD in the logarithmic and stationary 
phases were extracted for CL acyl composition analysis by HPLC-mass 
spectrometry, described under “Experimental Procedures.” (C) WT and cld1Δ cells 
grown in SC media in the logarithmic and stationary phases were extracted for CL 
acyl composition analysis by HPLC-mass spectrometry, described under 
“Experimental Procedures.” 
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need to respire. To test this prediction, we examined the expression of CLD1 in 
response to acute removal of glucose and in respiration-deficient cells (ρ0 cells). As 
expected, expression of CLD1 but not the other CL biosynthetic genes was greatly 
increased in response to glucose starvation, by 6-fold and 10-fold, during 30-min and 
60-min starvation, respectively (Figure 2-4A). Furthermore, CLD1 transcription was 
increased in the stationary phase in ρ+ cells but not in respiration incompetent ρ0 cells 
(Figure 2-4B). These findings indicate that CLD1 expression is upregulated during 
respiratory conditions and in response to glucose deprivation.  
Using the Promoter Database of Saccharomyces cerevisiae (SCPD) to search 
for putative regulatory elements in the upstream region of the CLD1 gene, we identified 
consensus sequences for Hap2 and Mig1 (Figure 2-4C), transcription factors that 
mediate activation of respiratory gene expression and glucose repression, respectively 
(Nehlin and Ronne, 1990; Pfeifer et al., 1989; Santangelo, 2006). Consistent with this 
observation, the HAP complex regulates CLD1. As seen in Figure 2-4D, CLD1 
expression in the stationary phase was greatly reduced in hap2Δ, hap3Δ, hap4Δ, and 
hap5Δ mutants, indicating that the HAP complex up-regulates CLD1 transcription. Mig1 
has been shown to repress gene expression in the presence of glucose (Santangelo, 
2006; Schuller, 2003). If Mig1 repressed CLD1 transcription in the presence of glucose, 
CLD1 transcription would be increased in mig1Δ cells. However, CLD1 transcription in 
mig1Δ cells was decreased in these conditions (Figure 2-4E). Thus, Mig1 appears to be 
a positive regulator of CLD1 expression. This is consistent with reported activator 
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activity of Mig1 (Bu and Schmidt, 1998; Wu and Trumbly, 1998). Taken together, these 
findings indicate that expression of CLD1 is increased in response to respiration 
conditions, and this increase is mediated by the HAP and Mig1 transcriptional factors. 
Constitutive overexpression of CLD1 leads to decreases in respiration and 
mitochondrial aconitase activity, and instability of mitochondrial DNA. 
As expression of CLD1 is deleterious to tafazzin-deficient cells, we predicted that 
increased CLD1 expression alters metabolism and perturbs cell growth. Consistent with 
this, cell growth was decreased when CLD1 was overexpressed (Figure 2-5A). One 
possible explanation for this is that increased CLD1 expression perturbs respiration. In  
Figure 2-3. CLD1 expression is increased in response to respiration and 
activated by HAP.  
(A) Glucose limitation. WT cells harvested in the mid-logarithmic phase were washed 
with pre-warmed media with or without glucose and resuspended in fresh media with 
or without glucose for 30-min and 60-min. Analyses of PGS1, GEP4, CRD1, CLD1, 
and TAZ1 expression was determined using RT-qPCR and normalized to ACT1, as 
described under “Experimental Procedures.” The data represent as fold change 
relative to expression in media containing glucose and include the mean ± S.E. (n = 
6). (B) Respiratory competency. ρ
+
 and ρ
0
 cells were grown to the mid-logarithmic 
(ML) and early stationary (ES) phases. The values shown represent the fold change 
relative to expression of WT ρ
+
 cells in ML, and include mean ± S.E. (n = 6). (C) 
Sequence alignment depicting consensus sequences for Mig1 and Hap2 in the 
upstream region of the CLD1 gene using the Promoter Database of Saccharomyces 
cerevisiae (SCPD).  1 indicates a 100% match with putative consensus sequences, 
and 0.88 and 0.82 indicates one mismatch. (D) Effect of the HAP complex. 
Expression was determined in hap2Δ, hap3Δ, hap4Δ, and hap5Δ cells grown to the 
mid-logarithmic phase. Data shown are mean ± S.E. (n = 6). (E) Effect of MIG1. 
Expression was determined in WT and mig1Δ cells grown to the mid-logarithmic 
phase. Data shown are mean ± S.E. (n = 3). 
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support of this, basal respiration in mitochondria from cells that overexpressed CLD1 
was about half that of control cells (Figure 2-5B). This difference was even more 
pronounced comparing the maximum respiratory capacity that was achieved by 
uncoupling the respiratory chain with trifluorocarbonylcyanide phenylhydrazone (FCCP). 
Therefore, constitutive overexpression of CLD1 decreases mitochondrial respiration. 
A possible mechanism to account for decreased respiration in CLD1 
overexpressing cells is suggested by the observation that over 60% of cells became 
cytoplasmic petites. The respiratory growth deficiency of the petites was not 
complemented by crossing to ρ- tester strains, and mitochondrial DNA was not 
observed in the petite cells stained with DAPI. As aconitase is required for mitochondrial 
genome maintenance (Chen et al., 2005b), we tested the possibility that aconitase 
activity might be decreased in cells overexpressing CLD1. In fact, the kinetics of 
aconitase enzymatic activity in mitochondria from CLD1 overexpressing cells exhibited 
a 60% decrease compared to cells overexpressing empty vector (Figure 2-5C). Taken 
together, these studies indicate that increasing CL deacylation by constitutive 
Figure 2-4. Overexpression of CLD1 decreases cell growth, respiration, and 
mitochondrial aconitase activity. 
(A) Growth of WT cells in SC media overexpressing CLD1 or empty vector (EV). 
Cells were inoculated at an initial A550 of 0.05, and A550 was measured at the 
indicated times. The growth curves shown in the figure are representative of three 
experiments. (B) Oxygen consumption was measured in logarithmically growing 
cells using a Clark-type electrode as described under “Experimental Procedures.” 
Data shown are mean ± S.E. (n = 3-6). (C) The kinetics of aconitase enzymatic 
activity in mitochondria from control and CLD1 overexpressing cells grown to the 
logarithmic phase were determined as described under “Experimental Procedures”. 
Data shown are mean ± S.E. (n = 3). 
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overexpression of CLD1 impairs cell growth and respiration and decreases 
mitochondrial DNA stability, suggesting that deacylation of CL is an important control 
point for mitochondrial function. 
Increased fermentation compensates for decreased respiration in cells 
overexpressing CLD1. 
As respiration was decreased in cells overexpressing CLD1, we expected to see 
a concomitant decrease in ATP synthesis. The contribution of mitochondria to cellular 
ATP production can be estimated by the decrease in oxygen consumption resulting 
from the addition of oligomycin, an inhibitor of ATP synthesis. Under basal conditions, 
the decrease in respiration caused by oligomycin was significantly less in mitochondria 
from CLD1 overexpressing cells than in controls (Figure 2-5B), suggesting that 
mitochondrial ATP synthesis was decreased. Interestingly, however, total ATP levels 
were actually higher in CLD1 overexpressing cells (Figure 2-6A). This suggested that 
cells may compensate for the respiratory loss by increasing ATP generation from 
fermentation. Consistent with this, ethanol production was significantly higher in CLD1-
overexpressing cells than in controls (Figure 2-6B).  To determine if up-regulation of 
genes in glycolysis/fermentation could account for increased ethanol production, we 
analyzed expression of GAPDH and PGK1, which encode enzymes that catalyze key 
steps in glycolysis (glyceraldehyde-3-P dehydrogenase and phosphoglycerate kinase, 
respectively), as well as ADH1 and ADH2, which encode the fermentation enzyme 
alcohol dehydrogenase. As seen in Figure 2-6C, expression of ADH1 and ADH2 was 
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Figure 2-5. Overexpression of CLD1 leads to increased ATP and ethanol.  
(A) ATP levels in logarithmically growing cells overexpressing CLD1 or empty vector 
(EV) were determined as described under “Experimental Procedures.” Data shown 
are mean ± S.E. (n = 3). (B) Ethanol concentrations were determined as described 
under “Experimental Procedures”. Data shown are mean ± S.E. (n = 6) (*p<0.05, 
**p<0.01). (C) WT cells overexpressing CLD1 or EV grown to the logarithmic phase 
were harvested for mRNA extraction. Expression of ADH1, ADH2, GAPDH, and 
PGK1 was determined using RT-qPCR as described under “Experimental 
Procedures”. Values of each gene were normalized to the internal control ACT1. 
Transcripts normalized to ACT1 are represented as fold change relative to those in 
control cells. Data shown are mean ± S.E. (n = 3) 
A 
C 
B 
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increased 2-fold, which most likely accounts for the increase in ethanol production.  
Expression of GAPDH and PGK1 was not altered. These findings indicate that 
overexpression of CLD1 leads to decreased mitochondrial respiration and ATP 
synthesis, which is compensated by increasing glycolysis.  
DISCUSSION 
A deficiency in CL reacylation catalyzed by tafazzin is deleterious in eukaryotes 
(Acehan et al., 2011; Gu et al., 2004; Schlame et al., 2003; Valianpour et al., 2002; 
Vreken et al., 2000; Xu et al., 2006a), most notably in humans where it leads to the life-
threatening disorder BTHS (Barth et al., 1983; Barth et al., 2004; Barth et al., 1999a). 
The loss of tafazzin results in perturbation of CL metabolism. Specifically, the CL/MLCL 
ratio is decreased, as are the levels of unsaturated CL species. Although many studies 
suggest that the deleterious effects of tafazzin deficiency result from the absence of 
unsaturated CL (Schlame et al., 2003; Schlame and Ren, 2006; Schlame et al., 2002; 
Valianpour et al., 2003; Xu et al., 2003), no reports to date have distinguished between 
decreased unsaturated CL and decreased CL/MLCL as the cause of the cellular defects. 
In the current study, we addressed this question by characterizing the effects of CLD1 
deletion on tafazzin deficient yeast cells. The cld1Δ mutant has decreased unsaturated 
CL (similar to the taz1Δ mutant), but the CL/MLCL ratio is not decreased. We report that 
cld1Δ rescues growth and respiration defects of the taz1Δ mutant, indicating that the 
decreased CL/MLCL ratio, and not decreased unsaturated CL, leads to the defects in 
tafazzin-deficient cells.  
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Interestingly, the double mutant cld1Δtaz1Δ exhibited defective growth in 
glycerol/ethanol medium at 37˚C as reported in Beranek et al (Beranek et al., 2009). We 
tested growth of WT, crd1Δ, cld1Δ, taz1Δ, and cld1Δtaz1Δ cells in media containing 
glucose, glycerol, ethanol, or glycerol/ethanol as carbon sources. Indeed, we found that 
the double mutant grew poorly compared to WT when glycerol/ethanol was used as 
carbon source, similar to the observation of Beranek et al.  However, in these carbon 
sources, we did not observe respiratory growth defects in taz1Δ at 30˚C. Although 
taz1Δ exhibited decreased growth in glycerol/ethanol at 37˚C, high temperature stress 
complicates respiration defects. In marked contrast, we observed that taz1Δ cells 
exhibit a significant respiratory growth defect in ethanol medium at 30˚C.  Under these 
conditions, we observed that the double mutant rescued the respiratory defects of taz1Δ. 
As cld1Δ restores CL levels but not unsaturated CL species in taz1Δ, this finding 
indicates that rescue of respiratory growth of taz1Δ by cld1Δ results from restoration of 
CL levels.  
While deletion of CLD1 does not appear to affect growth, expression of the gene 
is deleterious in the absence of reacylation, as taz1Δ cells that have the wild type CLD1 
gene are defective, while those carrying the cld1Δ mutation grow normally. To gain 
insight into the mechanism underlying the deleterious effects of increased CLD1, we 
characterized growth and mitochondrial function of cells overexpressing this gene. 
Interestingly, overexpression of CLD1 resulted in increased ATP levels (Figure 2-6A) 
despite a significant reduction in mitochondrial respiration (Figure 2-5B).  Two 
possibilities may explain this seemingly surprising finding.  First, overexpression of 
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CLD1 leads to growth slowdown, therefore less ATP is required and utilized to maintain 
cellular functions.  Second, CLD1 overexpression shifts metabolism from respiration 
toward glycolysis and fermentation (Figure 2-7), compensating for defective oxidative 
phosphorylation.  This indicates that regulation of Cld1-mediated deacylation of CL 
influences energy metabolism by modulating the relative contribution of glycolysis and 
respiration.  CL is an essential component of oxidative phosphorylation complexes.  For 
example, it was identified in the crystal structure of cytochrome c oxidase (Shinzawa-
Itoh et al., 2007), the proposed rate-limiting enzyme of the electron transport chain 
(reviewed in (Huttemann et al., 2012)) and is required for optimal enzyme function and 
activity (Koshkin and Greenberg, 2000).  Therefore, reduced mitochondrial respiration in 
CLD1 overexpressing cells would be expected if the CL pool is modified. (We 
hypothesize that during stationary growth, when oxidative phosphorylation is used, CL 
may be tuned towards increased membrane fluidity or association with the 
supercomplexes).  Furthermore, such alterations lead to mitochondrial DNA instability. 
Apparently, there is yet another level of regulation of the CL metabolic pathway 
intersecting with cytochrome c oxidase regulation.  We show here that CLD1 gene 
regulation is mediated by the Hap2/3/4/5p transcription factor complex (Figure 2-4E), 
which is also a crucial regulator of cytochrome c oxidase subunit V isoforms Va and Vb 
(Kwast et al., 1999).  These isoforms result in an enzyme with higher affinity for oxygen 
when the substrate is scarce.  Furthermore, overexpression of components of the 
Hap2/3/4/5p complex rescues cytochrome c oxidase deficiencies (Fontanesi et al., 
2008).  In another example of coordinate control, regulation of COX4 translation 
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requires Pgs1, the enzyme that catalyzes the committed step of CL synthesis (Su and 
Dowhan, 2006). Taken together these findings suggest an integrated and concerted 
response to environmental stress that affects the CL pathway and oxidative 
phosphorylation, both of which are interconnected.   
Our findings suggest that increased CLD1 is deleterious to cells because it 
decreases respiration. However, CLD1 expression was increased during respiratory 
growth and regulated by the HAP complex (Figure 2-4), the transcriptional activator that 
responds to respiratory growth signals. This raises the question of what is the function 
of the CL remodeling pathway, and the corollary question of why is CLD1 expression 
increased in response to respiratory conditions.  We speculate that the function of CL 
remodeling is to remediate the deleterious effects of respiration (Figure 2-7). In support 
of this possibility, superoxides generated by respiratory complex III cause peroxidation 
of CL and decreased cytochrome c oxidase activity (Paradies et al., 2000; Paradies et 
al., 2001; Paradies et al., 1998). Exogenous supplementation of CL, but not peroxidized 
CL or other phospholipids, rescued both reduced activity of cytochrome c oxidase and 
increased generation of ROS in reperfused heart (Paradies et al., 2001; Petrosillo et al., 
2007). In this light, CL remodeling may be a mechanism whereby damaged fatty acyl 
chains are replaced. Although different approaches have been used, this proposed 
model is similar to the model described in Baile et al (Baile et al., 2013), in which they 
suggested a feedback loop between oxidative phosphorylation and CL remodeling. 
Specifically, they found that CLD1 expression is regulated by carbon sources, and the 
activity of Cld1 is increased by dissipating the mitochondrial membrane potential 
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Figure 2-6. Proposed model.   
Regulation of Cld1-mediated deacylation of CL influences energy 
metabolism.  CLD1 expression is upregulated in response to increased 
respiration.  Increased CLD1 expression modulates the relative contributions of 
oxidative phosphorylation and glycolysis to cellular energy production. We speculate 
that the function of CL deacylation, which is increased during respiratory conditions 
that are known to increase oxidative stress, is to remove peroxidized acyl chains 
from damaged CL.  
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(Baile et al., 2013). They suggested that CL remodeling functions to increase oxidative 
phosphorylation efficiency and/or replace peroxidized CL.  
Our findings have implications for understanding the mechanism underlying 
BTHS. Many studies of BTHS have concluded that the disorder is due to the complete 
lack of the ‘normal’ unsaturated (tetralinoleoyl, or L4) CL in the heart (Schlame et al., 
2003; Schlame and Ren, 2006; Schlame et al., 2002; Valianpour et al., 2003; Xu et al., 
2003). However, the current study indicates that in yeast, a total lack of the ‘normal’ 
unsaturated CL species is not deleterious to cells. The large number of mammalian 
phospholipases complicates the ability to distinguish between decreased CL/MLCL vs. 
decreased unsaturated CL in human cells. Gross and co-workers (Kiebish et al., 2013b) 
reported that ablation of phospholipase iPLA2g in the mouse reduced MLCL levels by 
only ~50% indicating that other phospholipases deacylate CL. Mass spectrometry 
analysis of phospholipase activity identified at least four phospholipases that deacylate 
CL in vitro (Hsu et al., 2013). The identification of mammalian CL-specific 
phospholipases may ultimately enable this question to be addressed. 
  
46 
 
 
 
ACKNOWLEGMENTS 
I collaborated with Cunqi Ye to conceive and design the study in this chapter. We 
prepared the experimental samples and collected the data. Specifically, I constructed 
the CLD1 expression plasmid and the cld1Δtaz1Δ strain; performed the experiments 
indicating effects of overexpression of CLD1 on cell growth, respiration, mitochondrial 
aconitase activity, and ethanol production. qPCR experiments were carried by Yiran Li 
(Figures 2-4D, E and 2-6C). A mass spectrometry analysis of lipid profile was performed 
by Shuliang Chen and the Amsterdam AMC group several years ago and was included 
in this study (Figures 2-3). Oxygen consumption and ATP measurements were carried 
out by Maik Huttemann’s lab (Figure 2-6A).  
 
  
47 
 
 
 
CHAPTER 3 LIPIDOMICS CHARACTERIZATION OF BIOSYNTHETIC 
AND REMODELING PATHWAYS OF CARDIOLIPINS IN GENETICALLY 
AND NUTRITIONALLY MANIPULATED YEAST CELLS 
 
The work described in this chapter has been published in Tyurina* Y. Y., W. Lou*, 
F. Qu*, V. A. Tyurin, D. Mohammadyani, J. Liu, M. Hüttemann, M. A. Frasso, P. Wipf, H. 
Bayir, M. L. Greenberg, and V. E. Kagan. 2016. Lipidomics characterization of 
biosynthetic and remodeling pathways of cardiolipins in genetically and nutritionally 
manipulated yeast cells. ACS Chemical Biology. *Equal contributors 
http://pubs.acs.org/doi/pdf/10.1021/acschembio.6b00995#notes-1 
INTRODUCTION 
The well-established tissue specificity of cardiolipins (CL)s (Kagan et al., 2015; 
Schlame, 2008) has led to a paradigm that the molecular speciation of CLs – achieved 
through the process of remodeling of the nascent species - is defined by the unique 
mitochondrial demands of a particular tissue. This commonly accepted paradigm has 
been recently challenged by a clear demonstration that unremodeled CLs are 
functionally indistinguishable from remodeled CLs for yeast mitochondrial morphology 
and major bioenergetic functions, such as in oxidative phosphorylation (OxPhos) (Baile 
et al., 2014), where it is a required structural component of the individual OxPhos 
complexes as well as supercomplexes (Eble et al., 1990; Mileykovskaya and Dowhan, 
2014; Pfeiffer et al., 2003; Poyry et al., 2013; Sharpley et al., 2006; Shinzawa-Itoh et al., 
2007). Recent findings have demonstrated that respiratory supercomplexes are 
destabilized by disturbed CL remodeling in heart mitochondria from tafazzin knockdown 
mice, resulting in disruption of interactions between the electron transporting complexes 
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and the fatty acid (FA) oxidation enzymes (Huang et al., 2015). 
The two major reactions in the remodeling process are a phospholipase-driven 
production of monolyso-CL (MLCL) intermediates followed by an acyltransferase 
(tafazzin) dependent “rebuilding” of the molecule that reacylates MLCL via the acyl-
CoA-independent transfer of an acyl group from a donor phospholipid (Baile et al., 2014; 
Beranek et al., 2009; Gu et al., 2004).    
Recent developments, elucidating the role of mitochondria as a platform 
coordinating many metabolic processes as well as life and death decisions, imply that 
essential functions not associated with bioenergetics may dictate the necessity for the 
highly diversified molecular speciation of CLs in tissues with signaling functions (e.g., in 
the brain). Not only has it been shown that mitochondria have functions other than 
bioenergetics, but CL in particular has extra-bioenergetic functions. The first 
demonstration of a role for CL in cell viability apart from bioenergetics was the 
demonstration that the crd1Δ (CL synthase) mutant has a temperature-sensitive growth 
defect, unlike yeast mitochondrial bioenergetics mutants which do not exhibit 
temperature sensitivity (Jiang et al., 1999). Perturbation of CL synthesis has been 
shown to affect MAPK signaling (Zhong et al., 2007; Zhou et al., 2009) and vacuolar 
function in yeast (Chen et al., 2008). This is in sharp contrast to such tissues as cardiac 
and skeletal muscles in which mitochondrial energy production dictates the dominance 
of homo-acylated tetraoleoyl-CL ((C18:1)4-CL) or tetralinoleoyl-CL ((C18:2)4-CL) 
species over a rich assortment of hetero-acylated CLs that may be required for 
signaling purposes (Patil and Greenberg, 2013; Tyurina et al., 2014).  
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CL signaling may be realized through the production of oxygenated lipid 
mediators (Tyurina et al., 2014), thus requiring CL species containing polyunsaturated 
fatty acids (PUFA). Therefore, the plasticity that is fine-tuned by adaptive changes in the 
microenvironment – rather than a rigid constitutive program – is likely to define the 
functions and mechanisms of CL remodeling. The machineries realizing these adaptive 
responses may include the availability of polyunsaturated fatty acids as well as 
enzymatic mechanisms involved in CL remodeling – including phospholipases A and 
acyl-transferases (Lu and Claypool, 2015; Schlame, 2013). 
Yeast cells may be ideal organisms for the exploration of these pathways 
because they: i) can be grown on media completely devoid of PUFA or supplemented 
with PUFA, ii) rely on only one CL-specific phospholipase A, Cld1, iii) utilize Taz1 as the 
major tool for reacylation of MLCL, and iv) employ only one – Cld1/Taz1-dependent – 
pathway for CL remodeling. With this in mind, in the current work we employed detailed 
phospholipidomics analysis to explore the effects of PUFA supplementation as well as 
cld1Δ and taz1Δ mutants on the molecular speciation of CLs in S. cerevisiae. Herein, 
we report the results of differential phospholipidomics studies of S. cerevisiae that 
provide new insights into CL remodeling and biosynthesis. Our findings identified the 
roles of Cld1 and Taz1 as the major regulatory mechanisms, which are governed by the 
availability of PUFA esterified into phospholipids that act as donors for the Taz1-
catalyzed reaction.  
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METHODS AND MATERIALS 
Yeast strains, media, and growth conditions—The Saccharomyces cerevisiae 
strains used in this work are listed in Table 2-1. Single deletion mutants were obtained 
from the yeast knock-out deletion collection (Invitrogen). Double mutants were obtained 
by tetrad dissection. Complex media contained yeast extract (1%), peptone (2%), and 
glucose (2%) (YPD) or glycerol (3%) and ethanol (1%) (YPGE). The effect of fatty acids 
was determined in YPD or YPGE medium supplemented with 0.2% oleic, arachidonic, 
linoleic, or docosahexaenoic acid solubilized in the media with tergitol (1%). 
Unsupplemented controls contained only tergitol. Synthetic complete (SC) medium 
contained all the essential components of Difco yeast nitrogen base, 2% glucose, 0.2% 
ammonium sulfate, vitamins, adenine (20.25 mg/L), arginine (20 mg/L), histidine (20 
mg/liter), leucine (60 mg/L), lysine (200 mg/liter), methionine (20 mg/L), threonine (300 
mg/L), tryptophan (20 mg/L), uracil (20 mg/L), and inositol (75 μM). For solid medium, 2% 
agar was added.  For selection of cells carrying plasmids, appropriate amino acids were 
omitted from the media. Yeast strains were grown at 30°C. E. coli strain DH5 was used 
for plasmid maintenance and amplification. Bacteria were grown at 37°C in LB medium 
(0.5% yeast extract, 1% tryptone, 1% NaCl), supplemented with ampicillin (100 μg/mL) 
for selection purposes. Solid medium contained 1.5% agar. Growth in liquid cultures 
was monitored spectrophotometrically. Cells were harvested and centrifuged at 4oC 
(4,300 rpm, 5 min). Supernatant was discarded and glass beads (0.3g) were added to 
the centrifuge tubes. Samples were vortexed (5 X 1min intervals) and frozen at -80oC 
for lipidomics analysis.   
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Construction of plasmids and expression of His6-tagged CLD1 in S. cerevisiae—
To construct a His6-tagged CLD1 overexpression plasmid, a 1373-bp sequence 
containing the entire open reading frame without stop codon of CLD1 was amplified 
from yeast genomic DNA using an EcoRI-tagged forward primer CLD1_EcoRI_F3 (5’-
TGATTAATAAGAATTCAACACAATGTTCAAGTCAACTTTAAACTC-3’) and an XbaI-
tagged reverse primer CLD1_XbaI_R3 (5’-
ATTTTGAGATTCTAGATATTTTTTGCATTTCTTTCG-3’). The PCR products were 
purified using the Wizard SV gel and PCR clean-up system (Promega). The purified 
DNA fragments were ligated into pYES2/CT cut with EcoRI and XbaI downstream of the 
GAL1 promoter. All the plasmids were amplified and extracted using standard protocols. 
The plasmids were transformed into yeast strains using a one-step transformation 
protocol. 
Purification of His6-tagged Cld1—S. cerevisiae strain BY4741 was used to express 
the recombinant His6-tagged Cld1. Cells were grown at 30°C in synthetic complete 
raffinose medium lacking uracil. Galactose (2%) was added to induce expression of the 
recombinant protein. Cell extracts were prepared by disrupting cells with glass beads 
(0.5 mm diameter), vortexing for 5 min intermittently in disruption buffer containing 50 
mM Tris-Cl (pH 8.0) and 300 mM NaCl. Protease inhibitor (cOmplete EDTA-free, Roche) 
was added to the disruption buffer before breaking the cells. His6-tagged Cld1 was 
purified with Millipore® PureProteome nickel magnetic beads following the 
manufacturer's instructions. Millipore® UFC503024 Amicon® Ultra-0.5 centrifugal filter 
concentrator (30 KD) was used to concentrate the protein and remove imidazole. 
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Protein concentration was determined with a BIO-RAD DC protein assay kit using 
bovine serum albumin as the standard. 
LC/MS assessment of phospholipids—Lipids were extracted from yeast using the 
Folch procedure (Folch et al., 1957) and lipid phosphorus was determined by a micro-
method (Boettcher et al., 1961). LC/MS of phospholipids was performed in negative 
mode using a Dionex UltimateTM 3000 RSLCnano system coupled online Q-Exactive 
hybrid quadrupole-orbitrap mass spectrometer (ThermoFisher Scientific, San Jose, CA). 
Total lipids were separated on a normal phase column (Silica Luna 3 µm, 100A, 150x2 
mm, (Phenomenex, Torrance CA)) with flow rate 0.2 mL/min using gradient solvents 
containing 5 mM CH3COONH4 (A – n-hexane:2-propanol:water, 43:57:1 (v/v/v) and B - 
n-hexane:2-propanol:water, 43:57:10 (v/v/v). The gradient conditions (all linear) were as 
follows: 0-23 min (10%B to 32%B); 23-32 min (32%B to 65%B); 32-35 min (65%B to 
100%B) 35-62 min (hold at 100%B); 62-64 min (100%B to 10%B); 64-80 min (10%B). 
Flow rate was maintained at 200 microliters/min except for the 35-62 min time frame 
where the flow rate was increase to 225 microliters/min. MS analysis was performed in 
negative ion mode (profile) at a resolution of 140,000 for the full MS scan and 17,500 for 
the MS2 scan in a data-dependent mode with appropriate inclusion and exclusion lists. 
The scan range for MS analysis was 400-1800 m/z with a maximum injection time of 
128 ms using 1 microscan. A maximum injection time of 500 ms was used for MS2 (high 
energy collisional dissociation (HCD)) analysis with collision energy set to 24. An 
isolation window of 1.0 Da was set for the MS2 scans. Capillary spray voltage was set at 
3.5 kV, and capillary temperature was 320 oC. The S-lens Rf level was set to 60 with a 
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sheath gas flow of 8. To quantitatively assess phospholipids, PE-(17:0/17:0); PC-
(17:0/17:0); CL-(14:0/14:0/14:0/14:0); LPE-(17:1/0:0); LPC-(17:1/0:0) from Avanti Polar 
Lipids have been used as internal standards. Reference standards PE-(18:1/18:1); PC-
(18:1/18:1); CL-(18:2/18:2/18:2/18:2); LPE-(18:0/0:0); LPC-(18:0/0:0) were used for 
calibrations and were also from AvantiPolar Lipids. Both Internal and reference 
standards of MLCLs were prepared from CL-(14:0/14:0/14:0/14:0) CL-
(18:2/18:2/18:2/18:2), respectively as described (Kim and Hoppel, 2011). Precursor ions 
[M-H]- were identified with mass accuracy less than 5ppm. Therefore, phospholipids, 
including CL, were identified by accurate mass and MS2 fragmentation analysis. The 
fragmentation pattern provided information on fatty acids but not on their position. 
Assuming that sn-1 position in phospholipids is commonly occupied by saturated and 
monounsaturated acids we used this information to identify PE and PC molecular 
species. Clearly, this is a more difficult task for CL molecular species with four acyl 
chains in the molecule.  Therefore, we presented CL molecular species based on the 
information provided in the paper by Liebisch et al.(Liebisch et al., 2013). Spectra 
subtraction was done by Background Subtraction Module in Xcalibur (Thermo Fisher 
Scientific). By defining one file as background (subtractor) and another file as 
foreground (minuend), the difference can be evaluated from the differential spectra. 
Since negative spectra cannot be calculated and exported from Xcalibur, we performed 
swapping of the subtractor and the minuend which afforded the calculations and 
presentation of the negative spectra.  
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Respiration measurements—Oxygen consumption rate (OCR) of intact yeast cells 
was analyzed via the polarographic method in a closed 500 L chamber equipped with 
a micro Clark-type oxygen electrode (Oxygraph Plus System, Hansatech Instruments) 
at 30°C. Yeast cells were grown in synthetic YPD media supplemented with oleic acid, 
linoleic acid, or arachidonic acid. Cells were harvested during the stationary phase. 
Cells were mixed in fresh media using a final protein concentration of 0.5 mg/mL 
following measurements of respiration. KCN (0.2 mM) was added at the end of the 
experiment to inhibit cytochrome c oxidase to correct for cytochrome c oxidase-
independent oxygen utilization. Oxygen consumption was recorded on a computer and 
analyzed with the Oxygraph plus software. Oxygen consumption rate (ORC) is defined 
as consumed O2 (nmol)/min/total protein (mg). 
Synthesis of Cardiolipins—General Experimental Conditions. All air and moisture 
sensitive reactions were carried out under a nitrogen or argon atmosphere. All reactions 
carried out above room temperature were performed using an oil bath set to the 
specified temperature and monitored with an external thermometer. THF and diethyl 
ether were distilled from sodium/benzophenone ketyl. Dichloromethane was distilled 
from CaH2. Diisopropylethylamine (DIPEA) and diisopropylamine were distilled from and 
stored over KOH. Pyridine was filtered through activated basic alumina and stored over 
freshly activated 4 Å molecular sieves for at least 24 h prior to use. Amberlite-IR120H 
resin was activated by stirring with 6 N HCl for 30 min, filtering, and rinsing once with 
equal volumes of water and methanol. All other reagents were used as received. 
Concentrating under reduced pressure refers to removing solvents by the use of a 
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rotary evaporator connected to a PIAB Lab Vac H40. Reactions were monitored by thin 
layer chromatography analysis (pre-coated silica gel 60 F254 plates, 250 μm layer 
thickness) and visualized with a 254 nm UV light or by staining with a KMnO4 solution. 
Flash chromatography on SiO2 (Silicycle, 40-63 μm) was used for purification where 
indicated. All products were placed under high vacuum to remove trace solvents. 
Melting points were determined using a Laboratory Devices Mel-Temp II and are 
uncorrected. Infrared spectra were obtained from neat solids or oils on a Perkin Elmer 
ATR IR or Smiths Detection IdentifyIR FT-IR spectrometer. High-resolution mass 
spectra were obtained on a Thermo Scientific Exactive Orbitrap mass spectrometer 
using electrospray ionization. Low-resolution mass spectra were obtained on an Advion 
Expression L compact mass spectrometer using electrospray ionization. 1H NMR 
spectra were obtained on a Bruker Avance at 300 MHz, 400 MHz, or 500 MHz in CDCl3, 
CD2Cl2, or CD3OD. Chemical shifts were reported in parts per million with the residual 
solvent peak used as an internal standard 1H / 13C (solvent): 7.26 / 77.00 (CDCl3); 
5.32/53.84 (CD2Cl2). 1H NMR spectra were obtained and are tabulated as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of 
doublets, m = multiplet, bs = broad singlet), number of protons, and coupling constant(s). 
13C NMR spectra were recorded using a proton-decoupled pulse sequence run at 100 
MHz or 125 MHz and are tabulated by observed peaks. 31P NMR spectra were recorded 
using a complete decoupled pulse sequence run at 162 MHz. 
 
O OH
OH
C15H31
O
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1-O-Palmitoylglycerol (1a) (Lok et al., 1985; Mori, 2012). General Procedure A. A 
solution of palmitic acid (5.5 g, 21.4 mmol, 1.0 eq.), 50% glycidol in CH2Cl2 (3.0 mL, 
22.8 mmol, 1.06 eq.) and tributylamine (0.1 mL, 0.4 mmol, 0.02 eq.) was heated to 
85 °C and stirred for 5 h. The crude product was recrystallized from i-Pr2O:Et2O (1:1) to 
yield 1-O-palmitoylglycerol (1a, 4.88 g, 14.8 mmol, 69%) as a colorless solid: Mp 71.9-
72.5 °C; IR 3293, 2913, 2848, 1728 cm-1; 1H NMR (CDCl3, 300 MHz) 4.22 (dd, 1 H, J = 
4.8, 11.7 Hz), 4.15 (dd, 1 H, J = 6.0, 11.4 Hz), 3.97-3.90 (m, 1 H), 3.70 (dd, 1 H, J = 4.2, 
11.7 Hz), 3.60 (dd, 1 H, J = 5.7, 11.4 Hz), 2.35 (t, 2 H, J = 7.7 Hz), 1.66-1.58 (m, 2 H), 
1.28-1.25 (m, 25 H), 0.85 (t, 3 H, J = 6.8 Hz); 13C NMR (CDCl3, 100 MHz) 174.4, 70.3, 
65.2, 63.3, 34.1, 31.9, 29.7-29.6 (multiple peaks), 29.4, 29.3, 29.1, 24.9, 22.7, 14.1.  
 
1-O-Stearoylglycerol (1b) (Lok et al., 1985; Mori, 2012). According to General 
Procedure A but using stearic acid, 1-O-stearoylglycerol (1b, 4.36 g, 12.2 mmol, 71%) 
was obtained as a colorless solid: 1H NMR (CDCl3, 300 MHz) 4.21 (dd, 1 H, J = 4.8, 
11.7 Hz ), 4.14 (dd, 1 H, J = 5.7, 11.4 Hz), 3.96-3.90 (m, 1 H), 3.70 (dd, 1 H, J = 3.9, 
11.4 Hz), 3.60 (dd, 1 H, J = 6.0, 11.4 Hz), 2.71 (bs, 2 H), 2.35 (t, 2 H, J = 7.7 Hz), 1.65-
1.60 (m, 2 H), 1.28-1.25 (m, 29 H), 0.88 (t, 3 H, J = 6.6 Hz). 
 
1,2-O-Dipalmitoyl-3-O-dimethoxyltriylglycerol (2a). General Procedure B. To a solution 
of 1a (4.57 g, 13.8 mmol, 1.0 eq.) in pyridine:CH2Cl2 (1:2, 35 mL) at 0 °C was added 
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dimethoxyltrityl chloride (DMTCl, 4.82 g, 14.1 mmol, 1.0 eq.) and dimethylaminopyridine 
(DMAP, 0.177 g, 1.43 mmol, 0.1 eq.) The orange solution was stirred at this 
temperature for 15 min., then warmed to room temperature and stirred for 13 h. The 
orange reaction mixture was quenched with water (30 mL) and extracted with CH2Cl2 
(2x50 mL). The organic portion was rinsed with water (40 mL), brine (40 mL), dried 
(MgSO4), and concentrated. The residue was then concentrated from toluene (2x20 mL) 
and the resulting orange oil used without further purification. A solution of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDCI, 2.93 g, 15.3 mmol, 1.1 eq.), palmitic acid 
(3.91 g, 15.3 mmol, 1.1 eq.) and DMAP (0.851 g, 6.90 mmol, 0.5 eq.) in CH2Cl2 (60 mL) 
was allowed to stir at room temperature under nitrogen for 15 min. Then, a solution of 
the previously obtained oil from the dimethoxyltrityl protection (8.77 g, 13.9 mmol 1.0 eq) 
in CH2Cl2 (30 mL) was added and stirring was continued for 4 h. The reaction mixture 
was diluted with water (50 mL) and the organic layer was rinsed with water (50 mL), 
brine (50 mL), dried (MgSO4), and concentrated. Purification by filtration through SiO2 
(9:1 CH2Cl2:hexanes) gave 1,2-O-dipalmitoyl-3-O-dimethoxyltriylglycerol (2a, 7.94 g, 
9.11 mmol, 66%) as a colorless solid. Pure 2a can also be obtained by repeated 
trituration with MeOH. Mp 64.5-66.0 °C; IR 2915, 2846, 1729 cm-1; 1H NMR (CDCl3, 300 
MHz) 7.42 (d, 2.0 H, J = 2 Hz), 7.40-7.20 (m, 7 H), 6.82 (d, 4 H, J = 8.7 Hz), 5.28-5.22 
(m, 1 H), 4.34 (dd, 1 H, J = 3.6, 11.7 Hz), 4.25 (dd, 1 H, J = 6.6, 11.7 Hz), 3.79 (s, 6 H), 
3.22 (d, 2 H, J = 5.1 Hz), 2.33 (t, 2 H, J = 7.5 Hz), 2.23 (t, 2 H, J = 7.5 Hz), 1.65-1.53 (m, 
4 H), 1.28-1.25 (m, 48 H), 0.91 (t, 3 H, J = 6.6 Hz); 13C NMR (CDCl3, 125 MHz) 173.4, 
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173.0, 158.5, 144.5, 135.7, 130.0, 128.1, 127.8, 126.8, 113.1, 86.0, 70.5, 62.9, 62.0, 
55.1 34.4, 34.1, 31.9, 29.7-29.1 (multiple peaks), 25.0, 24.8, 22.7, 14.1. 
 
1,2-O-Distearoyl-3-O-dimethoxyltriylglycerol (2b). According to General Procedure B but 
using 1b and purification by trituration with MeOH gave 1,2-O-distearoyl-3-O-
dimethoxyltriylglycerol (2b, 6.68 g, 6.48 mmol, 53%) as a colorless solid: Mp 67-68.4 °C; 
IR 2915, 2848, 1730 cm-1; 1H NMR (CDCl3, 300 MHz) 7.45 (d, 2 H, J = 7.2 Hz), 7.35-
7.24 (m, 7 H), 6.85 (d, 4 H, J = 9.0 Hz), 5.29-5.28 (m, 1 H), 4.35 (dd, 1 H, J = 8.1, 11.7 
Hz), 4.25 (dd, 1 H, J = 6.6, 11.7 Hz), 3.82 (s, 6 H), 3.25 (d, 2 H, J = 3.3 Hz), 2.36 (t, 2 H, 
J = 7.5 Hz), 2.27 (t, 2 H, J = 7.5 Hz), 1.69-1.56 (m, 4 H), 1.29 (m, 58 H), 0.91 (t, 3 H, J = 
6.6 Hz); 13C NMR (CDCl3, 125 MHz) 173.4, 173.0, 158.5, 144.6, 135.8, 130.1, 128.1, 
127.8, 126.8, 113.1, 113.0, 86.1, 70.5, 62.9, 62.1, 55.2, 34.4, 34.1, 31.9, 29.7-29.1 
(multiple peaks), 25.0, 24.8, 22.7, 14.1. 
 
1-O-Palmitoyl-2-O-palmitoleoyl-3-O-dimethoxyltriylglycerol (2c). According to General 
Procedure B but using 1a and purification by chromatography on SiO2 (95:5, 
hexanes:ethyl acetate) gave 1-O-palmitoyl-2-O-palmitoleoyl-3-O-dimethoxyltriylglycerol 
(2c, 0.619 g, 0.712 mmol, 65%) as a clear colorless oil: IR 2923, 2853, 2093, 1741, 
1250 cm-1; 1H NMR (CDCl3, 300 MHz) 7.43 (d, 2 H, J = 8.4 Hz), 7.31-7.25 (m, 7 H), 6.82 
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(d, 4 H, J = 8.7 Hz), 5.40-5.30 (m, 2 H), 5.29-5.22 (m, 1 H), 4.34 (dd, 1 H, J = 3.6, 11.7 
Hz), 4.23 (dd, 1 H, J = 6.6, 12.0 Hz), 3.79 (s, 6 H), 3.23-3.21 (m, 2 H), 2.33 (t, 2 H, J = 
7.5 Hz), 2.23 (t, 2 H, J = 7.7 Hz), 2.02-2.00 (m, 4 H), 1.67-1.53 (m, 4 H), 1.29 (m, 40 H), 
0.88 (t, 6 H, J = 6.8 Hz); 13C NMR (CDCl3, 125 MHz) 173.4, 173.0, 158.5, 144.6, 135.8, 
135.7, 130.0, 129.7 128.1, 127.8, 126.8, 113.1, 86.1, 70.5, 62.9, 62.0, 55.2, 34.4, 34.1, 
31.9, 31.8, 29.8-29.0 (multiple peaks), 27.2, 25.0, 24.9, 22.7, 22.6, 14.1. 
 
1,2-O-Dipalmitoylglycerol (3a) (Roodsari et al., 1999). General Procedure C. To a 
solution of 2a (7.94 g, 9.11 mmol, 1.0 eq.) in CHCl3:MeOH (1:1, 90 mL) was added 
Amberlite IR-120H (4.0 g). The reaction mixture was stirred for 2.5 h, then filtered 
through basic alumina (EtOAc). The resulting yellow oil was precipitated from 
Et2O:hexanes (3:1) and filtered to give 1,2-O-dipalmitoylglycerol (3a, 3.75 g, 5.50 mmol, 
60%, purity by 1H NMR: 90%) as a colorless solid: 1H NMR (CDCl3, 400 MHz) 5.10-5.06 
(m, 1 H), 4.32 (dd, 1 H, J = 4.8, 12.0 Hz), 4.24 (dd, 1 H, J = 6.0, 12.0 Hz), 3.74-3.73 (m, 
2 H), 2.33 (apparent q, 4 H, J = 8 Hz), 1.65-1.58 (m, 4 H), 1.28-1.25 (m, 48 H), 0.88 (t, 3 
H, J = 6.6 Hz).  
 
1,2-O-Distearoylglycerol (3b) (Lee et al., 2007). According to General Procedure C but 
using 2b, and purification by trituration with Et2O:hexanes (3:1) gave 1,2-O-
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distearoylglycerol (3b, 2.08 g, 3.39 mmol, 72%) as a colorless solid: 1H NMR (CDCl3, 
500 MHz) 5.10-5.06 (m, 1 H), 4.32 (dd, 1 H, J1 = 4.5 Hz, J2 = 12 Hz), 4.24 (dd, 1 H, J1 = 
5.5 Hz, J2 = 12 Hz), 3.79-3.72 (m, 2 H), 2.34 (m, 4 H), 1.99 (t, 1 H, J = 4.0 Hz), 1.64-
1.54 (m, 4 H), 1.29-1.25 (m, 56 H), 0.88 (t, 3 H, J = 7.0 Hz). 
 
1-O-Palmitoyl-2-O-palmitoleoylglycerol (3c). According to General Procedure C but 
using 2c and purification by chromatography on SiO2 (1:0 to 5:1, CH2Cl2:ethyl acetate) 
gave 1-O-palmitoyl-2-O-palmitoleoylglycerol (3c, 64 mg, 0.113 mmol, 98%) as a light 
yellow oil: IR 3502, 2919, 2850, 2093, 1737, 1163 cm-1; 1H NMR (CDCl3, 300 MHz) 
5.40-5.30 (m, 2 H), 5.10-5.05 (m, 1 H), 4.32 (dd, 1 H, J = 4.8, 12.3 Hz), 4.24 (dd, 1 H, J 
= 5.4, 11.7 Hz), 3.73 (m, 2 H), 2.33 (apparent q, 4 H, J = 7.3 Hz), 2.02-2.00, (m, 4 H), 
1.64-1.54 (m, 4 H), 1.30-1.27 (m, 40 H), 0.88 (t, 6 H, J = 6.7 Hz); 13C NMR (CDCl3, 125 
MHz) 173.8, 173.4, 130.0, 129.7 128.1, 72.1, 62.0, 61.6, 34.3, 34.1, 31.9, 29.7-29.0 
(multiple peaks), 27.2, 25.0, 24.9, 22.7, 22.6, 14.1; HRMS (ESI+) m/z calculated for 
C35H67O5 [M+H] 567.4983, found 567.4960. 
 
N, N-Diisopropylamidomethylchlorophosphite (4) (Stadlbauer et al., 2009). To a solution 
of PCl3 (3.2 mL, 36 mmol, 1.04 eq.) and pyridine (2.9 mL, 36 mmol, 1.04 eq.) in Et2O 
(120 mL) at -78 °C under argon was added dry MeOH (1.4 mL, 35 mmol, 1.0 eq.) in 
Et2O (4 mL) over 30 min. The reaction mixture was stirred for 3 h at room temperature. 
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diluted with Et2O (40 mL) and cooled to 0 °C. Diisopropylamine (9.6 mL, 67.9 mmol, 2.0 
eq.) was added over 0.5 h and stirring was continued for 22 h at room temperature. The 
salts were filtered off under argon, rinsed with Et2O (50 mL) and the solvent was 
distilled off. The resulting yellow oil was purified by vacuum distillation to give N,N-
diisopropylamidomethylchlorophosphite (4, 3.73 g, 18.9 mmol, 56%) as a clear colorless 
oil: Bp 88 °C (12 Torr); 1H NMR (CD2Cl2, 400 MHz) 3.74-3.64 (m, 2 H), 3.51 (d, 3 H, J = 
14.4 Hz), 1.20-1.16 (m, 12 H); 31P NMR (CD2Cl2, 162 MHz) 183.8.  
 
4-((Benzyloxy)methyl)-2,2-dimethyl-1,3-dioxolane (5). (Lee et al., 2007) A slurry of 60% 
NaH in mineral oil (360 mg, 9.00 mmol, 1.2 eq.) in THF (10 mL) at 0 °C under nitrogen 
was added to a solution of 2,2-dimethyl-1,3-dioxolane-4-methanol (1.0 mL, 7.8 mmol, 
1.0 eq.) in THF (5 mL). The reaction mixture was stirred for 30 min, then BnBr (0.98 mL, 
1.4 mmol, 1.05 eq.) was added in a drop wise fashion. The reaction mixture was 
warmed to room temperature and stirred for 2.5 h. The reaction was quenched with 
water (8 mL), diluted with Et2O (20 mL), and the layers were separated. The aqueous 
layer was extracted with Et2O (25 mL) and the combined organic layers were rinsed with 
brine (10 mL), dried (MgSO4), and concentrated. Purification by chromatography on 
SiO2 (95:5 to 9:1 to 85:15, hexanes:ethyl acetate) gave 4-((benzyloxy)methyl)-2,2-
dimethyl-1,3-dioxolane (5, 1.15 g, 5.17 mmol, 67%) as a clear colorless oil: 1H NMR 
(CDCl3, 400 MHz) 7.35-7.29 (m, 5 H), 4.59, 4.56 (AB, 2 H, J = 12.0 Hz), 4.34-4.28 (m, 1 
H), 4.06 (dd, 1 H, J = 6.4, 8.0 Hz), 3.75 (dd, 1 H, J = 6.4, 8.4 Hz), 3.56, 3.45 (ABd, 2 H, 
J = 5.6, 9.6 Hz), 3.46 (dd, 1 H, J = 5.6, 9.6 Hz), 1.42 (s, 3 H), 1.37 (s, 3 H). 
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1-O-Benzyl-2,3-O-bis(tert-butyldimethylsilyl)glycerol (6). A solution of 5 (1.15 g, 5.17 
mmol, 1.0 eq.) in THF:H2O (2:1, 10 mL) was treated with 12 M HCl (2.1, 25 mmol, 4.9 
eq.), and the reaction mixture was stirred for 1 h at room temperature, poured into sat. 
NaHCO3 (30 mL) and extracted with Et2O (3x 25 mL). The combined organic layers 
were rinsed brine (25 mL), dried (MgSO4), and concentrated. The resulting yellow oil 
was dissolved in CH2Cl2 (8.7 mL) at 0 °C under nitrogen and treated with Et3N (1.4 mL, 
9.9 mmol, 2.3 eq.) and TBSOTf (2.2 mL, 9.5 mmol, 2.2 eq.). The cloudy white reaction 
mixture was then stirred for 3 h at room temperature, quenched with H2O (8 mL) and 
diluted with CH2Cl2 (10 mL). The organic layer was rinsed with brine (8 mL), dried 
(MgSO4), and concentrated. Purification by chromatography on SiO2 (99:1 to 95:5, 
hexanes:ethyl acetate) gave 1-O-benzyl-2,3-O-bis(tert-butyldimethylsilyl)glycerol (6, 
1.72, 4.31 mmol, 83% over 2 steps) as a clear colorless oil: 1H NMR (CDCl3, 500 MHz) 
7.35-7.33 (m, 4 H), 7.28-7.26 (m, 1 H), 4.54 (s, 2 H), 3.89-3.84 (m, 1 H), 3.61 (dd, 1 H, J 
= 6.0, 10.0 Hz), 3.57-3.52 (m, 2 H), 3.42 (dd, 1 H, J = 5.5, 10.0 Hz), 0.87 (s, 18 H), 
0.070 (d, 6 H, J = 1.5 Hz), 0.042 (s, 6 H).  
 
2,3-O-Bis(tert-butyldimethylsilyl)glycerol (7). (Harried et al., 2009) To a solution of 6 
(1.62 g, 4.06 mmol, 1.0 eq.) in ethyl acetate (20 mL) was added 10% Pd/C (0.161 g, 
0.152 mmol, 0.037 eq.). The reaction mixture was submitted to hydrogenation on a Parr 
hydrogenator under H2 (5 atm) for 1 h, filtered through Celite (ethyl acetate) and 
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concentrated to give 2,3-O-bis(tert-butyldimethylsilyl)glycerol (7, 1.15 g, 3.59 mmol, 
88%) as a clear colorless oil that was used without further purification. An analytically 
pure sample was obtained by chromatography on SiO2 (95:5 to 9:1, hexanes:ethyl 
acetate): 1H NMR (CDCl3, 300 MHz) 3.79-3.74 (m, 1 H), 3.69-3.53 (m, 4 H), 2.10 (bs, 1 
H), 0.90 (s, 18 H), 0.1-0.06 (m, 12 H).  
 
3-(((2,3-Bis((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-
diyl dipalmitate (8a).7 General Procedure D. To a solution of 3a (1.73 g, 2.89 mmol, 1.0 
eq.) and diisopropylethylamine (DIPEA, 0.53 mL, 3.2 mmol, 1.1 eq.) in CH2Cl2 (30 mL) 
under nitrogen was added 7 (6.0 mL, 3.0 mmol, 1.1 eq.). The reaction mixture was 
stirred for 1 h, and treated dropwise with a solution of 6 (0.921 g, 2.87 mmol, 0.99 eq.) 
and 4,5-dicyanoimidazole (0.700 g, 5.80 mmol, 2 eq.) in THF (4.9 mL). The solution was 
stirred for 1 h, cooled to 0 °C, treated with Bu4NIO4 (1.46 g, 3.36 mmol, 1.2 eq.), and 
stirring was continued for 30 min. The mixture was diluted with water (15 mL) and the 
combined organic layers were rinsed with sat. Na2S2O3 (15 mL), sat. NaHCO3 (15 mL), 
and brine (15 mL), dried (MgSO4), and concentrated. The crude residue was filtered 
through a plug of SiO2 (1:1, hexanes:ethyl acetate) and concentrated. Purification by 
chromatography on SiO2 (5:1 to 3:1, hexanes:ethyl acetate) gave 3-(((2,3-bis((tert-
butyldimethylsilyl)oxy)propoxy)(methoxy) phosphoryl)oxy)propane-1,2-diyl dipalmitate 
(8a, 1.42 g, 1.47 mmol, 51%) as a clear colorless oil: IR 2922, 2854, 1741, 1252, 835 
cm-1; 1H NMR (CDCl3, 300 MHz) 5.25-5.19 (m, 1 H), 4.36-4.30 (m, 1 H), 4.19-4.09 (m, 4 
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H), 3.97-3.83 (m, 2 H), 3.76 (d, 3 H, J =11.1 Hz; diasteromers), 3.56-3.54 (m, 2 H), 
2.34-2.27 (m, 4 H), 2.23 (t, 2 H, J = 7.5 Hz), 1.61-1.56 (m, 4 H), 1.28-1.25 (m, 48 H), 
0.88-0.85 (m, 24 H), 0.08 (s, 3 H), 0.07 (s, 3 H), 0.05 (s, 6 H); 13C NMR (CDCl3, 125 
MHz) 173.2, 172.7, 72.0 (d, J = 7.5 Hz), 69.4 (d, J = 7.5 Hz), 69.1 (d, J = 6.5 Hz), 65.4-
65.3 (multiple peaks), 64.0, 61.6, 55.4 (d, J = 6.3 Hz)  34.1, 34.0, 31.9, 31.6, 29.7-29.1 
(multiple peaks), 25.8, 25.7, 24.8, 22.6, 18.3, 18.1,14.1, -4.7, -4.8, -5.5; HRMS (ESI+) 
m/z calculated for C51H106O10PSi2 [M+H]+ 965.7057, found 965.7086. 
 
3-(((2,3-Bis((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-
diyl distearate (8b). (Harried et al., 2009) According to General Procedure D but using 
3b and purification by chromatography on SiO2 (5:1, hexanes:ethyl acetate) gave 3-
(((2,3-bis((tert-butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl 
distearate (8b, 0.605 g, 0.592 mmol, 67%) as a waxy colorless solid: Mp 31.0-31.9 °C; 
IR 2923, 2852, 1743, 1252, 835 cm-1; 1H NMR (CDCl3, 300 MHz) 5.24-5.20 (m, 1 H), 
4.37-4.31 (m, 1 H), 4.22-4.09 (m, 4 H), 3.97-3.84 (m, 2 H), 3.76 (d, 3 H, J =11.1 Hz; 
diasteromers), 3.57-3.54 (m, 2 H), 2.31 (apparent q, 4 H, J = 7.0 Hz), 1.61-1.57 (m, 4 H), 
1.28-1.25 (m, 56 H), 0.88-0.86 (m, 24 H), 0.09 (s, 3 H), 0.08 (s, 3 H), 0.05 (s, 6 H); 13C 
NMR (CDCl3, 125 MHz) 173.2, 172.2, 72.0 (d, J = 8.8 Hz), 69.4 (d, J = 7.5 Hz), 69.2-
69.1 (m), 65.4-65.3 (m), 64.0, 61.6, 54.4 (d, J = 5.0 Hz), 34.2, 34.0, 31.9, 29.7-29.1 
(multiple peaks), 25.9, 25.7, 24.8, 22.7, 22.6, 18.3, 18.1,14.1, -4.7, -4.8, -5.4, -5.5; 
HRMS (ESI+) m/z calculated for C55H114O10PSi2 [M+H]+ 1021.7688, found 1021.7766. 
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3-(((2-((Tert-butyldimethylsilyl)oxy)-3-hydroxypropoxy)(methoxy)phosphoryl)oxy) 
propane-1,2-diyl dipalmitate (9a). General Procedure E. To a solution of 8a (800 mg, 
0.829 mmol, 1.0 eq.) in CH2Cl2:MeOH (1:1, 8.3 mL) at 0 °C was added camphorsulfonic 
acid (195 mg, 0.823 mmol, 1.0 eq.). The reaction mixture was maintained between -5 
and 5 °C and stirred for 5.5 h. The solution was filtered through a small plug of basic 
alumina (ethyl acetate) and concentrated. Purification by chromatography on SiO2 (3:1 
to 1:1, hexanes:ethyl acetate) gave 3-(((2-((tert-butyldimethylsilyl)oxy)-3-
hydroxypropoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate (9a, 435 mg, 
0.511 mmol, 62%) as a colorless solid: Mp 27.8-28.0 °C; IR 2922, 2854, 1741, 1252, 
835 cm-1; 1H NMR (CDCl3, 400 MHz) 5.29-5.20 (m, 1 H), 4.33 (dd, 1 H, J = 4.4, 12.0 Hz), 
4.21-4.14 (m, 3 H), 4.06-4.01 (m, 2 H), 3.93-3.89 (m, 1 H), 3.80-3.76 (m, 3 H), 3.67-3.50 
(m, 2 H), 2.35-2.31 (m, 5 H), 1.62-1.60 (m, 4 H), 1.28-1.25 (m, 48 H), 0.90-0.86 (m, 15 
H), 0.11 (s, 6 H); 13C NMR (CDCl3, 100 MHz) 173.2, 172.8, 71.1 (d, J = 7.0 Hz), 69.4-
69.3 (multiple peaks), 67.7 (m), 65.6-65.5 (multiple peaks), 63.0, 61.6, 54.6 (multiple 
peaks), 34.1, 34.0, 31.9, 29.7-29.1 (multiple peaks), 25.7, 24.8, 22.7, 18.0, 14.1, -4.8, -
4.9; HRMS (ESI+) m/z calculated for C45H92O10PSi [M+H]+ 851.6192, found 851.6180. 
 
O O
O
C15H31
O
C15H31
O
P
OMe
O
O
OH
OTBS
O O
O
C17H35
O
C17H35
O
P
OMe
O
O
OH
OTBS
66 
 
 
 
3-(((2-((Tert-butyldimethylsilyl)oxy)-3-hydroxypropoxy)(methoxy)phosphoryl)oxy) 
propane-1,2-diyl distearate (9b). According to General Procedure E but using 8b and 
purification by chromatography on SiO2 (4:1 to 1:1, hexanes:ethyl acetate) gave 3-(((2-
((tert-butyldimethylsilyl)oxy)-3-hydroxypropoxy)(methoxy)phosphoryl)oxy)propane-1,2-
diyl distearate  (9b, 470 mg, 0.518 mmol, 55%) as a waxy colorless solid: Mp = 41.2-
41.7 °C; IR 3535, 2921, 2850, 1739, 733 cm-1; 1H NMR (CDCl3, 300 MHz) 5.25-5.22 (m, 
1 H), 4.34 (dd, 1 H, J = 4.2, 12.0 Hz), 4.19-4.11 (m, 3 H), 4.05-4.02 (m, 2 H), 3.95-3.90 
(m, 1 H), 3.78 (d, 3 H, J  = 11.4 Hz; diasteromers), 3.67-3.60 (m, 2 H), 2.36-2.29 (m, 5 
H), 1.62-1.58 (m, 4 H), 1.28-1.25 (m, 56 H), 0.90-0.86 (m, 15 H), 0.11 (s, 6 H); 13C NMR 
(CDCl3, 125 MHz) 173.3, 172.8, 71.1 (d, J = 7.1 Hz), 69.4 (multiple peaks), 67.7 
(multiple peaks), 65.6 (multiple peaks), 63.0, 61.6, 54.6 (multiple peaks), 34.2, 34.0, 
31.9, 29.7-29.1 (multiple peaks), 25.7, 24.8, 22.7, 18.0, 14.1, -4.7, -4.9; HRMS (ESI+) 
m/z calculated for C49H100O10PSi [M+H]+ 907.6818, found 907.6785. 
 
3-(((3-(((2,3-(Palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tert-
butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate 
(10a). (Harried et al., 2009) To a solution of 9a (322 mg, 0.378 mmol, 1.0 eq.) in CH2Cl2 
(3.7 mL) at 0 °C under nitrogen was added DIPEA (0.069 mL, 0.42 mmol, 1.1 eq.) and a 
0.5 M solution of 7 in CH2Cl2 (0.83 mL, 0.42 mmol, 1.1 eq.). The reaction mixture was 
warmed to room temperature, stirred for 1.5 h, and treated with a solution of 3a (364 mg, 
0.416 mmol, 1.1 eq.) and 4,5-dicyanoimidazole (90 mg, 0.76 mmol, 2.0 eq.) in THF (1.5 
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mL) in a drowpwise fashion. The reaction mixture was stirred for 2 h, cooled to 0 °C, 
treated with Bu4NIO4 (186 mg, 0.429 mmol, 1.1 eq.) and stirred for 40 min. The mixture 
was diluted with water (3 mL) and CH2Cl2 (5 mL) and and the organic layer was rinsed 
with sat. Na2S2O3 (3 mL) and brine (3 mL), dried (MgSO4), and concentrated. The crude 
product was filtered through a plug of SiO2 (1:1 hexanes:ethyl acetate) and 
concentrated. Purification by chromatography on SiO2 (3:1 to 2:1 to 1:1, hexanes:ethyl 
acetate) gave 3-(((3-(((2,3-(palmitoyloxy)propoxy)(methoxy) phosphoryl)oxy)-2-((tert-
butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate 
(10a, 381 mg, 0.255 mmol, 67%) as a colorless solid: Mp 36.5-37.5 °C; IR  2913, 
2848, 1737, 1465, 913, 744 cm-1; 1H NMR (CDCl3, 400 MHz) 5.25-5.22 (m, 2 H), 4.36-
4.31 (m, 2 H), 4.22-4.12 (m, 6 H), 4.05-3.97 (m, 5 H), 3.78 (d, 6 H, J = 11.2 Hz; 
diasteromers), 2.32 (apparent q, 8 H, J = 7.9 Hz), 1.61-1.57 (m, 8 H), 1.28-1.25 (m, 96 
H), 0.89-0.86 (m, 21 H), 0.11 (s, 6 H); 13C NMR (CDCl3, 125 MHz)  173.1, 172.7, 69.8 
(multiple peaks), 69.4 (d, J = 6.3 Hz), 67.8 (2, J = 6.3 Hz), 65.7 (multiple peaks), 61.6, 
54.6 (d, J = 6.3 Hz), 34.2, 34.0, 31.9, 29.7-29.1 (multiple peaks), 25.6, 24.9, 22.7, 18.0, 
14.1, -4.9; HRMS (ESI+) m/z calculated for C81H161O17P2Si [M+H]+ 1496.0973, found 
1496.0903. 
 
3-(((3-(((2,3-(Stearoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tert-
butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl distearate 
(10b). General Procedure F (Abe et al., 2011). To a solution of 3b (356 mg, 0.570 mmol, 
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1.0 eq.) and DIPEA (0.10 mL, 0.63 mmol, 1.1 eq.) under nitrogen was added a 0.5 M 
solution of 7 (1.2 mL, 0.63 mmol, 1.1 eq.) in CH2Cl2. The reaction was mixture stirred for 
1 h, and treated drowpwise with a solution of 9b (470 mg, 0.518 mmol, 1.0 eq.) and 4,5-
dicyanoimidazole (125 mg, 1.04 mmol, 2.0 eq.) in THF (1.5 mL). The mixture was 
stirred for 3 h, cooled to 0 °C, treated with Bu4NIO4 (173 mg, 0.399 mmol, 1.2 eq.), 
stirred for 45 min and diluted with water (2 mL) and CH2Cl2 (5 mL). The organic layer 
was rinsed with sat. Na2S2O3 (2x3 mL), sat. NaHCO3 (3 mL), and brine (3 mL), dried 
(MgSO4), and concentrated. The crude residue was filtered through a plug of SiO2 (1:1, 
hexanes:ethyl acetate), concentrated, dissolved in CH2Cl2 (4 mL) and treated with 
TBSCl (43 mg, 0.29 mmol 0.5 eq.), imidazole (21 mg, 0.31 0.6 eq.) and DMAP (3 mg, 
0.024 mmol 0.04 eq.). The reaction mixture was stirred for 4.5 h, quenched with water 
(4 mL) and diluted with CH2Cl2 (4 mL). The organic layer was rinsed with brine (4 mL), 
dried (MgSO4), and concentrated. Purification by chromatography on SiO2 (5:1 to 3:1 to 
1:1, hexanes:ethyl acetate) gave 3-(((3-(((2,3-
(stearoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tert-butyldimethylsilyl) oxy)propoxy) 
(methoxy)phosphoryl)oxy)propane-1,2-diyl distearate (10b, 335 mg, 0.208 mmol, 40%) 
as a waxy colorless solid: Mp 48.1-48.2 °C; IR 2918, 2851, 1741, 1043 cm-1; 1H NMR 
(CDCl3, 300 MHz) 5.25-5.22 (m, 2 H), 4.35-4.30 (m, 2 H), 4.29-4.04 (m, 11 H), 3.78 (d, 
6 H, J = 11.4 Hz; diasteromers), 2.32 (apparent q, 8 H, J = 7.2 Hz), 1.61-1.57 (m, 8 H), 
1.25 (m, 112 H), 0.89-0.86 (m, 21 H), 0.11 (s, 6 H); 13C NMR (CDCl3, 125 MHz) 173.2, 
172.8, 69.7 (multiple peaks), 69.4 (multiple peaks), 67.9 (multiple peaks), 65.6 (multiple 
peaks), 61.6, 54.6 (d, J = 5.9 Hz), 34.1, 34.0, 31.9, 29.7-29.1 (multiple peaks), 25.6, 
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24.8, 22.7, 18.0, 14.1, -4.9; HRMS (ESI+) m/z calculated for C89H177O17P2Si [M+H]+ 
1608.2225, found 1608.2190. 
 
3-(((3-(((2-Palmitoleoyloxy-3-(palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tert-
butyldimethylsilyl)oxy)propoxy)(methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate 
(10c). According to General Procedure F using 3c and 9c and a purification by 
chromatography on SiO2 (5:1 to 3:1 to 1:1, hexanes:ethyl acetate) gave 3-(((3-(((2-
palmitoleoyloxy-3-(palmitoyloxy)propoxy)(methoxy)phosphoryl)oxy)-2-((tert-
butyldimethylsilyl)oxy)propoxy) (methoxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate 
(10c,145 mg, 0.0970 mmol, 39%) as a clear colorless oil: IR 2919, 2850, 1741, 1465, 
1034 cm-1; 1H NMR (CDCl3, 300 MHz) 5.35-5.33 (m, 2 H), 5.25-5.22 (m, 2 H), 4.36-4.32 
(m, 2 H), 4.23-4.12 (m, 6 H), 4.05-4.00 (m, 5 H), 3.78 (d, 6 H, J = 11.4 Hz; diasteromers 
visible), 2.32 (apparent q, 8 H, J = 7.2 Hz), 2.02-2.00 (m, 4 H), 1.61-1.54 (m, 8 H), 1.30-
1.26 (m, 88 H), 0.89-0.86 (m, 21 H), 0.11 (s, 6 H); 13C NMR (CDCl3, 125 MHz) 173.2, 
172.8, 130.0, 129.7, 69.7 (m), 69.4 (d, J = 6.5 Hz), 67.8 (d, J = 5.5 Hz), 65.6 (m), 61.6, 
54.6 (d, J = 6.0 Hz), 34.1, 34.0, 31.8, 29.7-29.0 (multiple peaks), 25.6, 24.8, 22.7, 22.6 
18.0, 14.1, -4.9; HRMS (ESI+) m/z calculated for C81H159O17P2Si [M+H]+ 1494.0816, 
found 1494.0825. 
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Tetrapalmitoylcardiolipin diammonium salt (11a).  General Procedure G. A solution of 
10a and NaI (24 mg, 0.16 mmol, 4 eq.) in 2-butanone (0.8 mL) was heated at reflux for 
13.5 h and concentrated. The crude waxy yellow solid was dissolved in 1 M 
HCl:THF:H2O (0.1:2:1, 1 mL) and the resulting yellow solution was stirred for 12 h, and 
quenched with 30% NH4OH (2 mL). The resulting white slurry was extracted with CHCl3 
(3x5 mL), concentrated, and triturated with Et2O to give tetrapalmitoylcardiolipin 
diammonium salt (11a, 40 mg, 0.029 mmol, 73%) as a colorless solid containing 5-7% 
(ESI-MS) monolyso (tripalmitoyl) cardiolipin as an impurity that was removed by thin 
layer chromatography: 1H NMR (CDCl3, 400 MHz) 7.46 (bs, 8 H), 5.21(bs, 2 H), 4.37 (m, 
2 H), 4.17-4.13 (m, 2 H), 3.91 (bs, 9 H), 2.29 (apparent q, 8 H, J = 8.5 Hz), 1.58 (m, 8 H), 
1.28-1.25 (m, 98 H), 0.87 (t, 12 H, J = 6.8 Hz); HRMS (ESI-) m/z calculated for 
C73H141O17P2 [M-H]- 1351.9639, found 1351.9648.  
 
 
Tetrastearoylcardiolipin diammonium salt (11b) (Abe et al., 2011), According to General 
Procedure G using 10b and purification by precipitation from hot THF gave 
tetrastearoylcardiolipin diammonium salt (11b, 53 mg, 0.035 mmol, 38%) as a colorless 
powder containing 5-7% (ESI-MS) monolyso (tristearoylcardiolipin) cardiolipin as an 
impurity that was removed by thin layer chromatography: 1H NMR (CDCl3, 400 MHz) 
7.44 (bs, 8 H), 5.21 (bs, 2 H), 4.37-4.35 (m, 2 H), 4.17-4.13 (m, 2 H), 3.92 (bs, 9 H), 
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2.30 (apparent q, 8 H, J = 8.3 Hz), 1.59-1.58 (m, 8 H), 1.28-1.25 (m, 112 H), 0.88 (t, 12 
H, J = 6.8 Hz); MS (ESI-) m/z calculated for C81H156O17P2 [M-2H]2- 731.5, found 731.8.  
 
Tripalmitoyl-monopalmitoleoylcardiolipin diammonium salt (11c). According to General 
Procedure G using 10c and purification by trituration with Et2O gave tripalmitoyl-
monopalmitoleoylcardiolipin diammonium salt (11c, 83 mg, 0.060 mmol, 70%) as a 
colorless powder containing 5-7% (ESI-MS) monolyso-11c as an impurity that was 
removed by thin layer chromatography: 1H NMR (CDCl3, 400 MHz)  7.44 (bs, 8 H), 
5.35-5.32 (m, 2 H), 5.21 (bs, 2 H), 4.39-4.35 (m, 2 H), 4.17-4.13 (m, 2 H), 3.84 (bs, 9 H), 
2.30 (apparent q, 8 H, J = 8.1 Hz), 2.01-1.99 (m, 4 H), 1.66-1.58 (m, 8 H), 1.28-1.25 (m, 
106 H), 0.88 (t, 12 H, J = 6.4 Hz); MS (ESI-) m/z calculated for C73H138O17P2 [M-2H]2- 
674.5, found 674.7. 
Assessment of Substrate Specificity of Purified Cld1—Activity of Cld1 was detected 
in liposomes by accumulation of MLCL after CL hydrolysis. Liposomes containing 
DOPC and CL (10 µM, 1:1) were prepared by sonication (Ultrasonic Homogenizer 4710 
series, Cole-Parmer Instrument Co., Chicago, IL) and treated with Cld1 (0.1−0.5 μg of 
protein per 250µl sample) in 50 mM HEPES pH 7.45, containing 100 μM DTPA for 20 
min at 37°C. After incubation with CLD1, lipids were extracted by Folch procedure and 
analysis of MLCL was performed using LC−ESI-MS. Internal standards of MLCLs were 
prepared from respective CLs in PLA2 (porcine pancreatic, Sigma) driven reaction as 
described by Kim and Hoppel (2011) (Kim and Hoppel, 2011) with slight modifications. 
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Molecular modeling—The homology model of CLD1 was built using I-TASSER (Yang 
et al., 2015) webserver. Hsad, a steroid-degrading hydrolase from Mycobacterium 
Tuberculosis (PDB ID: 2VF2 (Lack et al., 2008)), was utilized as a template. C-score for 
the constructed model was equal to 1.78. The C-score is a confidence score to estimate 
the quality of predicted models by I-TASSER, in the range of [-5,2], where a C-score of 
higher value defines a model with a high confidence (Yang et al., 2015). The model 
showed a TM-score equal to 0.5. TM-score is a scale for measuring the structural 
similarity of two protein models, with lower sensitivity to the local error compared to 
RMSD (a TM-score >0.5 indicates a model of correct topology independent from protein 
length) (Zhang and Skolnick, 2004). The overlay of the cavities and cartoon 
representations was employed to explore the active site and a possible channel 
facilitating access of CL acyl chain to the hydrolase domain of CLD1. Three homo-
acylated-CL species, including (C14:0)4-CL, (C16:0)4-CL and (C18:2)4-CL were 
docked to the predicted structure of CLD1 using default settings by AutoDock Vina 
(http://vina.scripps.edu) (Trott and Olson, 2010). The pdb into pdbqt format conversion 
of lipids and protein structures was performed using MGL Tools. A grid box was 
centered at coordinates 39.861, 40.057, 74.975 with 100Å, 80Å and 90Å units in x, y 
and z directions, respectively, to cover the entire protein structure. AutoDock Vina 
reports the 9 lowest energy conformations, which were inspected using PyMOL 
software (www.pymol.org).  
Statistical Analysis—The results are presented as mean ± S.D. values from at least 
three experiments, and statistical analyses were performed by paired/unpaired 
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Student's t-test. The statistical significance of differences was set at p< 0.05.  
RESULTS 
Exogenous FAs define the molecular speciation of CLs in wt and mutant S. 
cerevisiae cells.  
In wt S. cerevisiae cells grown without FA supplementation, there is an 
assortment of CL molecular species with different FA residues ranging from C10 to C18. 
Among those, only singly-unsaturated CL species were present whereas PUFA were   
not detected (Figure 3-1A). To gain insight into the mechanisms of CL remodeling and 
biosynthesis, we chose to expose yeast cells to FAs with different chain lengths as well 
as unsaturation. In particular, we employed oleic (18:1), linoleic (18:2), arachidonic 
(20:4) and docosahexaenoic (22:6) acids as components of the growth medium and 
established their effects on the phospholipidomes of S. cerevisiae cells.    
Supplementation of the growth medium with either 18:1 or 18:2 FAs caused 
dramatic changes in CLs composition (Figure 3-1B). Only CL molecular species 
containing from one to four 18:1 or C18:2 were detectable, while essentially all other 
Figure 3-1. LC/MS analysis of CL in S. cerevisiae.  
A. 3D-mass spectra (left panels) and MS maps (right panels) of CL obtained from 
wild type and cld1Δ, taz1Δ, cld1Δ/taz1Δ mutants before and after supplementation 
with different fatty acids. (OA, oleic acid C18:1; LA, linoleic acid C18:2, DHA, 
docosahexaenoic acid C22:6, AA, arachidonic acid C20:4). Insert: Mass spectrum of 
CL from yeast supplemented with C20:4 (AA). MS signals of C20:4 containing CL 
molecular species with m/z 1393.92, 1395.92, 1421.95, 1423.95, 1445.95, 1447.95, 
1449.98, 1471.98, 1473.98, 1500.00 identified as C16:1/C16:1/C16:1/C20:4, 
C16:1/C16:1/C16:0/C20:4, C16:1/C16:1/C18:1/C20:4, C16:0/C16:1/C18:1/C20:4, 
C16:0/C16:1/C20:4/C20:4, C16:0/C16:0/C20:4/C20:4, C16:1/C18:1/C18:1/C20:4, 
C16:1/C18:1/C20:4/C20:4, C16:0/C18:1/C20:4/C20:4 and C18:1/C18:1/C20:4/C20:4, 
respectively and shown in blue. B. Quantitative assessment of hetero- and homo-
acylated molecular species of CLs in wt yeast cells before and after supplementation 
with different FAs.  
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molecular species of CLs with shorter chains and devoid of C18-containing species 
were not found (Figure3- 1). Notably, a huge preponderance of homo-acylated – 
(18:1)4-CL- and (18:2)4-TLCL species – was observed (Figure 3-1B). The second 
largest cluster of CLs included hetero-acylated - tri-C18:1 and tri-C18:2-species, 
respectively (Figure 3-1). These robust effects of exogenously added C18 FAs in wt 
cells were much less pronounced when C20:4 was used (Figure 3-1). In fact, only 
singly- and doubly- 20:4-acylated CL species were detectable; no tri- or tetra-20:4-CL 
species were observed (Figure 3-1B, Supplementary Figure 4). Upon treatment with 
22:6, CLs speciation remained unchanged vs untreated w/t cells (Figure 3-1B); 22:6-
contaning CL species were not detectable. Overall, these data indicate that the 
remodeling and biosynthetic pathways for CLs are very specific and favor the synthesis 
of C18-containing molecular species. The balance of natural processes of CL hydrolysis 
and re-acylation yields only very low concentrations of MLCLs – as intermediates of 
these reactions.  Supplementation with FAs did not significantly affect the MLCL content 
in wt cells (Figure 3-2).  
CL remodeling from MLCL in yeast cells occurs via a single metabolic reaction 
catalyzed by Taz1 (Ren et al., 2014):  
PL-2FA + MLCL-3FA  LPL-1FA + CL-4FA 
where PL-2FA is a donor di-acylated phospholipid, MLCL-3FA is an acceptor MLCL, 
LPL is lyso-phospholipid formed, and CL-4FA is a remodeled CL. For CL reacylation, 
the enzyme utilizes donor phospholipids, particularly PC and PE. Therefore, we also 
studied the effects of C18:1 and C18:2 supplementations on the phospholipidome of 
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these cells. We found no changes in the total content of phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) in supplemented cells. However, supplementation with 
18:1 resulted in the accumulation of PE and PC species containing 18:1 FA residues 
(Figure 3-3). Similarly, addition to the medium of 18:2 was associated with higher levels 
of 18:2-containing PE and PC (Figure 3-3). The enrichment with C18 FA residues was 
at the expense of the decreased contents of PE and PC species containing 16:0 and 
16:1  (Figure 3-3). Further, we found that supplementation of cells with either 18:1 or 
18:2 resulted in the accumulation of homo-acylated PC and PE molecular species 
(containing either 18:1 or 18:2 in both sn-1 and sn-2 positions). Subsequently, we 
Figure 3-2. LC/MS analysis of mono-lyso-CL (MLCL) in S. cerevisiae.   
A. Mass spectra of MLCL obtained from wt (left panel) yeast cells and cld1Δ, taz1Δ, 
cld1Δ/taz1Δ mutants supplemented with C18:1 (OA) (middle panel) and C18:2 (LA) 
(right panel). B. Quantitative assessments of MLCL performed for wild type yeast 
cells and cld1Δ, taz1Δ, cld1Δ/taz1Δ mutants.  
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Figure 3-3. LC/MS analysis and quantitative assessment of 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) as well as their 
hydrolysis products – lyso-PC (LPC) and lyso-PE (LPE) - in S. cerevisiae.  
A. Mass spectra of PC (left panels) and LPC (right panels) for wild type yeast cells 
before and after supplementation with either C18:1 (OA) or C18:2 (LA). B. A. Mass 
spectra of PE (left panels) and LPE (right panels) for wild type yeast cells before 
and after supplementation with either C18:1 (OA) or C18:2 (LA). C, D. Heat maps of 
PC, PE, LPC and LPE for wild type yeast cells before and after supplementation 
with either C18:1 (OA) or C18:2 (LA). Values in heat maps pixels show the fold 
change in phospholipid content in supplemented yeast cells compared to non-
supplemented wild type cells. Red pixels without numbers inside designate lipid 
species produced only after LA supplementation (but not detectable in non-C18:2-
supplemented cells).  
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detected an increased content of 18:1-LPC/LPE and 18:2-LPC/LPE after 
supplementation of cells with these FAs. This suggests that homo-acylated species of 
PC and PE were effectively utilized by Taz1 as preferred substrates for the re-acylation 
of MLCL. It is also possible that these FAs were readily incorporated via de novo 
biosynthesis (presumably of phosphatidic acid (PA)). Direct experimental assessment of 
the contribution of these alternative pathways can be deduced from our lipidomics data 
obtained from wt and mutant cells supplemented with FA, as shown below. 
Both Cld1 and Taz1 modify the cardiolipinome.  
Cld1 is a critical participant of the CL remodeling process, as it catalyzes 
phospholipid hydrolysis with a significant selectivity towards 16:0 and 16:1-containing 
molecular species (Beranek et al., 2009). This suggests that disruption of this process in 
the cld1Δ mutant should result in an altered molecular speciation of CLs, particularly 
with regards to longer-chain (C16 and C18) species. However, according to a recently 
reported shotgun lipidomics study, the lipid profile of cld1Δ was similar to that of wt, 
whereas taz1Δ had a reduction of CL and an accumulation of MLCL (Baile et al., 2014). 
To resolve this apparent conundrum, we performed detailed LC-MS based 
characterization of cardiolipinomes in wt and mutant S. cerevisiae cells. We found that 
composition of CL from wt cells was different from that detected in either cld1Δ, taz1Δ 
or cld1Δ/taz1Δ mutants. In addition, cld1Δ contained slightly (but significantly) higher 
levels of CLs compared to wt cells (Figure 3-1B). In line with published data, the 
changes in the total content of CL and MLCL found in taz1Δ mutants were no longer 
detectable in cld1Δ/taz1Δ mutants. Indeed, dramatic accumulation of MLCL was 
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detected in taz1Δ but not in cld1Δ or cld1Δ/taz1Δ mutants (Figure 3-2). However 
molecular speciation of CLs in wt cells vs double-mutant cells were markedly different. 
Similar results were obtained with wt cells and mutants supplemented with OA or LA 
(Figure 3-2). These data are compatible with the role of Cld1 in “preparing” CLs for 
remodeling via hydrolysis/reacylation, and suggest that elimination of the hydrolytic 
pathway by deletion of Cld1 would lead to “conservation” of CLs. Consistent with this 
prediction, cld1Δ mutant cells were essentially unable to produce remodeled tetra- and 
tri-18:1 species of CLs (Figure 3-1B). Instead, their CLs were enriched with 16:0 and 
16:1 containing molecular species (Figure 3-1B).   
Assuming that Cld1 is a participant in the only remodeling process in S. 
cerevisiae cells, one can distinguish between the contribution of de novo biosynthesis 
vs remodeling processes in the overall diversification of CLs. In wt cells, both the 
biosynthesis and de novo remodeling reactions contribute to the overall diversity and 
content of CLs. Deletion of Cld1 would eliminate the remodeling process, thus revealing 
the nascent CL species generated via its de novo biosynthesis. Thus, two categories of 
CLs can be determined by comparison of LC-MS spectra of CLs from wt and cld1Δ cells 
(Figure 3-4), including: i) those produced by the biosynthetic pathway, revealed in the 
cld1Δ mutant, ii) those generated as products (increased) or utilized as substrates by 
the remodeling pathway (decreased). These latter respective categories of CLs can be 
identified in the LC-MS spectra of CLs in ± (wt minus cld1Δ) by the differential analysis.   
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By applying these differential (subtraction) protocols1, we found significant differences in 
molecular speciation of CLs in wt and mutant cells. In cld1Δ cells (lacking the 
remodeling pathway), CLs formed in the reaction catalyzed by CL synthase were   
mainly represented by molecular species containing 16:0, 16:1 and 18:1 FA residues 
(Figure 3-4). This was supported by LC/MS analysis of the CL biosynthesis precursor, – 
phosphatidylglycerol (PG). We found that PGs were predominantly represented by 
16:1/18:1, 16:1/18:1 and 16:0/16:1 molecular species in wt cells (Figure 3-5). On the 
other hand, during the remodeling, esterified 16:0 was substituted with the 16:1 fatty 
acid residue (Figure 3-5). These data suggest that in non-FA-supplemented w/t cells, 
                                                          
1 Please note that the specific feature of the software utilized for the subtraction disallows plotting of the negative 
spectra; therefore -(WT- cld1Δ) plots were used as explained in detail in Materials and Methods. 
Figure 3-4. Contribution of de novo biosynthesis vs remodeling processes to 
the diversification of CLs in S. cerevisiae.  
Mass spectra of CL obtained from wild type yeast cells and cld1Δ mutant cells with 
or without oleic/linoleic acid (OA/LA) supplementation.  The resulting differential 
mass spectra of CL species produced and consumed by the remodeling process 
were obtained, as shown in the positive and negative spectra of w/t minus cld1Δ 
mutants, respectively. A. Mass spectra of CL obtained from non-supplemented wild 
type yeast cells and cld1Δ mutant. CL molecular species were identified as 
C10:0/C16:1/C16:1/C16:1 (m/z 1261.8249); C10:0/C16:0/C16:0/C16:1 (m/z 
1265.8593); C10:0/C16:1/C16:1/C18:1 (m/z 1289.8574); C12:0/C16:0/C16:0/C16:1 
(m/z1293.8904); C12:0/C16:1/C16:1/C18:1 (m/z 1317.8840); 
C12:0/C16:0/C16:1/C16:1 (m/z 1321.9176); C16:1/C16:1/C16:1/C16:1 (m/z 
1343.9041); C12:0/C16:1/C18:1/C18:1 (m/z 1345.9184); C12:0/C16:0/C16:1/C18:0 
(m/z 1347.9318); C16:1/C16:1/C16:1/C18:1 (m/z 1371.9380); 
C16:0/C16:1/C16:0/C18:1 (m/z 1375.9669); C16:1/C18:1/C16:1/C18:1 (m/z 
1399.9688); C16:0/C18:1/C16:0/C18:1 (m/z 1403.9988); C16:1/C18:1/C18:1/C18:1 
(m/z 1428.0015); C16:0/C18:1/C18:0/C18:1 (m/z 1432.0336); 
C18:1/C18:1/C18:1/C18:1 (m/z 1456.0292). B. Mass spectra of CL obtained from 
OA supplemented w/t yeast cells and cld1Δ mutant. Major CL species are annotated 
on mass spectra. C. Mass spectra of CL obtained from LA supplemented w/t yeast 
cells and cld1Δ mutant. Major CL species are annotated on mass spectra 
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Figure 3-5. LC/MS analysis of phosphatidylglycerol (PG) in wild type S. 
cerevisae before and after supplementation with different fatty acids.  
Mass spectra and quantitative assessments (inserts) of PG obtained from control wild 
type yeast cells and wild type yeast cells supplemented with C18:1 (OA), C18:2 (LA), 
C20:4 (AA) and C22:6 (DHA). 
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Cld1 predominantly hydrolyzed 16:0-containing CLs that were then remodeled with 16:1 
by Taz1-catalyzed re-acylation.   
We further applied the same approach to distinguish between the CL species  
formed through either biosynthetic or remodeling pathways in wt cells supplemented 
with either 18:1 or 18:2. This analysis revealed that the remodeling route was entirely 
accountable for the replacement of fatty acid residues in CLs yielding predominantly 
homo-acylated tetra-18:1 or tetra-18:2 molecular species of CLs, respectively (Figure 3-
1B, Figure 3-4B, C). Based on these newly developed protocols for the assessment of 
biosynthetic vs remodeling origins of the CL species, we compared the relative 
contributions of these two pathways to all CLs in determining the pool of homo-acylated 
species. We found that biosynthesis was the major (wt cells, 18:2-treated cells) or 
significant (C18:1-treated cells) contributor to the entire pool of CLs. Interestingly, the 
remodeling process was, by far, the most important contributor to the pool of homo-
acylated CLs.   Specifically, we found that CL(18:1/18:1/18:1/18:1) was the major 
product (Figure 3-4B, WT-cld1Δ), while CL(16:1_18:1_16:1_18:1) and 
CL(16:0_18:1_18:1_18:1) were the major substrates of the remodeling process (Figure 
3-4B, -(WT-cld1Δ)). Based on the cld1Δ spectra, we determined that both major 
substrates of the remodeling originated from CL biosynthesis. For LA-supplemented 
cells, we found that CL (18:2/18:2/18:2/18:2) was the major product (Figure 4C, WT-
cld1Δ), while CL(16:0/18:2/16:0/18:2) and CL(16:0/18:2/18:2/18:2) were the major 
substrates of the remodeling process (Figure 3-4C, -(WT-cld1Δ)).  Similar to OA- 
supplementation, both major remodeling substrates represented the products of CL 
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biosynthesis. Further, the differential analysis demonstrated that after OA- or LA- 
supplementation, Cld1 had preferentially hydrolyzed C16:0- and C16:1-fatty acid 
residues over C18:1- and C18:2-containing CL species. As a result, the remodeling 
process tended to convert hetero-acylated CL to homo-acylated CLs, provided C18:1 or 
C18:2 were available.  
As all major phospholipids can serve as acyl sources for Taz1-catalyzed 
remodeling, we further looked at the content of several phospholipids as well as their 
monolyso-forms in wt and taz1Δ mutant cells. Included in our phospholipidomics 
analyses were several major classes of phospholipids: i) a biosynthetic precursor of CL, 
phosphatidylglycerol (PG); ii) two major phospholipids present in both mitochondria and 
extra-mitochondrial compartments, PE and PC, and iii) an extra-mitochondrial 
phospholipid, phosphatidylserine (PS).  We found that the effects of taz1Δ deletion were 
CL specific. Other phospholipids such as PC, PG, PS were not sensitive to taz1Δ 
deletion.  
Exogenous FAs do not affect molecular speciation of CL in remodeling of mutant 
S. cerevisiae cells.  
While Cld1 and Taz1 represent the two major components of the machinery 
involved in the CL remodeling process, the immediate motive force(s) triggering the 
process remain unknown. As exogenously added C18 FAs caused efficient remodeling 
of CL to generate mostly homo-acylated tetra-18:1 and tetra-18:2 molecular species in 
wt cells, we further explored the CL composition in mutant cells. The dramatic changes 
in molecular speciation of CLs induced by exogenous C18-FAs in wt cells were 
85 
 
 
 
essentially not found in any of the remodeling mutant cells, including cld1Δ, taz1Δ, and 
cld1Δ/taz1Δ (Figure 3-1).     
Because Cld1 is specific for the hydrolysis and remodeling of CLs but Taz1 can 
participate in remodeling of other phospholipids (Ye et al., 2014), we were interested in 
assessing the effects of deletion of Cld1 as well as Taz1 on the phospholipidomes of 
the mutant cells grown in the presence of 18:1 and 18:2 FAs. Our findings clearly 
demonstrate that deletion of cld1Δ did not cause any changes in PE and PC molecular 
species in either 18:1- or 18:2-supplemented cells. The absence of Taz1 also did not 
substantially affect the content or molecular speciation of PC and PE (except for the 
accumulation of 16:0/16:1 and 16:1/16:1 PC molecular species but in cells 
supplemented with C18:1). 
Specificity of Cld1 for different molecular species of CLs.  
Because of the apparent preference of CL remodeling triggered by exogenous 
fatty acids for C18 species, we further investigated the specificity of Cld1 in the 
hydrolysis of different molecular species of CLs. We used commercially available homo-
acylated CLs - (14:0)4-CL, (18:1)4-CL, (18:2)4-CL and also synthesized several 
molecular species of CL - (16:0)4-CL, (18:0)4-CL, and (16:1) (16:0)3-CL.  The multistep 
preparations of (16:0)4-CL, (18:0)4-CL and (16:1) (16:0)3-CL followed a modular 
approach to achieve optimal synthetic efficiency. Selectively protected glycerol building 
blocks were loaded with palmitoate, stearate, and palmitoleoate in the presence of 1-
ethyl-3-(3-dimethyl-aminopropyl) carbodiimide (EDCI) and N, N-dimethyl-4-
aminopyridine (DMAP) and then condensed with 1-chloro-N,N-diisopropyl-1-
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methoxyphosphinamine. The formation of the second phosphoester bond utilized 4,5-
dicyanoimidazole, and the resulting phosphite was subsequently peroxidized to the  
phosphate with tetrabutylammonium periodate. Iterative couplings generated a fully 
protected CL precursor that was O-demethylated with sodium iodide to release the 
phosphate anions and O-desilylated under mild, carefully controlled acidic conditions to 
generate the secondary alcohol in the glycerol moiety. Ammonium hydroxide was used 
to prepare the final CL diammonium salts that were used for biological analysis.  
Figure 3-6. Effect of Cld1 isolated from S. cerevisiae on accumulation of 
mono-lyso-CLs after hydrolysis of different CLs in a biochemical system in 
vitro. 
 *p<0.05 vs (14:0)3, 
#
p<0.002 vs.  (18:1)3, 
$
p<0.005 vs (18:2)3, (n=4-10). 
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Figure 3-7. Typical LC-ESI-
MS spectrum of CL isolated 
from cld1Δ mutants  
(A), LC-MS profiles (B) and 
MS/MS spectra (C) of MLCLs 
after CL hydrolysis by Cld1 and 
heat map of mono-lyso-CLs 
molecular species (D) after the 
release fatty acids from CLs 
induced by Cld1 in the CLs 
isolated from cld1Δ mutants 
and from the heart of Northern 
Red Snapper (Lutjanus 
campechanus). 
88 
 
 
 
We found that (14:0)4-CL, (18:1)4-CL, (18:2)4-CL were very poor substrates for Cld1 
(Figure 3-6). Both (16:0)4-CL and (16:1) (16:0)3-CL and also (18:0)4-CL were  readily 
hydrolyzed by Cld1 (Figure 3-6).   To verify the specificity of Cld1 toward CL containing 
palmitic acid, we performed experiments using several types of mixtures of different CLs. 
In particular, we were interested in testing Cld1 substrate specificity towards different 
CL species present in S. cerevisiae cells as well as long-chain polyunsaturated CL 
species “unusual” for these cells. To this end, we prepared two types of liposomes, 
DOPC liposomes containing either CLs isolated from cld1Δ yeast mutant (to obtain the 
most diversified set of yeast CLs in conditions of suppressed remodeling process) or 
long chain polyunsaturated CLs isolated from fish heart (Northern Red Snapper, 
Lutjanus campechanus) (Figure 3-7). These experiments provided interesting details 
regarding the specificity of Cld1 towards different molecular species of CLs as 
substrates. We found that hydrolysis of yeast CLs by Cld1 resulted in the release of 
predominantly palmitic acid (16:0) and the formation of four major MLCL species such 
as 12:0_14:0_18:1; (14:0_14:0__18:1; 16:0_16:1_18:1 and 18:1_18:1_18;1. We did not 
observe significant accumulation of MLCL and free fatty acids or decreased CL content  
when liposomes containing fish heart CLs (with highly diversified CLs containing C22:5 
and C22:6 fatty acid residues) were treated with Cld1. Thus, Cld1 specifically 
hydrolyzed CL species containing palmitic acid. 
Computational studies of the interactions of homo-acylated-CL with Cld1.  
To get insights into specifics of Cld1 hydrolysis of CL and its molecular species, a 
homology model of full-length structure of the protein was generated using Hsad, a 
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steroid-degrading hydrolase, from Mycobacterium tuberculosis as a template (Figue 3-
8A)  (Lack et al., 2008). The choice was based on the sequence analysis using the  
Protein BLAST tool (Altschul et al., 1990). This resulted in five templates with the 
highest levels of identities to Cld1. Accordingly, five homology models of Cld1 were built 
using I-TASSER 31 webserver. The model based on Hsad, a steroid-degrading 
hydrolase from Mycobacterium Tuberculosis (PDB ID: 2VF2 13), demonstrated the 
greatest C-score (C-score was equal to -1.78). Therefore, it was selected for molecular 
Figure 3-8. A homology model of Cld1, generated using iTassar server. 
A. A full-length structure of Cld1 and its N-terminus region called mitochondrial 
target signal (MTS). B. The known lipase motif (
228
AHSLG
232
). C.  Acyl transferase 
motif (
424
HHLYLD
429
). D. The catalytic triad, including S230, D392 and H424, 
introduced by Baile et al.  
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docking modeling. The known lipase motif (228AHSLG232) and acyl transferase motif 
(424HHLYLD429) are shown in Figure 3-8B-C, respectively. According to Baile et al. 
(Baile et al., 2014), S230, H424 and D329 are the catalytic triad of Cld1 (Figure 3-8D). 
Figure 3-9. Interactions of (C16:0)4-CL with Cld1 structure, generated using 
homology modeling. 
A. One of the acyl chains of TPCL aligned toward the active site. B.  A channel 
represents the CL acyl chain to the active site, which may define the specificity of 
Cld1 toward particular fatty acids based upon its size. 
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Intriguingly, the overlay of cavity and cartoon representation of the model structure 
revealed a channel toward the catalytic site. Subsequently, molecular docking method 
was utilized to investigate the interactions of three homo-acylated-CL species - (14:0)4- 
CL, (16:0)4-CL and (18:2)4-CL. Notably, a palmitoyl residue (16:0) perfectly fit in this 
cavity (Figure 3-9). However, neither chains of tetra-myristoyl CL, nor chains of tetra-
linoleoyl CL penetrated the active site channel. This indicates that the channel can 
introduce a CL acyl chain to the active site. Moreover, the length of the channel may 
function as a “ruler” defining the specificity of Cld1 towards particular molecular species 
of CLs – in reasonable agreement with the experimentally tested homo- and hetero-
acylated CLs. 
Effects of C18:1, C18:2 and C20:4 FAs supplementation on mitochondrial 
bioenergetic function in S. cerevisiae cells.  
As CL is an essential structural component of the OxPhos machinery, we tested one 
possible effect of fatty acid supplementation on intact cell respiration of yeast cells. 
Interestingly, yeast cells analyzed in stationary phase in YPD media showed 45% and 
21% increased respiration rates when the media was supplemented with linoleic acid 
and arachidonic acid, respectively, but not with oleic acid, where respiration was 
decreased by -26% compared to control (Figure 3-10). These data suggest that CL 
composition plays an important role for mitochondrial function at the level of the 
oxidative phosphorylation system, and that linoleic acid supplementation produces 
highest respiration rates. 
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DISCUSSION 
Predominantly localized in mitochondria, CLs interact with numerous 
mitochondrial proteins (Eble et al., 1990; Mileykovskaya and Dowhan, 2014; Pfeiffer et 
al., 2003; Poyry et al., 2013; Sharpley et al., 2006; Shinzawa-Itoh et al., 2007) thus 
defining their role and significance in mitochondrial structural organization and 
metabolic/signaling functions. Similar to other phospholipids, CLs are subject to 
continuous turnover, resulting in changes in their molecular species that may be 
associated with their modified interactions with proteins. The molecular mechanisms 
Figure 3-10. Yeast cells were grown in synthetic fermentable (YPD) media 
supplemented with tergitol alone (control), or tergitol plus oleic acid, linoleic 
acid, or arachidonic acid.  
Respiration of intact cells was analyzed via the polarographic method. *p<0.05 
versus control (n=3). 
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and the significance of these changes – also called remodeling – in normal physiology 
and disease conditions are the subject of intensive investigation (Barth et al., 2004). We 
discovered that nutritional “pressure” by high levels of free FAs in the growth medium 
triggered massive synthesis of unusual homo-acylated di-oleoyl- and di-linoleoyl- 
molecular species in all major classes of phospholipids, including direct CL precursors 
as well as donors of acyl-groups for the remodeling reactions.  Not surprisingly, this 
resulted in the preponderant accumulation of the respective homo-acylated CL species. 
By employing detailed phospholipidomics analysis, this work established that the 
availability of specific FA precursors is the major factor defining the diversity and 
molecular speciation of CLs in S. cerevisiae. Supplementation with C18 FAs resulted in 
the predominant accumulation of homo-tetra-acylated 18:1 and 18:2 species of CL. 
Based on the engagement of only one biosynthetic and one remodeling pathway for 
CLs in S. cerevisiae, the specific contributions of these respective mechanisms to the 
overall molecular diversification/speciation of CLs in different growth conditions as well 
as in mutant forms can be established. For example, we established that the remodeling 
process is the major contributor to the pool of homo-acylated (C18:1)4-CL and (C18:2)4-
CL in cells supplemented with these FAs.  
The hydrolase is a major part of the remodeling pathway. To convert nascent CL, 
containing short saturated FA, to homo-acylated CL with log chain polyunsaturated FAs, 
CL first has to undergo deacylation. In yeast, Cld1 fulfills this function and has been 
identified as a CL-specific hydrolase enzyme. Modeling data revealed the presence of a 
channel adjacent to the active site of Cld1, which may introduce a fatty acid of CL to the 
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active site to be hydrolyzed. In line with LC/MS data demonstrating preferable 
hydrolysis of 16:0 fatty acids by Cld1, and modeling results revealing most likely 
interactions of 16:0 fatty acid with the channel it is tempting to speculate that the 
channel acts as a “molecular ruler” defining the specificity of Cld1 to particular fatty acid 
residues in CLs.  
By appropriately designing genetic manipulations (e.g., creating and producing 
appropriate deletion mutants such as cld1Δand targeted transfection with mammalian 
remodeling genes such as iPLA2β or iPLA2γ), yeast cells supplemented with desired 
PUFA can be used as effective models in studies of mammalian CL metabolism.  
Similarly, the taz1Δ mutant transfected with acyltransferases alcat1 or mlcat1 may lead 
to the elucidation of their specific contributions to CL metabolic processes. In all these 
cases, the approach based on differential (subtractive) lipidomics analysis may be 
particularly powerful in examination of remodeling and biosynthesis.  
Supplementation with exogenous C18 FAs stimulated CL remodeling.  As FAs 
can be integrated into yeast CLs only via MLCL/Taz1-driven reactions, the acyl-CoA-
dependent pathways are not utilized to remodel CL. However, it has been reported that 
acyl-CoAs are essential for reacylation of other phospholipids (Rijken et al., 2009). 
Thus, detailed lipidomic analyses of other phospholipids in addition to CL are essential 
for comprehensive analysis of CL remodeling pathways.  
It has been well established that taz1Δ cells are characterized by lower levels of 
CLs and markedly increased content of MLCL relative to wt cells (Ye et al., 2014). Our 
results are in full agreement with these earlier studies. In terms of molecular speciation 
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of CLs, the same altered features of CLs molecular speciation were also characteristic 
of taz1Δ mutant and double mutant cld1Δtaz1Δ cells, suggesting that the selectivity of 
Cld1 for C16-containing CLs is the major factor defining the overall molecular speciation 
and remodeling of CLs in S. cerevisiae. This is clearly illustrated by the analysis of 
MLCL molecular species that accumulate in taz1Δ cells, in which 16:1_16:1_16:0, 
16:1_16:0_18:1, and 16:1_18:1_18:1 individual species dominated. Only minimal 
amounts of MLCLs were detected in cld1Δ and cld1Δ/taz1Δ mutant cells, reconfirming 
that the Taz1-catalyzed reaction was the major contributor to the re-
acylation/remodeling of CLs in S. cerevisiae.  
A recent study demonstrated that simultaneous deletion of cld1Δ and taz1Δ 
provided protection against mitochondrial injury triggered by single deletion of taz1Δ (Ye 
et al., 2014). However, molecular speciation of CLs in w/t and double mutant cells 
cld1Δ/taz1Δ was markedly different. This suggests that the accumulated MLCL – rather 
than the changed CL speciation – are the major contributors to mitochondrial 
dysfunction. A recent study demonstrated that unremodeled CLs are functionally 
indistinguishable from remodeled CLs for yeast major bioenergetic functions (Baile et al., 
2014). In contrast, we found that mitochondrial respiration rates were altered in the 
presence of different FA. Surprisingly, monounsaturated oleic acid had a small inhibitory 
effect on intact cell respiration whereas the PUFAs - linoleic acid and arachidonic acid - 
significantly increased mitochondrial respiration. This may give yeast cells a survival 
advantage by shifting metabolism from glycolysis to the much more efficient OxPhos 
process under non-proliferating conditions. Interestingly, CL with four linoleic acid 
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chains is the primary CL species in some mammalian tissues including cow heart 
(Schlame et al., 1993), a tissue that fully depends on aerobic energy production, 
suggesting that linoleic acid is the evolutionarily preferred CL side chain to support 
optimal high levels of oxidative phosphorylation. It should be noted that the effect of the 
studied fatty acids on mitochondrial function can be the result of several independent 
mechanisms. One primary mechanism is likely through changes in CL fatty acid 
composition (i.e., length and saturation versus unsaturation state), which will affect the 
structure of the OxPhos complexes. Another mechanism may be through cell signaling. 
For example, it is known that arachidonic acid, a well-studied signaling molecule in 
higher organisms, also affects cell signaling in yeast, where it leads to changes in the 
phosphorylation state of many proteins and in particular protein kinase C (PKC) 
signaling (Kuo et al., 1994). PKC has been shown to regulate mitochondrial respiration 
by acting on OxPhos complexes both in mammals and yeast (Machida et al., 1998; 
Ogbi and Johnson, 2006), suggesting that cell signaling may contribute to the observed 
changes in the presence of arachidonic acid. 
Interestingly, these general considerations can be applied to specific pathogenic 
pathways in disease conditions such as, for example, the one likely operating in patients 
suffering from the X-linked disease Barth syndrome (BTHS) leading to a rare childhood 
cardiomyopathy with cyclic neutropenia (Barth et al., 2004). Recent detailed studies 
have identified seven functional classes of BTHS mutations with several distinct loss-of-
function mechanisms leading to a partial or total loss of catalytic activity (Claypool et al., 
2011; Whited et al., 2013). It has also been demonstrated that accumulation of MLCL 
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(decreased CL/MLCL ratio) rather than deficiency of “correct” unsaturated CL species is 
the major reason of mitochondrial dysfunction in yeast cells (Ye et al., 2014).  Based on 
our data on the effective remodeling of CLs supplemented with PUFA, one may wonder 
whether the supplementation with C18:2 may be of therapeutic value, particularly in 
cases with a partial loss of TAZ catalytic activity (Valianpour et al., 2003).   
It has been long believed that remodeling of PUFA phospholipids is driven, at 
least in part, by their peroxidation with subsequent hydrolysis of oxidatively modified FA 
residues and re-acylation (Kagan et al., 1978; Salgo et al., 1993; Vankuijk et al., 1987). 
The results of this work clearly indicate that the remodeling process occurs even in the 
absence of peroxidizable PUFA. This suggests that different mechanisms, independent 
of peroxidation, may drive the CL recycling process yielding the molecular species of CL 
optimized in response to specific cell/tissue demands. Our results are compatible with 
the dominant role of Taz in re-acylation of Cld1-hydrolyzed CLs and explain the high 
selectivity of the overall remodeling process towards homo-acylated 18:2 species of 
CLs and the role of the tazΔ mutations in the pathogenesis of Barth syndrome. However, 
further detailed studies of the specificity and the role of PLAs in the re-acylation of 
peroxidized vs non-peroxidized polyunsaturated CL species may be necessary to better 
understand these intriguing and important general mechanisms of biological adaptation.  
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CHAPTER 4 EXPRESSION OF ∆12-DESATURASE PROMOTES 
CARDIOLIPIN PEROXIDATION IN SACCHAROMYCES CEREVISIAE: A 
MODEL FOR CL SIGNALING 
 
INTRODUCTION 
The dimeric mitochondrial phospholipid cardiolipin (CL) is most abundant in the 
mammalian heart, where it was first discovered (Pangborn, 1942); however, it is present 
in nearly all mammalian tissues and throughout the eukaryotic kingdom (Schlame et al., 
2000b). The cellular and subcellular functions of CL have been studied for decades 
using the powerful yeast genetic model, Saccharomyces cerevisiae (Schlame and 
Greenberg, 2017). Yeast genes encoding the CL biosynthetic enzymes (Figure 4-1) 
have been identified, and well-characterized mutants are available for each step of the 
pathway, enabling in vivo studies of CL function that are not easily carried out in 
mammalian cells (Joshi et al., 2009b).  The yeast model has, thus, been pivotal in 
demonstrating the critical role of CL in mitochondrial bioenergetics (Claypool et al., 
2008b; Gohil et al., 2004; Jiang et al., 2000; Patil et al., 2013; Raja et al., 2017), 
mitochondrial protein import (Gebert et al., 2009), mitochondrial dynamics (Joshi et al., 
2016; Joshi et al., 2012), cell cycle progression (Chen et al., 2010), cellular aging (Zhou 
et al., 2009), mitophagy (Shen et al., 2017), and apoptosis (Gonzalvez and Gottlieb, 
2007; Schug and Gottlieb, 2009), among other essential functions.  
CL that is synthesized de novo undergoes remodeling, in which it is deacylated 
to monolysocardiolipin (MLCL), which is reacylated by the transacylase tafazzin, t hus 
forming CL species that are more highly unsaturated (Baile et al., 2013; Beranek et al., 
2009; Brandner et al., 2005; Gu et al., 2004; Testet et al., 2005).  Unsaturated 
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tetralinoleoyl-CL is the major CL species detected in the heart, skeletal muscle and liver; 
however, the physiological significance of tetralinoleoyl-CL remains unclear. It is absent 
in cells from patients with Barth syndrome (BTHS), an X-linked recessive disorder 
associated with variable cardiomyopathy, skeletal myopathy, neutropenia, and organic 
aciduria (Barth et al., 1983). BTHS is caused by mutations in the TAZ gene that codes 
for tafazzin (Bione et al., 1996). Accordingly, BTHS patient cells accumulate MLCL and 
are devoid of tetralinoleoyl-CL, owing to a loss in the final step of the CL remodeling 
pathway (Shen et al., 2015). In yeast, unremodeled and remodeled CL are thought to 
be functionally indistinguishable (Baile et al., 2014), and deletion of the CL-specific 
phospholipase, Cld1, was found to rescue the defects caused by loss of the CL-
transacylase, Taz1 (Ye et al., 2014). This raises the question of why cells remodel CL, 
and how CL-enriched with polyunsaturated fatty acid (PUFA) is functionally distinct from 
that of saturated or mono-unsaturated fatty acyl CL species. Recent studies implicate 
peroxidation of CL, yielding CLOX, in the cellular signaling events that initiate apoptosis, 
as enzymatic hydrolysis of CLOX results in the release of lipid mediators with diverse 
signaling properties (Kagan et al., 2014; Kagan et al., 2005a).  
In the wild, yeast cells proliferate in diverse environments (Huffnagle and Noverr, 
2013; Spencer and Spencer, 2013; Spencer and Spencer, 1997; Vadkertiova et al., 
2012), from which PUFAs may be readily incorporated into CL. We previously 
demonstrated that yeast cells supplemented with PUFAs linoleic acid  (C18:2) or 
arachidonic acid (C20:4) readily incorporate these fatty acids into CL (Tyurina et al., 
2017), suggesting that the yeast model may be exploited to dissect the mechanisms 
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underlying the generation and function of CLOX. Cipak and co-workers demonstrated 
that yeast cells expressing the H. brasiliensis Δ12-desaturase synthesize PUFA and 
exhibit sensitivity to oxidative stress (Andrisic et al., 2015; Cipak et al., 2006).  In the 
current study, we show that S. cerevisiae yeast cells that express the H. brasiliensis 
Δ12-desaturase synthesize CL acyl species containing PUFA.  Furthermore, multiple 
species of CLOX, including CL-hydroperoxides and CL-dihydroperoxides, are present in 
these cells.  Peroxidized species of mitochondrial phospholipids PC and PE were also 
detected, but peroxidized PS (which is largely non-mitochondrial) was not. Importantly, 
the presence of PUFA-containing CL and the production of CLOX were not associated 
with major growth defects under optimum conditions. However, mild temperature 
sensitivity and increased sensitivity to mitochondral lipid peroxidation were observed. 
Thus, our findings illustrate that yeast cells synthesizing PUFA readily generate 
phospholipid hydroperoxides and dihydroperoxides, including various CLox species, 
within the mitochondira. Moreover, yeast provides a powerful genetic model that can be 
exploited to elucidate mechanisms underlying the generation and function of CL 
peroxidation. 
METHODS AND MATERIALS 
Strains, Media, and Growth Conditions—The S. cerevisiae strain used in this work is 
BY4741(MATa his31 leu20 met150 ura30). The plasmids pYES2-EV and pYES2-
desa employed in this study were kindly given by Dr. Ana Cipak Gasparovic from the 
Rudjer Boskovic Institute in Zagreb, Croatia. Expression of the Δ12-desaturase is 
controlled by a Gal promoter and is induced by growth on galactose-containing media. 
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Complex media contained yeast extract (1%), peptone (2%), and glucose (2%) (YPD). 
The solid medium contained agar (2%) in addition to the ingredients mentioned above. 
Synthetic complete (SC) ura- medium contained adenine (20.25 mg/liter), histidine (20 
mg/liter), arginine (20 mg/liter), lysine (200 mg/liter), leucine (60 mg/liter), methionine 
(20 mg/liter), tryptophan (20 mg/liter), threonine (300 mg/liter) all the essential 
components of yeast nitrogen base without amino acids (Difco), 0.2% ammonium 
sulfate, and glucose/galactose (2%). Yeast strains were grown at 30°C. E. coli strain 
DH5 was used for plasmid maintenance and amplifications. Bacteria were grown at 
37°C in LB medium (0.5% yeast extract, 1% tryptone, 1% NaCl), supplemented with 
ampicillin (100 μg/ml) for selection purposes. For growth on plates, media were 
supplemented with 1.5 and 2% agar for E. coli and yeast, respectively. Growth in liquid 
cultures was monitored spectrophotometrically. Cells were harvested and centrifuged at 
4°C (4,300 rpm, 5 min). The supernatant was discarded, and glass beads (0.3g) were 
added to the centrifuge tubes. Samples were vortexed (5 X 1 min intervals) and frozen 
at -80 ℃ for lipidomic analysis.   
Chronological Life Span—As described in Chapter 2  
Spotting Assay—As described in Chapter 2 
Determination of mitochondrial membrane potential (MMP)—Cells were grown in 
SC Gal Ura- medium to log phase and incubated with 500 nM TMRM for 30 min at 30°C. 
Cells were washed, resuspended in warm medium and divided in half. One group was 
treated with 6 µM FCCP and the other group was untreated. The TMRM fluorescence 
intensity was determined in 30,000 cells from each group using LSR II flow cytometer at 
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the Wayne State University Microscopy, Imaging and Cytometry Resources Core. 
Median fluorescence intensity was calculated after correcting for background TMRM 
fluorescence (values obtained after treatment with FCCP) using FlowJo v10.2.  
Determination of O2 consumption—Cells were grown in SC Gal Ura- medium to the 
mid-log phase to obtain a suspension containing 1.4 x 107 cells/ml. Cell respiration was 
measured in a 5 mL glass chamber using a Clark-type electrode (YSI 5300) operated by 
TracerDAQ software at 30 °C. After measurements of basal respiration, 5 µM FCCP 
was added to measure maximal respiration. KCN (0.2 mM) was added to measure 
cytochrome c oxidase-independent oxygen consumption.  
Synthesis of Mito-AAPH— 
 
3                                           4
NaOH
SOCl
2
; DMF
-HCl; -SO
2
-NaCl; - H
2
O
1                                           2
5  
2-[(E)-(2-amino-2-imino-1,1-dimethyl-ethyl)azo]-2-methyl-propanamidine hydrochloride 
(2; yield, 82%): In ice-cold methanol (100 mL), 2,2’-azobis-2-methyl-propanimidamide  
(AAPH; 2,2’-azobis-2-methyl-propanimidamide, 1; 1 g; 3.7 mmol) was neutralized with 
NaOH (0.3 g; 7.4 mmol). The solvent was rotor-evaporated (25 oC; 10 torr) and the 
crystals formed were suspended in chloroform (100 mL). Undissolved 1 and NaCl were 
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filtered off. Rotor-evaporation of the filtrate afforded 2 (0.6 g; 3 mmol), which was used 
immediately for the preparation of 5.  
(4-chloro-4-oxo-butyl)-triphenyl-phosphonium bromide (4; yield, 65%): 3-
carboxypropyl(triphenyl)phosphonium bromide (3, 1 g; 2.3 mmol) was dissolved in 
chloroform (50 mL) containing thionyl chloride (3 g; 25 mmol) and dimethylformamide 
(DMF; 0.05 g; 0.68 mmol), and the reaction solution was refluxed for 4 hours. The 
volume of the solvent was reduced to ~ 5 mL (rotor-evaporation; 25 oC; 150 torr) and 
trituration with n-hexane afforded 4 (0.68 g), which was dried under vacuum (40 oC; 10 
torr) for 1 hour. 
[2-[(E)-[2-imino-1,1-dimethyl-2-(4-triphenylphosphaniumylbutanoylamino)ethyl]azo]-2-
methyl-propanimidoyl]ammonium chlorobromide (5; yield 45%): Chloroform (50 mL) 
containing 2 (0.5 g; 2.5 mmol) and 4 (1.12 g; 2.5 mmol) was incubated for 24 hours at 0 
oC. Thereafter, the solvent was rotor-evaporated (20 oC; 10 torr) and the dry residue 
was redissolved in minimal volume of ethanol. Trituration of the solution with diethyl 
ether afforded 5 (0.69 g), which was filtered and dried under vacuum (20 oC; 1 torr) for 
30 min. ESI MS calculated for the triphenylphosphonium cation of 5 (C30H38N6OP+), 529.64; 
found, 529.80. 
Mito-AAPH Treatment—Mito-AAPH was diluted with ethanol to make a 50 mM stock. 
For the spotting assay, 50 µM Mito-AAPH was directly spread on the plate before the 
experiment. For liquid culture, 50 µM Mito-AAPH was added at log phase (A550≈0.5). 
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Statistical Analysis—All results are presented as mean ± S.D. from at least three 
experiments. Statistical analyses were performed by paired and unpaired Student's t-
tests, and the level of statistical significance was set at p< 0.05.  
LC/MS assessment of phospholipids—Lipids were extracted from yeast and LC/MS 
of phospholipids was performed as previously described (Tyurina et al., 2017). Briefly, 
phospholipids were analyzed in negative mode using a Dionex UltimateTM 3000 
RSLCnano system coupled online to Q-Exactive hybrid quadrupole-orbitrap mass 
spectrometer (ThermoFisher Scientific, San Jose, CA). Lipids were separated on a 
normal phase column (Silica Luna 3 µm, 100A, 150x2 mm, (Phenomenex, Torrance 
CA)) with flow rate 0.2 mL/min using gradient solvents containing 5 mM CH3COONH4 (A 
– n-hexane:2-propanol: water, 43:57:1 (v/v/v) and B - n-hexane:2-propanol: water, 
43:57:10 (v/v/v). MS lipid standards used in this study were from Avanti polar lipids 
(Alabaster, AL). Analysis of LC-MS data was performed using software package 
Compound DiscovererTM (ThermoFisher Scientific) with an in-house generated analysis 
workflow and peroxidized phospholipid database. 
RESULTS 
Expression of the H. brasiliensis Δ12-desaturase alters the molecular speciation of 
CL in S. cerevisiae cells  
Yeast cells that are not supplemented with exogenous fatty acids produce only 
saturated and Δ9-mono-unsaturated fatty acyl residues, as these cells cannot 
synthesize PUFA (Tyurina et al., 2017). To construct a yeast model with PUFA- 
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Figure 4-1 Cardiolipin biosynthesis and remodeling in S. cerevisiae.  
Yeast cells readily produce 16:0-CoA and 18:0-CoA, which can be converted to 16:1-
CoA and 18:1-CoA via endogenous 
9
-desaturase activity or the expressed D
12
-
desaturase. 16:1-CoA and 18:1-CoA can be further converted to 16:2-CoA and 18:2-
CoA following a second, complementary desaturation. All available acyl-CoA species 
can be incorporated into PA and used in the de novo synthesis of CL via CL synthase 
(Crd1). Newly synthesized CL contains predominantly unsaturated fatty acyl chains. 
Nascent CL may undergo Cld1-catalyzed deacylation to form MLCL. The 
transacylase, Taz1, utilizes donor phospholipids, particularly PC and PE, to reacylate 
MLCL to CL. PC and PE are also synthesized from PA. Multiple cycles of 
deacylation-reacylation generate CL that contains mainly unsaturated acyl chains.  
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containing CL, we expressed the H. brasiliensis ∆12-desaturase gene in yeast (Cipak et 
al., 2006) and established its effect on the phospholipidome of these cells.  
As described in Figure 4-1, yeast readily produces 16:0-CoA and 18:0-CoA, 
which can be converted to 16:1-CoA and 18:1-CoA via endogenous 9-desaturase 
activity. These acyl-CoA species can be incorporated into phosphatidic acid (PA) and 
used in the de novo synthesis of CL via the CL synthase (Crd1)-catalyzed reaction to 
form nascent CL, which contains predominately unsaturated fatty acyl chains (Chang et 
al., 1998b; Jiang et al., 1997; Tamai and Greenberg, 1990; Tuller et al., 1998). Nascent 
CL is deacylated by the phospholipase Cld1 to form monolysocardiolipin (MLCL) (Baile 
et al., 2013; Beranek et al., 2009). The transacylase Taz1 utilizes donor phospholipids, 
particularly PC and PE, to acylate MLCL to form CL (Brandner et al., 2005; Gu et al., 
2004; Testet et al., 2005). Multiple cycles of deacylation-reacylation lead to the 
synthesis of mature CL containing mainly unsaturated acyl chains (Beranek et al., 2009; 
Gu et al., 2004; Vaz et al., 2003). As we showed previously, Cld1 has a greater affinity 
for C16-containing acyl chains than for C18-containing acyl chains (Tyurina et al., 2017). 
Accordingly, the predominant CL species detected in yeast contain C18 acyl chains. 
The expression of ∆12-desaturase results in the production of 16:2-CoA and 18:2-
CoA, which are incorporated into CL through de novo synthesis or via CL remodeling.  
As shown in Figure 4-2A-B, expression of the ∆12-desaturase caused dramatic changes 
in CL composition. WT yeast cells have predominantly CL64:3, CL66:4, CL68:4, CL70:4 
and CL72:4, while cells expressing the ∆12-desaturase contained predominantly CL66:5, 
CL68:5, CL70:6 and CL72:8. The CL species detected in WT and ∆12-desaturase-
108 
 
 
 
109 
 
 
 
  
expressing cells are shown in Figure 4-2C. Quantitative comparison of individual 
CL species indicates that ∆12-desaturase expression resulted in the production of 
multiple PUFA-containing CL species and a concomitant reduction in the abundance of 
CL species containing saturated or monounsaturated fatty acids (Figure 4-2C-D).  
MLCL species were also altered by ∆12-desaturase expression (Figure 4-3). Total MLCL 
was significantly reduced in ∆12-desaturase-expressing cells when compared to WT. 
Furthermore, quantitative comparison of individual MLCL species indicates that ∆12-
desaturase expression resulted in the reduction of MLCL species containing saturated 
or monounsaturated fatty acids. Additionally, PUFA-containing MLCL species were 
detected (in low abundance) in the ∆12-desaturase-expressing cells.  
Because phosphatidylglycerol (PG) is the precursor of nascent CL produced via de 
novo synthesis (Chang et al., 1998b; Jiang et al., 1997; Osman et al., 2010; Tamai and 
Greenberg, 1990; Tuller et al., 1998), we also examined the effect of ∆12- desaturase 
Figure 4-2. CL species synthesized in ∆
12
-desaturase-expressing cells.  
(A) Mass spectra of CL obtained from wild type yeast cells expressing the empty 
vector (EV) or ∆
12
-desaturase (desa). Major CL molecular species are identified: 
CL58:3 (m/z 1261.8241); CL60:3 (m/z 1289.8578); CL62:3 (m/z 1317.8895); CL64:3 
(m/z 1345.9180); CL66:4 (m/z 1371.9358); CL68:4 (m/z 1399.9666); CL70:4 (m/z 
1427.9991); CL72:4 (m/z 1456.0305); CL60:4 (m/z 1287.8410); CL62:4 (m/z 
1315.8712); CL64:4 (m/z 1343.9119); CL66:5 (m/z 1369.9176); CL68:5 (m/z 
1397.9476); CL70:6 (m/z 1423.9635); CL72:7 (m/z 1449.9794). (B) A differential 
mass spectra of CL species was obtained by highlighting individual CL species that 
were increased [+(desa-EV)] or decreased [-(desa-EV)] by the expression of the D
12
-
desaturase. (C) Heat map of CL quantified from wild type yeast cells expressing the 
empty vector (EV) or ∆
12
-desaturase (desa). (D) Quantitative comparison of CL 
molecular species in cells expressing the empty vector (EV) or ∆
12
-desaturase 
(desa). 
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Figure 4-3. MLCL species in ∆
12
-desaturase-expressing cells.  
(A) Mass spectra of MLCL. Major MLCL molecular species are identified: MLCL50:2 
(m/z 1137.7310); MLCL50:3 (m/z 1135.7225); MLCL50:4 (m/z 1133.7018); MLCL52:2 
(m/z 1165.7626); MLCL52:3 (m/z 1163.7540); MLCL52:4 (m/z 1161.7366); MLCL52:5 
(m/z 1159.7208). (B) Heat map of MLCL. (C) Quantitative assessment of total MLCL. 
(D) Quantitative comparison of MLCL molecular species. 
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expression on PG (Figure 4-4). In WT cells, the predominant PG species  (34:1 and 
32:1) contain one saturated acyl chain and one mono-unsaturated acyl chain. The 
expression of ∆12-desaturase resulted in a significant reduction of PG34:1 and PG32:1. 
Furthermore, when compared to WT, ∆12-desaturase-expressing cells had significantly 
increased PG32:2 and PG34:2. Additionally, PG34:3 was detected in ∆12-desaturase-
Figure 4-4. PG in ∆
12
-desaturase-expressing cells.  
(A) Mass spectra of PG. Major PG molecular species identified: PG32:1 (m/z 
719.5); PG32:2 (m/z 717.5); PG34:1 (m/z 747.5); PG34:2 (m/z 745.5); PG34:3 (m/z 
743.5). (B) Heat map of PG.  (C) Quantitative assessment of PG. 
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expressing cells but not WT cells. 
∆12-desaturase expression leads to accumulation of peroxidized CL.  
The accumulation of CLOX was readily observed in cells expressing the ∆12-
desaturase (Figure 4-5A-C).  CL-hydroperoxide and CL-dihydroperoxide species were 
observed in these cells. As anticipated, peroxidized CL species were not detected in 
Figure 4-5. Oxygenated CL (CLOX) in ∆
12
-desaturase-expressing cells.  
(A) Heat map of CLox. (B) Quantitative assessment of total. (C) Quantitative 
assessment of CLox molecular.   
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WT cells.  Neither peroxidized MLCL nor peroxidized PG was detected in the ∆12-
desaturase-expressing cells. As the lipid profile has been altered in ∆12-desaturase 
expression yeast cells, we next sought to determine if presence of PUFA-containing or 
peroxidized CL species affected yeast growth  
Detection of other peroxidized phospholipids in ∆12-desaturase-expressing cells.  
The effects of ∆12-desaturase expression on PC, PE, and PS (Figure 4-6) were 
determined. All phospholipids analyzed in these cells contained C16:2 and/or C18:2 
fatty acyl chains. Peroxidized species of PC and PE were readily detected in ∆12-
desaturase-expressing cells.  Interestingly, however, peroxidized PS species were not 
Figure 4-6. PC, PE, and PS in ∆
12
-desaturase-expressing cells.  
Heat map of PC (A), PE (B), and PS (C).  
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detected. Given that PC and PE species are enriched within mitochondrial membranes 
while PS species contribute minimally to the mitochondrial phospholipidome (Carman 
and Zeimetz, 1996; Wright and McMaster, 2002), this finding suggests that phospholipid 
peroxidation observed in ∆12-desaturase-expressing cells likely occurs within the 
mitochondrial subcellular compartment. 
∆12-desaturase expression results in a mild growth phenotype and increased 
sensitivity to mitochondria-targeted lipid peroxidation.  
In accordance with the findings of Cipak and coworkers (Andrisic et al., 2015; 
Cipak et al., 2006), we observed a mild growth phenotype in the ∆12-desaturase cells, 
characterized by a prolonged lag phase and a slower rate of growth during stationary 
phase in liquid growth medium (Figure 4-7A). Growth on solid medium was unaffected 
at 30℃ but was decreased at 39℃ (Figure 4-7B). Interestingly, chronological lifespan 
was largely unaffected by ∆12-desaturase expression at 30℃ (Figure 4-7C). The 
expression of ∆12-desaturase resulted in an increase in the mitochondrial membrane 
potential, which was associated with minimal changes in basal mitochondrial respiration 
(Figure 4-7D-E). We next used the mitochondria-targeted lipid peroxidation reagent, 
mito-AAPH, to further examine how CL peroxidation and growth are affected in ∆12-
desaturase-expressing cells. We determined that ∆12-desaturase-expressing cells 
exhibit increased sensitivity to mito-AAPH (Figure 4-8A). Exposure to mito-AAPH 
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resulted in an increased generation of specific CL-dihydroperoxide species, including 
CL(62:6)+2[O], CL (64:8)+2[O], CL(66:7)+2[O], CL(66:8)+2[O], CL(68:8)+2[O] (Figure 4-
8B). PC(36:4)+2[O] (Figure 4-8C), PE(32:4)+2[O], and PE(34:4)+2[O] (Figure 4-8D) 
were also increased. CL(66:7)+2[O] and PE(34:3)+2[O] were found only in desaturase-
Figure 4-7. Physiologic phenotype in desaturase-expressing cells.   
(A) Cell growth. Cells were inoculated at an initial A550 of 0.05, and A550 was 
measured at the indicated times. The growth curves shown are representative of 
three experiments. (B) Serial 10-fold dilutions of cells were spotted on SC medium 
containing 2% glucose or 2% galactose as carbon source. Plates were incubated at 
the indicated temperature for 5 days. (C) Chronological life span. The data depicted 
are representative of three experiments. (D) Membrane potential was determined in 
logarithmically growing cells by measuring the TMRM fluorescence intensity in 
30,000 cells from each group using LSR II flow cytometer. (E) Oxygen consumption 
was measured in logarithmically growing cells using a Clark-type electrode.  
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expressing cells exposed to mito-AAPH. Oxygenated mCL, PG, and PS were not found  
in desaturase-expressing cells exposed to mito-AAPH. These results suggest that the 
increased mitochondrial lipid peroxidation contributes to the overall growth defects 
observed in the ∆12-desaturase-expressing cells.  
Figure 4-8. Effect of mito-AAPH on desaturase-expressing cells.  
(A) Serial 10-fold dilutions of cells were spotted on SC medium containing 2% 
galactose as carbon source. Mito-AAPH was spread on the plates immediately 
before spotting. Plates were incubated at 30°C for 3 days. (B) Quantitative 
assessment of CLox molecular species in cells expressing the ∆
12
-desaturase (desa) 
treated with or without mito-AAPH. (C) Quantitative assessment of PCox molecular 
species in cells expressing the ∆
12
-desaturase (desa) treated with or without mito-
AAPH. (D) Quantitative assessment of PEox molecular species in cells expressing 
the ∆
12
-desaturase (desa) treated with or without mito-AAPH.   
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DISCUSSION 
This study demonstrates for the first time that ∆12-desaturase expression in yeast 
promotes the formation of PUFA-containing CL species that are readily peroxidized in 
vivo. To date, the study of processes governing CL peroxidation and the various cellular 
signaling functions of CLOX and CLOX-derived lipid mediators has not been carried out 
using yeast model systems. We have confirmed that 16:2-CoA and 18:2-CoA produced 
by yeast expressing the ∆12-desaturase are incorporated into CL. This likely occurs, in 
part, during de novo synthesis of CL from PUFA-containing PG and CDP-diacylglycerol 
by CL synthase. Subsequent enrichment of CL with PUFA occurs during CL remodeling. 
Consistent with our previous observations in yeast cells supplemented with exogenous 
PUFA (Tyurina et al., 2017), in the current study, MLCL levels were significantly 
decreased in ∆12-desaturase-expressing cells compared to WT. This may suggest that 
CL remodeling is down-regulated in cells containing PUFA. Alternatively, the relative 
activities of Cld1 and Taz1 may be altered by the availability of PUFA. Nonetheless, the 
enrichment of PUFA-containing CL combined with reduced detection of the CL 
remodeling intermediate, MLCL, in ∆12-desaturase-expressing cells supports a model in 
which a major role of CL remodeling is to generate PUFA-enriched CL, which may 
serve to increase mitochondrial membrane potential.  
This is the first report of CL peroxidation in the yeast S. cerevisiae.  CL 
peroxidation provides a critical signal for the initiation of apoptosis (Kagan et al., 2004; 
Mao et al., 2016; Nakagawa, 2004), and therapeutic reduction of CL peroxidation is 
being explored to treat human diseases associated with apoptosis (Jiang et al., 2014; 
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Maddalena et al., 2017; Zhong et al., 2017). Additionally, hydrolysis of CLOX likely 
serves as a key mitochondrial source of peroxidized fatty acid lipid signaling molecules 
(Tyurina et al., 2014). Given that in their natural environments, yeast cells likely 
encounter PUFA, it is reasonable to speculate that yeast may readily synthesize CL-
enriched with PUFA in these environments and produce CLox in the absence of 
stressors. The ∆12-desaturase-expressing yeast provides a powerful tool for the study of 
CL peroxidation and CLOX signaling Future studies will explore potential inducers of CL 
peroxidation as well as functions of CLox using this model system.   
The expression of exogenous desaturase enzymes in yeast has variable effects 
on cellular function and viability depending on the yeast strain and growth conditions 
used (Andrisic et al., 2015; Cipak et al., 2006; Cipak et al., 2008; Johansson et al., 
2016). Johansson and coworkers observed severe growth defects in cells expressing 
both 12 and 6-desaturase enzymes (Johansson et al., 2016). Cipak and coworkers 
report distinct effects of ∆12-desaturase expression depending on the yeast strain used 
(Andrisic et al., 2015; Cipak et al., 2006; Cipak et al., 2008). The current study is the 
first to perform unbiased lipidomic analysis of yeast cells expressing an exogenous 
desaturase enzyme. Our findings indicate that CLOX is readily detected in the ∆12-
desaturase-expressing yeast under normal growth conditions, suggesting that CL 
peroxidation may occur in the absence of cytotoxic stressors.  
The accumulation of CLOX may be subject to factors beyond the rate of CL 
peroxidation. Peroxidized forms of other phospholipids known to localize within the 
mitochondrial membranes (PC and PE) were detected in the ∆12-desaturase-expressing 
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cells. As Taz1, the yeast CL-transacylase transfers fatty acids from phospholipids to 
MLCL without specificity (Xu et al., 2006b), CLOX may be formed in a Taz1-dependent 
manner during the transmission of a peroxidized fatty acid residue from a donor 
phospholipid. However, because PCOX and PEOX are relatively non-abundant, this 
mechanism likely contributes minimally to the total pool of CLOX. 
Increased sensitivity to lipid peroxidation were previously reported using this 
genetic yeast model (Andrisic et al., 2015). However, our comprehensive lipidomic 
approach provides compelling evidence to implicate mitochondrial free radicals and CL 
peroxidation in contributing to the growth defects observed in ∆12-desaturase-
expressing cells.  Excessive generation of CLOX in response to mitochondrial oxidative 
stress likely contributes to the small but significant growth defect observed under these 
conditions. In the current study, we found that ∆12-desaturase-expressing cells exhibit 
increased sensitivity to mito-AAPH (Figure 4-8A), and treatment with mito-AAPH was 
associated with an increase in specific CLOX species (Figure 4-8B). The absence of 
peroxidized PS supports a model of mitochondria-localized phospholipid peroxidation. 
PS species are confined almost exclusively to the cell membrane and secretory vesicles 
(Zinser et al., 1991). Although PS is imported into mitochondrial membranes, its 
intramitochondrial transport is linked to enzymatic conversion to PE by PS 
decarboxylase (Atkinson et al., 1980; Carman and Henry, 1989; Simbeni et al., 1993). 
Thus, the relative abundance of PS within the mitochondrial membranes is minimal 
when compared to PC and PE (Zinser et al., 1991). Peroxidation of CL, PC, and PE but 
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not PS suggests that phospholipid peroxidation observed in ∆12-desaturase-expressing 
cells likely occurs within the mitochondrial subcellular compartment.  
While hydrolysis of CL may be driven, at least in part, by CL peroxidation (Kagan 
et al., 1978), in the current study, we detected decreased MLCL in the ∆12-desaturase-
expressing cells containing CLOX, indicating that some degree of CLOX can be tolerated 
in yeast. Future in vitro studies will focus on the specificity of CL hydrolysis for 
peroxidized vs. non-peroxidized CL substrates. Additionally, using the in vivo ∆12-
desaturase expression system, the relationship between CL remodeling and CL 
peroxidation will be further explored.  
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CHAPTER 5 LOSS OF CLD1 IN Δ12-DESATURASE EXPRESSION 
CELLS LEADS TO INCREASED PEROXIDIZED CL SPECIES THAT 
DECREASES CELLULAR MEMBRANE POTENTIAL AND 
CHRONOLOGICAL LIFE SPAN 
 
INTRODUCTION 
As the signature lipid of mitochondria, cardiolipin (CL) plays a  critical role in 
mitochondrial bioenergetics (Claypool et al., 2008b; Gohil et al., 2004; Jiang et al., 
2000), mitochondrial protein import (Gebert et al., 2009), cell cycle progression (Chen et 
al., 2010), cellular aging (Zhou et al., 2009) and apoptosis (Gonzalvez and Gottlieb, 
2007; Schug and Gottlieb, 2009). Following de novo synthesis, CL undergoes 
remodeling in which acyl chains are exchanged. Cld1 is the only known CL-specific 
phospholipase in yeast and is required to initiate the CL remodeling pathway. In this 
process, CL is deacylated by Cld1 on the matrix side of the inner mitochondrial 
membrane to form monolysocardiolipin (MLCL) (Baile et al., 2013; Beranek et al., 2009). 
The transacylase, Taz1, reacylates MLCL to reform CL using acyl groups from donor 
phospholipids, particularly PC and PE (Brandner et al., 2005; Gu et al., 2004; Testet et 
al., 2005). In addition to its role in CL remodeling, deacylation of CL results in the 
generation of mitochondria-derived free fatty acids, which may modulate various cellular 
functions. Peroxidation of CL, yielding CLOX, has been implicated in the cellular 
signaling events that initiate apoptosis, and CLOX can undergo enzymatic hydrolysis, 
resulting in the release of various lipid mediators with diverse signaling properties 
(Kagan et al., 2014; Kagan et al., 2005a).  Cancer cells evade apoptosis through 
modulation of CL oxidation and subsequent formation of reactive lipid electrophiles, 
especially 4-hydroxy-nonenal (4-HNE) (Zhong et al., 2017). Attenuating CL peroxidation 
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is being explored as a potential treatment to manage the clinical effects of aberrant 
apoptosis. For instance, 3-hydroxypropyl-triphenylphosphonium-conjugated imidazole-
substituted oleic acid (TPP-IOA) was developed as an apoptosis-specific inhibitor that 
prevents CL oxidation (Maddalena et al., 2017).  
Previous studies showed that unremodeled and remodeled CL are functionally 
indistinguishable in the yeast S. cerevisiae (Baile et al., 2014; Ye et al., 2014). However, 
the CL species of unsupplemented yeast contain only saturated and Δ9-mono-
unsaturated fatty acids, enriched primarily with palmitic (C16:0), stearic (C18:0), 
palmitoleic (C16:1) and oleic acids (C18:1) (Tyurina et al., 2017). In the wild, yeast 
proliferate in diverse environments (Huffnagle and Noverr, 2013; Spencer and Spencer, 
2013; Spencer and Spencer, 1997; Vadkertiova et al., 2012), from which 
polyunsaturated fatty acids (PUFA)’s may be readily incorporated into CL. Yeast 
supplemented with PUFA-containing CL readily synthesize peroxidized CL 
(unpublished). However, the functions of PUFA-containing CL and peroxidized CL are 
not clear. A recent study showed that the mammalian CL phospholipase iPLA2γ 
deacylates peroxidized CL, initiating diverse signaling pathways, including activation of 
caspase-3, expression of stress response genes, accumulation of ceramide, loss of 
mitochondrial membrane potential, and induction of apoptosis (Song et al., 2014). 
Accordingly, we speculated that Cld1 may function to deacylate peroxidized CL and 
regulate cellular signaling in yeast. We demonstrated that cells expressing the H. 
brasiliensis Δ12-desaturase synthesize C16:2 and C18:2 fatty acids, which are readily 
incorporated into CL. Multiple species of CLox, including CL-hydroperoxides and CL-
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dihydroperoxides, were detected in these cells (unpublished). However, the specific 
functions of Cld1 and CL remodeling in yeast cells with PUFA-containing CL have not 
been explored.  
In this study, we compared the CL profiles of Δ12-desaturase-expressing WT and 
cld1 cells to determine if Cld1 removes peroxidized CL. Δ12-desaturase-expressing 
cld1 cells contain increased amount of discrete peroxidized CL species, which leads to 
decreased growth, chronological life span and membrane potential. Furthermore, 
purified Cld1 protein exhibits higher affinity for peroxidized CL than non-peroxidized CL 
(C18:2)4. These results indicate a novel role for Cld1 in mitigating the effects of CL 
peroxidation. Additionally, MLCL levels were increased in desaturase-expressing cld1 
cells, suggesting the existence of an alternate, unidentified CL phospholipase that is 
capable of deacylating PUFA-containing CL. The findings from this study will serve as 
the basis on which we will improve our understanding of CL remodeling and its 
mechanistic roles in mitigating oxidative stress. 
METHODS AND MATERIALS 
Strains, Media, and Growth Conditions— The S. cerevisiae strain used in this work is 
BY4741(MATa his31 leu20 met150 ura30). The plasmids pYES2-EV and pYES2-
desa employed in this study were kindly given by Dr. Ana Cipak Gasparovic (Rudjer 
Boskovic Institute, Zagreb, Croatia). Expression of the Δ12-desaturase is controlled by a 
Gal promoter and is induced by growth on galactose-containing medium. Complex 
medium contained yeast extract (1%), peptone (2%), and glucose (2%) (YPD). Solid 
medium contained agar (2%) in addition to the ingredients mentioned above. Synthetic 
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complete (SC) ura- medium contained adenine (20.25 mg/liter), histidine (20 mg/liter), 
arginine (20 mg/liter), lysine (200 mg/liter), leucine (60 mg/liter), methionine (20 mg/liter), 
tryptophan (20 mg/liter), threonine (300 mg/liter), all the essential components of yeast 
nitrogen base without amino acids (Difco), 0.2% ammonium sulfate, and 
glucose/galactose (2%). Yeast strains were grown at 30°C. E. coli strain DH5 was used 
for plasmid maintenance and amplifications. Bacteria were grown at 37°C in LB medium 
(0.5% yeast extract, 1% tryptone, 1% NaCl), supplemented with ampicillin (100 μg/ml) 
for selection purposes. For growth on plates, media were supplemented with 1.5 and 2% 
agar for E. coli and yeast, respectively. Growth in liquid cultures was monitored 
spectrophotometrically. For lipidomic analysis, cells were harvested and centrifuged at 
4°C (4,300 rpm, 5 min). The supernatant was discarded, and glass beads (0.3g) were 
added to the centrifuge tubes. Samples were vortexed (5 X 1 min intervals) and 
centrifuged again at 4°C (4,300 rpm, 5 min). Supernatants were collected and frozen at 
-80 ℃ for lipidomic analysis.   
Construction of Plasmids and Expression of Yeast His6-tagged Cld1 in S. 
cerevisiae—As described in Chapter 3 
Purification of His6-tagged Cld1—As described in Chapter 3. 
Chronological Life Span—As described in Chapter 2  
Spotting Assay—As described in Chapter 2 
Real Time Quantitative PCR (RT-qPCR) Analysis—As described in Chapter 2  
Determination of mitochondrial membrane potential (MMP)—As described in 
Chapter 4 
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Determination of O2 consumption— As described in Chapter 4 
Mito-AAPH Treatment—Mito-AAPH was diluted with ethanol to make a 50 mM stock. 
For the spotting assay, 50 µM Mito-AAPH was directly spread on the plate before the 
experiment. For liquid culture, 50 µM Mito-AAPH was added at log phase (A550≈0.5). 
Statistical Analysis—The results are presented as mean ± S.D. values from at least 
three experiments, and statistical analyses were performed by paired/unpaired 
Student's t-test. The statistical significance of differences was set at p< 0.05. 
LC/MS assessment of phospholipids—Lipids were extracted from cells and LC/MS of 
phospholipids was performed as previously described (Tyurina et al., 2017). Briefly, 
phospholipids were analyzed in negative mode using a Dionex UltimateTM 3000 
RSLCnano system coupled online to Q-Exactive hybrid quadrupole-orbitrap mass 
spectrometer (ThermoFisher Scientific, San Jose, CA). Lipids were separated on a 
normal phase column (Silica Luna 3 µm, 100A, 150x2 mm, (Phenomenex, Torrance 
CA)) with flow rate 0.2 mL/min using gradient solvents containing 5 mM CH3COONH4 (A 
– n-hexane:2-propanol: water, 43:57:1 (v/v/v) and B - n-hexane:2-propanol: water, 
43:57:10 (v/v/v). MS lipid standards used in this study were from Avanti polar lipids 
(Alabaster, AL). Analysis of LC-MS data was performed using software package 
Compound DiscovererTM (ThermoFisher Scientific) with an in-house generated analysis 
workflow and peroxidized phospholipid database. LC/MS was carried out by 
collaborators from Dr. Valerian Kagan’s lab from Pittsburgh University. 
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RESULTS 
Expression of Δ9-desaturase in cld1 cells leads to increased levels of specific 
peroxidized CL species  
We have previously shown that expression of CLD1 is highest when cells are 
actively respiring (Ye et al., 2014).  These conditions lead to increased generation of 
ROS and, concomitantly, increased oxidation of lipids.  Increased CLD1 in these 
conditions suggests the possibility that this phospholipase deacylates peroxidized CL, in 
which case the loss of CLD1 would lead to increased peroxidized CL. Yeast cells can 
synthesize only saturated and Δ9-mono-unsaturated fatty acids, but when engineered to 
express Δ12-desaturase, they can synthesize PUFAs (Andrisic et al., 2015; Cipak et al., 
2006).  Furthermore, when supplemented with PUFA, they can synthesize PUFA-
containing phospholipid species (Tyurina et al., 2017).  To investigate the role of Cld1 in 
deacylating peroxidized CL, we expressed the Δ12-desaturase in cld1 cells. PUFA-
containing CL species were detected in the 12-desaturase-expressing cld1 cells, likely 
because some incorporation of PUFA into CL occurs during de novo CL biosynthesis. 
However, the level of PUFA-containing CL was significantly decreased in cld1 cells 
expressing ∆12-desaturase (cld1+desa) compared to WT cells expressing the 
desaturase (Figure 5-1). Surprisingly, although cld1+desa cells had decreased total 
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levels of peroxidizable CL, they contained significantly more CLox species within highly 
unsaturated CL species (64:7, 66: 7, 68:7, 68:8, 70:8) (Figure 5-2A-B).   
The expression of 12-desaturase increased the incorporation of PUFA not only into CL 
but also into other phospholipids known to localize to the mitochondrial membranes (e.g. 
PG and PC) in both wt and cld1 cells (need data for cld1). Interestingly, while 
desaturase expression increased the mitochondrial membrane potential in wt cells, the 
membrane potential in cld1 cells was decreased (Figure 5-2C). These results suggest 
that mitochondrial membrane potential is directly affected by the extent to which CL is 
enriched with PUFA and/or peroxidized.  
Increased MLCL in cld1 cells expressing12-desaturase indicate a novel CL 
phospholipase that prefer to deacylate PUFA-containing CL. 
Cld1 is the only known CL phospholipase capable of deacylating CL to form MLCL 
(Baile et al., 2013; Beranek et al., 2009; Ye et al., 2014). Although cld1 cells have 
decreased levels of MLCL compared to wt cells, small amounts of MLCL were 
Figure 5-1. Oxygenated CL (CLOX) in ∆12-desaturase-expressing cells.  
(A) Heat map of all CLox species quantified. (B) Quantitative assessment of specific 
molecular species of CLox that are increased in cld1 yeast cells expressing ∆
12
-
desaturase (desa). (C) Mitochondrial membrane potential was determined in 
logarithmically growing cells by measuring the TMRM fluorescence intensity. Analysis 
of 30,000 cells from each group demonstrated that mitochondrial membrane potential 
is significantly affected by the presence of ∆
12
-desaturase expression. (D) 
Chronological life span of wt and cld1 yeast cells expressing ∆12-desaturase (desa) 
or empty vector (EV). The data depicted are representative of three experiments. 
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Figure 5-2. Cld1 exhibits greater affinity for oxidized than non-oxidized CL in 
vitro.  
(A) Mixture of 10 μM cardiolipin (TLCL/TLCLox) in HEPES buffer pH 7.45 was 
incubated at 37℃ for 45 min with an increasing amount of Cld1. Total TLCL was 
extracted by the Folch procedure and TLCL, TLCLox, and MLCL were quantified by 
LCMS. Hydrolysis of CL was evident by an accumulation of MCL and concomitant 
reduction of CL. (B) Isolated Cld1 was incubated with non-oxidized TLCL (CL), TLCL 
containing one hydroperoxy-LA residue (CLOOH), or TLCL containing two 
hydroperoxy-LA residues (CL2OOH). In the presence of oxygenated CL (CLOOH or 
CL2OOH) Cld1 generated significantly increased free hydroperoxy-LA (m/z 311) than 
non-oxidized-LA (m/z 279). (C) Isolated Cld1 was incubated with increasing ratios of 
oxidized TLCL (CLOX) to non-oxidized TLCL (CL). As the CL: CLOX ratio was 
increased from 1:1 to 1:2, the generation of free hydroperoxy-LA (m/z 311) increased 
by nearly 50%. Further increasing the CL: CLOX ratio (1:4) had little effect on the 
generation of free hydroperoxy-LA. As the CL: CLOX ratio was increased, the 
generation of free non-oxidized-LA (m/z 279) was also increased.  
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Figure 5-3. Expression of desaturase increases the sensitivity of cells to mito-
AAPH.  
Serial 10-fold dilutions of wt and cld1 yeast cells expressing ∆12-desaturase (desa) 
or empty vector (EV) were spotted on SC medium containing 2% galactose as 
carbon source. Mito-AAPH was spread on the plates immediately before spotting. 
Plates were incubated at 30°C for 3 days. 
Figure 5-4. CLD1 expression is increased by exposure to H2O2. 
 WT cells were grown to the mid-logarithmic phase and treated with 1 mM H2O2 for 1 
h. Analyses CLD1 expression in H2O2-treated cells and non-treated cells was 
determined using RT-qPCR.  
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Figure 5-5. MLCL species in ∆
12
-desaturase-expressing cells.  
(A) Heat map of all MLCL species quantified. (B) Quantitative assessment of total 
MLCL in wt and cld1 yeast cells expressing ∆
12
-desaturase (desa) or empty vector 
(EV).  
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detectable in the mutant (Figure 5-3). Interestingly, the expression of 12-desaturase in 
cld1 cells increased MLCL levels by more than 100%, suggesting that an alternate, 
unidentified CL phospholipase may exist that is capable of deacylating PUFA-containing 
CL.  
Cld1 mitigates the effects of CL peroxidation 
 In vitro experiments revealed that Cld1 exhibits greater affinity for peroxidized 
than non-peroxidized CL (Figure 5-4). Thus, (18:2)4-CL was a poor substrate for Cld1, 
but peroxidized (18:2)4-CL was an excellent substrate. 
 We have previously shown that CLD1 expression is increased during respiratory 
growth and regulated by the HAP complex (Ye et al., 2014). It is plausible that 
increased CLD1 expression during respiratory growth mitigates the effects of 
superoxides generated by respiratory complex III, which likely contribute to the 
peroxidation of CL. Consistent with this possibility, wt cells treated in the log phase with 
H2O2 for 1 hr exhibited a 2-fold increase in CLD1 expression (Figure 5-5). Furthermore, 
the expression of desaturase increased the sensitivity of cld1cells to mito-AAPH 
(Figure 5-6), which has been shown to generate CLox (unpublished). The chronological 
life span of cld1was dramatically decreased by expression of desaturase (Figure 5-
2D), while the life span of wt cells expressing the desaturase was not affected.  
 Taken together, these findings support a role for Cld1 in mitigating the effects of 
CL peroxidation. 
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DISCUSSION 
This study demonstrates, for the first time, a role for Cld1 in mitigating the effects 
of CL peroxidation. Previously, we demonstrated that deletion of CLD1 rescues the 
respiratory growth defect of tafazzin deficient yeast cells, indicating that an increased 
MLCL/CL ratio, not decreased CL with unsaturated fatty acyl chains, is detrimental in 
tafazzin deficient cells (Ye et al., 2014). Similarly, a study by Baile and colleagues 
illustrated that unremodeled and remodeled cardiolipin are functionally indistinguishable 
in yeast (Baile et al., 2014). An interesting question arises from these observations: why 
do yeast require CL remodeling if there is no adaptive advantage of accumulating CL 
dominated by unsaturated fatty acyl chains. A clue to this question comes from our 
findings, it further indicate that expression of CLD1 is increased in response to 
respiratory growth conditions, and this increase is mediated by the HAP and Mig1 
transcriptional factors. Baile and coworkers revealed that Cld1 protein level and function 
are decreased in glucose and increased in lactate (Baile et al., 2013). They observed 
that CL remodeling is regulated by available carbon source and membrane potential. 
Mitochondria are the major producer of cellular ROS, and CL-hydroperoxides are known 
to reduce oxidative metabolism by inactivating complex IV (Musatov, 2006). Similarly, 
respiratory chain defects have been shown to increase ROS production and decrease 
the membrane potential (Grivennikova and Vinogradov, 2006; Minners et al., 2007). 
These findings support a model in which decreased membrane potential resulting from 
the accumulation of CL-hydroperoxides serves as a signal to activate CL remodeling. 
This model is further supported by the notion that CL remodeling may function to 
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remove peroxidized fatty acyl residues from CL, thereby mitigating the downstream 
consequences of mitochondrial CL-hydroperoxide accumulation, possibly including 
mitophagy or apoptosis. However, it is unclear if this model applies to yeast cells 
because loss of CLD1 does not cause any detectable functional defects (Baile et al., 
2014). CL-hydroperoxides are not produced in either WT or cld1Δ cells unless PUFA is 
supplied in the growth medium or an exogenous-desaturase is expressed (Tyurina et al., 
2017). WT yeast cells readily incorporate PUFA into CL, which suggests that CL 
enriched with PUFA may influence cellular function in S. cerevisiae. In the current study, 
we used 12-desaturase-expressing cells to study the functions of Cld1 and CL 
remodeling in the presence of PUFA-containing CL, and reveal that loss of Cld1 causes 
an accumulation of specific CLox species, decreased membrane potential, and 
decreased chronological life span (Figure 2). These results suggest that Cld1 is 
involved in removing specific CLox species. This is supported by the demonstration that 
purified Cld1 has a higher affinity for peroxidized than non-peroxidized (C18:2)4CL 
(Figure 3). This may explain the previous observation that CLD1 expression is 
upregulated during stationary phase and that CLD1 upregulation is respiration 
dependent (Ye et al., 2014). Consistent with this model, H2O2 treatment increases 
CLD1expression, which suggests that increased oxidative stress upregulates CLD1 
expression.  
We previously demonstrated that expression of 12-desaturase enables WT S. 
cerevisiae cells to make C16:2- and C18:2- containing phospholipids, including CL, PC, 
PE, and PS, and CLox (Chapter 4, unpublished). The LC-MS data showed that cld1 
135 
 
 
 
cells exhibit decreased PUFA-containing CL, but increased levels of specific CLox 
species. In our previous study, we showed that WT yeast cells expressing 12-
desaturase readily accumulate CLox, yet these cells do not exhibit detectable defects 
under optimum growth conditions (Chapter 4, unpublished). In this study, we showed 
that Cld1 is involved in removing specific CLox species, and that loss of CLD1 in 12-
desaturase-expressing cells led to severe physiological defects, including decreased 
mitochondrial membrane potential and decreased chronological life span. 
As Cld1 functions to removed CLox, we speculate that CLD1 expression is 
regulated by the cellular ROS level. This is supported by the finding that treatment of 
H2O2 increased CLD1 expression (Figure 5). This observation is consistent with the 
previous finding that CLD1 expression is upregulated in stationary phase, as cellular 
ROS are accumulated during respiration and reach high concentrations during this 
phase. Furthermore, upregulation of CLD1 expression is respiration dependent, and the 
transcription factor Mig1 is required for CLD1 upregulation. Mig1 has been shown to 
sense ROS and regulate gene expression in response to increased ROS production.  
Although Cld1 is the only known phospholipase that deacylates CL in yeast, 
MLCL was still detectable in cld1, and the MLCL level was significantly increased in 
12-desaturase-expressing cld1 cells. This observation suggests the existence of an 
unidentified phospholipase capable of deacylating CL containing PUFA.  
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CHAPTER 6 LOSS OF CARDIOLIPIN REMODELING RESULTS IN 
DECREASED C2C12 MYOBLAST DIFFERENTIATION: A MYOBLAST 
MODEL FOR BARTH SYNDROME AND CARDIOLIPIN DEFICIENCY 
 
INTRODUCTION 
Cardiolipin (CL) is a dimeric mitochondrial membrane phospholipid with multiple 
functions that are conserved from yeast to humans (Acehan et al., 2011; Chen et al., 
2008; Gebert et al., 2009; Jiang et al., 2000; Joshi et al., 2009a; Koshkin and 
Greenberg, 2000; Koshkin and Greenberg, 2002; McKenzie et al., 2006; Pfeiffer et al., 
2003; Soustek et al., 2011; Xu et al., 2006a). Newly synthesized CL contains 
predominately saturated fatty acyl chains, and acyl remodeling of CL is required to 
produce “mature”, highly unsaturated CL species. Deficient CL remodeling causes Barth 
syndrome (BTHS), a rare X-linked genetic disorder associated with a broad range of 
clinical manifestations, including cardiomyopathy, skeletal myopathy, neutropenia, and 
3-methylglutaconic aciduria (Barth et al., 1983; Mazzocco et al., 2007b). Specifically, 
BTHS results from mutations in the tafazzin gene (TAZ) encoding the transacylase 
responsible for remodeling of CL. Mutations in TAZ lead to reduced total CL content and 
an accumulation of monolyso-CL (MLCL), an intermediate of the CL remodeling 
pathway.   
Most patients diagnosed with BTHS exhibit pronounced skeletal myopathy, low 
muscle mass, delayed gross motor development, exercise intolerance, muscle 
weakness, and focal myofibrillar degeneration (Barth et al., 1999b; Spencer et al., 
2006b). Consistent with decreased mitochondrial function, skeletal muscle O2 utilization 
and peak work rate are significantly lower in BTHS patients than control participants 
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(Spencer et al., 2011). While it is widely accepted that skeletal myopathy associated 
with BTHS stems from mitochondrial dysfunction, the mechanisms linking defective CL 
remodeling and skeletal myopathy have not been clearly elucidated and likely extend 
beyond compromised ATP generation. Myogenic differentiation is largely controlled by 
myogenic transcription factors and is accompanied by major changes in mitochondrial 
metabolism (Abdel Khalek et al., 2014; Hamai et al., 1997; Philp et al., 2011; Zhu et al., 
2013), mitochondrial energy production (Abdel Khalek et al., 2014; Murray and Huss, 
2011), and mitochondria-mediated activation of apoptotic pathways (Camara et al., 
2007; Ciavarra and Zacksenhaus, 2011; Griffiths et al., 2015). Given the central role of 
mitochondria in regulating myoblast differentiation, we hypothesized that mitochondrial 
defects associated with BTHS may contribute to skeletal myopathy by interfering with 
normal myocyte differentiation.   
To determine the effect of defective CL remolding on myogenic determination, 
we sought to develop a tafazzin-deficient mammalian skeletal myoblast model. The 
C2C12 cell line was derived from murine skeletal myoblast cells and represents a 
widely used model for the study of skeletal muscle development (Burattini et al., 2004), 
skeletal myopathy (Arya et al., 2013; Bathe et al., 2007; Mullen et al., 2010), and 
skeletal muscle differentiation (Ardite et al., 2004; Jasmer and Kwak, 2006; Wallace et 
al., 2016). The cells readily proliferate in high-serum conditions, and differentiate and 
fuse in low-serum conditions. Tafazzin-deficient C2C12 myocytes would provide a 
metabolic model for which isogenic cells are available as controls, in contrast to 
currently used BTHS patient-derived lymphoblast cells. Furthermore, they are 
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experimentally easier and cheaper to manipulate than tafazzin-deficient induced 
pluripotent stem cells (iPSCs) (Dudek et al., 2013b).  
In this study, we constructed a CRISPR-generated stable tafazzin knockout 
(TAZ-KO) C2C12 myocyte cell line. The TAZ-KO cell line exhibits an increased 
MLCL/CL ratio, decreased mitochondrial respiratory capacity, increased mitochondrial 
ROS production, and defective myocyte differentiation. These results indicate that loss 
of CL remodeling influences myogenic determination and form the foundation for future 
studies exploring potential mechanisms by which CL remodeling is required for 
regulating myocyte differentiation. Although BTHS is the only known genetic disorder 
directly linked to CL, aberrant myocyte differentiation may contribute to the development 
of skeletal myopathy associated with other mitochondrial diseases. 
METHODS AND MATERIALS 
Cell line and growth conditions—Wild type C2C12 cell lines were kindly provided by 
Dr. Steven Cala, Wayne State University. Growth medium consisted of DMEM (Gibco) 
containing 10% FBS (Hyclone), 2 mM glutamine (Gibco), penicillin, (100 units/ml) and 
streptomycin (100 μg/ml) (Invitrogen). Cells were grown at 37°C in a humidified 
incubator with 5% CO2. C2C12 myoblast differentiation was induced by shifting cells to 
DMEM medium containing 2% horse serum (Gibco).  
Construction of TAZ-KO C2C12 cell line using CRISPR—A gRNA targeting mouse 
TAZ exon 3 was identified using the clustered regulatory interspaced short palindromic 
repeats (CRISPR) design tool at crispr.mit.edu (G2: TCCTAAAACTCCGCCACATC). To 
express Cas9 and guide RNA in the mouse-derived C2C12 myoblast cells, 
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complementary oligonucleotides containing the gRNA sequence preceded by a G (for 
expression from the U6 promoter) were cloned into the BbsI site of plasmid pX330 
(Cong et al., 2013) (a gift from Feng Zhang; Massachusetts Institute of Technology, 
Cambridge, Massachusetts, USA) [Addgene plasmid # 42230]). The sequence was 
verified using oligonucleotide primer 330/335 (ACTATCATATGCTTACCGTAAC). The 
plasmid pPGKpurobpa (a gift from Allan Bradley; Wellcome Trust Sanger Institute, 
Cambridge, UK) was co-transfected to allow selection under puromycin. Cells were 
transfected with plasmid pX330-TAZ and pPGKpurobpa using Lipofectamine 2000 (Life 
Technologies, Inc.). Cells were selected in puromycin-containing DMEM with 10% FBS. 
Cells were then diluted and put into 96-well plates. Single colonies were picked for 
screening. To screen for insertions or deletions at the target sites, the following 
oligonucleotide primers flanking mouse Taz exon 3 were used: FOR: 
CCAACCACCAGTCTTGCATG. REV: ATCCCTGCCTCCAAGACTTC. Wild type 
genomic DNA generates a product of 547 bp. Cells that did not generate this product 
were selected for further analysis.  
Real Time Quantitative PCR (RT-qPCR) Analysis—As described in Chapter 2 
Mitochondria extraction—Cells were grown to 100% confluency in 150 mm dishes, 
and collected by scraping followed by centrifugation at 800 rpm for 5 min. The cell 
pellets were washed with cold PBS and suspended in mitochondrial isolation buffer (280 
mM sucrose, 0.25 mM EDTA, 20 mM Tris-HCl, pH 7.2). Cells were manually 
homogenized with a glass homogenizer. Cell debris was removed by centrifugation at 
800 rpm for 5 min. Mitochondria were subsequently collected by centrifugation at 
141 
 
 
 
11,500 rpm for 10 min.  Protein concentration was determined using the DC protein 
assay kit (BIO-RAD).  
Determination of CL by mass spectrometry—Transacylation products were 
quantified by MALDI-TOF mass spectrometry using the method of Sun et al. (Sun et al., 
2008). Lipid extracts were dissolved in chloroform/methanol (1:1) and mixed 1:1 with 
matrix solution containing 20 g/L 9-aminoacridine in 2-propanol/acetonitrile (3:2, v/v). An 
aliquot of 1 μL or less of this mixture was spotted on a target plate. Measurements were 
performed with a MALDI Micro MX mass spectrometer (Waters) operated in reflectron 
mode. The pulse voltage was set to 2000 V, the detector voltage was set to 2200 V, and 
the TLF delay was set to 700 ns. The nitrogen laser (337 nm) was fired at a rate of 5 Hz 
and 10 laser shots were acquired per sub-spectrum. The instrument was operated in 
negative ion mode with a flight tube voltage of 12 kV, a reflectron voltage of 5.2 kV, and 
a negative anode voltage of 3.5 kV, and calibrated daily. We typically acquired 100 sub-
spectra (representing 1000 laser shots) per sample in a mass range from 400 to 2000 
Da. Spectra were only acquired if their base-peak-intensity was within 10–95% of the 
saturation level. Data were analyzed with the MassLynx 4.1 software. 
Western Blot—Mitochondrial protein concentration was measured using the DC 
Protein Assay Kit (BIO-RAD). Cell extract corresponding to 30 μg protein was analyzed 
by SDS-PAGE on a 10% gel. Immunoblotting was performed using primary antibodies 
against tafazzin, NDUFB6, and corresponding secondary antibodies conjugated to 
horseradish peroxidase. Immunoreactivity was visualized using enhanced 
chemiluminescence (ECL) substrate (Thermo).  
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MTT assay—3000 cells were suspended in 100 μL of growth medium and seeded into 
96-well plates. Viable cells were measured in triplicate using MTT (Fisher) after 3, 24, 
and 48 h. In brief, 10 µL of 5 mg/mL MTT were added to each well. Inclusion of an 
additional set of wells treated with MTT but containing no cells served as a negative 
control. The plate was incubated for 4 h at 37°C in a culture hood. The medium was 
carefully removed and 150 µL DMSO were added to dissolve the MTT product. The 
plate was covered with foil and incubated for 10 min at 37°C. Samples from each well 
were mixed well with a pipette, and absorbance was read at 570 nm. 
Mitochondrial respiration measurements— Intact cell respiration was analyzed in a 
closed 500 μL chamber equipped with a micro Clark-type oxygen electrode (Oxygraph Plus 
System, Hansatech Instruments) at 35 °C as described (Lee et al., 2010). Cells were cultured in 
high glucose DMEM medium (100 units/mL penicillin-streptomycin, 10% fetal bovine serum), 
trypsinized, and washed with PBS. Cells were then suspended in measuring buffer (120 mM 
KCl, 3 mM Hepes, 3 mM MgSO4 5 mM KPi), to a final protein concentration of 2 mg/mL. 
Following measurements of basal cell respiration, 0.5 μM FCCP was added to analyze 
uncoupled respiration. Oxygen consumption was recorded on a computer and analyzed with the 
Oxygraph plus software. Oxygen consumption rate (OCR) is defined as nM consumed 
O2/min/mg protein). 
Measurement of mitochondrial membrane potential via TMRM florescence—Cells 
were plated at 40% confluency in 96-well plates in growth medium. After 24 h, the 
mitochondrial membrane potential was measured using the fluorescent dye 
Tetramethylrhodamine methyl ester (TMRM) as described previously (Brown, 1999). 
Briefly, cells were treated with 150 nM TMRM in growth medium for 30 min at 37°C. The 
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cells were then washed 3 times in PBS and TMRM fluorescence was measured on a 
microplate reader (Excitation: 544 nm and Emission: 590 nm). Each assay was 
performed in parallel with samples containing 10 μM carbonyl-cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP), which collapses the mitochondrial 
membrane potential. All data were expressed as the total TMRM fluorescence minus 
the FCCP treated TMRM fluorescence. 
Measurement of ROS production using MitoSOX—ROS production was measured 
with MitoSOX™ mitochondrial superoxide indicator (M36008) (Fisher Scientific) 
following the manufacture ’s guide. In brief, the 5 mM MitoSOX™ reagent stock solution 
was diluted in growth medium to make a 5 μM MitoSOX™ reagent working solution. 1.0 
mL of 5 μM MitoSOX™ reagent working solution was applied to cover cells adhering to 
coverslips. Cells were incubated for 10 min at 37˚C, protected from light, then washed 
gently three times with warm buffer, counterstained with DAPI, and imaged using a Z1 
AxioObserver inverted fluorescence microscope equipped with an AxioVision MRm 
camera (Zeiss). Images were taken using a 20X objective. MitoSOX fluorescence was 
quantified in all cells within five randomly selected fields of view from three biological 
replicates using florescence density analysis with ZenPro software (Zeiss).  
Immunofluorescence imaging of myotubes—Cells were seeded on gelatin and 
fibronectin coated glass coverslips at 40% confluency. Following overnight culture, the 
growth media containing 10% FBS were replaced with differentiation media containing 2% 
horse serum. At the indicated times, the cells were fixed with 4% paraformaldehyde. 
The coverslips were washed three times in buffer (PBS + 0.3% Triton) and then blocked 
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using 10% horse serum (Invitrogen). Coverslips were incubated with primary antibody, 
mouse anti-MHC (Novus Biologicals; MAB4470), diluted in PBS supplemented with 10% 
horse serum for 24 h. After washing with PBS, coverslips were incubated with an 
AlexaFluor 488®-conjugated donkey anti-mouse secondary antibody (1:1000, Jackson 
ImmunoResearch Laboratories) overnight. Fluorescence microscopy was performed 
using a Z1 AxioObserver inverted fluorescence microscope equipped with an AxioVision 
MRm camera (Zeiss) operated by ZenPro software (Zeiss). All images were taken using 
a 20X objective. 
RESULTS 
Construction of a tafazzin knockout C2C12 cell line using CRISPR technology. 
We generated a TAZ-KO C2C12 myocyte cell line in order to interrogate a 
potential link between CL remodeling and myocyte differentiation. C2C12 is a well 
characterized myoblast cell line that exhibits a high metabolic demand, similar to 
skeletal muscle cells (Burattini et al., 2004). These cells proliferate as undifferentiated 
myoblast cells when grown in media containg high concentrations of serum (10%), and 
terminally differentiate into multinucleated myotubes when cultured in low serum-
containing media. We used the CRISPR approach to generate tafazzin-deficient C2C12 
myoblast cells. The pX330-TAZ and pPGKpurobpa plasmids were transfected into 
C2C12 myoblasts, which were grown in selective medium. Following serial dilution, 
cultures derived from single cells were picked and PCR was used to identify the gene 
knockout. Tafazzin mRNA levels were measured using RT-qPCR. The TAZ-KO C2C12 
myoblast cells exhibited a 90% decrease in tafazzin mRNA levels (Figure 6-1A). 
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Figure 6-1. Construction of TAZ-KO C2C12 cells.  
Mouse C2C12 myoblast cells were transfected with CRISPR plasmid targeting the 
tafazzin gene. (A) Genomic TAZ is altered in TAZ-KO cells. Cells were selected in 
puromycin-containing DMEM with 10% FBS. The knockout strain was identified by 
PCR using the 547 bp region of the tafazzin gene targeted by the Cas9 gRNA 
followed by a T7 endonuclease digestion. (B) Tafazzin mRNA levels were 
decreased in TAZ-KO cells. WT and TAZ-KO cells were grown in DMEM with 10% 
FBS and harvested for mRNA extraction. Tafazzin mRNA levels were quantified by 
RT-qPCR and normalized to mRNA levels of the internal control GAPDH (three 
independent experiments with three replicates each). (C) Tafazzin protein was not 
detectable in TAZ-KO cells. Cells were grown in DMEM with 10% FBS, harvested, 
and lysed for protein extraction. 30 μg of total cell extract from each sample were 
subjected to Western blot analysis using 10% polyacrylamide gels. The 
mitochondrial protein NDUFB6 was used as a loading control.  
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Tafazzin protein was not detectable via Western blot analysis (Figure 6-1B).  
Increased MLCL/CL ratio in TAZ-KO cells. 
The most direct biochemical phenotype associated with tafazzin deficiency is an 
accumulation of MLCL and a concomitant reduction in CL species containing 
unsaturated fatty acyl chains. Using MALDI-TOF mass spectrometry we confirmed the 
TAZ-KO C2C12 myoblast cells exhibit reduced tafazzin function, as indicated by the 
characteristic CL profile of tafazzin deficiency. The MLCL/CL ratio was significantly 
Figure 6-2.CL profile of TAZ-KO cells.  
(A) MLCL/CL ratio of TAZ-KO cells was increased compared to WT controls. WT and 
TAZ-KO cells grown in DMEM to confluence were extracted for CL and MLCL content 
analysis by MALDI-TOF mass spectrometry. (B) CL saturation of TAZ-KO cells is 
increased, consistent with defective CL remodeling.   
147 
 
 
 
increased in TAZ-KO cells compared to controls, and the degree of CL unsaturation 
was significantly reduced (Figure 6-2). 
Characterization of tafazzin-deficient C2C12 cells.  
We measured the proliferative growth of TAZ-KO myoblast cells using the MTT 
assay to determine if loss of tafazzin directly affects myoblast proliferation.  Deletion of 
tafazzin did not significantly influence the doubling time of C2C12 cells (Figure 6-3A). In 
other BTHS models, including BTHS patient-derived lymphoblast cells and iPSCs, loss 
of tafazzin results in decreased mitochondrial respiration, increased mitochondrial ROS 
production and decreased mitochondrial membrane potential (Dudek et al., 2013b; Xu 
et al., 2005). We assayed these parameters in the TAZ-KO myoblast cells. 
Mitochondrial respiration was measured in intact cells using a Clark-type electrode. 
Basal mitochondrial respiration was not significantly affected by tafazzin deficiency in 
the myoblast cells; however, maximal respiratory capacity of the TAZ-KO myoblast cells 
was significantly decreased compared to controls (Figure 6-3B). This observation 
contrasts with other BTHS models in which both basal and maximal mitochondrial 
respiration is compromised by tafazzin deficency (Dudek et al., 2013b). Assessment of 
mitochondrial membrane potential using TMRM fluorescence indicated a significant 
reduction in membrane potential in TAZ-KO myoblasts compared to controls (Figure 6-
3C). To quantify mitochondrial ROS production in the myoblast cells, we employed 
MitoSOX fluorescence staining. Mitochondrial ROS production was significantly 
increased in TAZ-KO myoblast cells compared to controls (Figure 6-4).
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Figure 6-3. Mitochondrial function is decreased in TAZ-KO cells.  
(A) C2C12 myoblast proliferation was not affected by tafazzin deficiency. WT and 
TAZ-KO cell proliferation in DMEM media with 10% FBS was measured using the 
MTT assay. (B) Mitochondrial respiratory capacity is decreased in TAZ-KO cells. 
Oxygen consumption was measured in intact cells using a Clark-type electrode. 
While basal mitochondrial respiration was not affected by tafazzin deficiency, 
maximal respiratory capacity was significantly decreased in TAZ-KO compared to 
control cells (p=<0.05). (C) Mitochondrial membrane potential is significantly 
reduced in TAZ-KO cells. Membrane potential of growing WT and TAZ-KO cells was 
determined by fluorescence quantification of the Δψ dependent dye TMRM. 
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Figure 6-4. Mitochondrial ROS production is increased in TAZ-KO cells.  
(A) An increase of mitochondrial ROS was observed in TAZ-KO cells. ROS 
production was measured via MitoSOX fluorescence using a Z1 AxioObserver 
inverted fluorescence microscope equipped with an AxioVision MRm camera (Zeiss). 
(B) Quantitative assesment of MitoSOX fluorescence was performed in all cells 
within five randomly selected fields of view from three biological replicates using 
fluorescence density analysis with ZenPro software (Zeiss). 
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CL remodeling is required for myocyte differentiation. 
C2C12 myoblast cells are routinely used to study skeletal muscle differentiation. 
These cells grow as undifferentiated myoblasts in growth medium containing 10% fetal 
bovine serum and myogenic differentiation can be initiated in cells reaching confluence 
by shifting the cells to medium containing 2% horse serum (Travaglione et al., 2005). To 
investigate how myocyte differentiation is affected by the loss of tafazzin, we initiated 
myogenic differentiation using the widely-used protocol outlined above. As shown by 
fluorescence microscopy (Figure 6-5), control myoblast cells morphologically responded 
to the serum depletion and expressed the skeletal muscle contractile protein myosin 
Figure 6-5. Myogenic differentiation is reduced in TAZ-KO cells.  
Myogenic differentiation was initiated in cells reaching confluence by switching the 
cells to DMEM medium containing 2% horse serum. Cells were cultured for 1, 3, or 7 
days. Antibody detection of skeletal muscle contractile protein myosin heavy chain 
(MHC) was used for immunofluorescent staining of differentiated myotubes.   
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heavy chain (MHC). In striking contrast, TAZ-KO myoblast cells exhibited severely 
impaired phenotypic differentiation into myotubes. 
DISCUSSION 
Previous studies have utilized TAZ-KO or BTHS patient-derived iPSCs to 
generate cardiomyocytes for studying the pathophysiology underlying the 
cardiomyopathy in BTHS  (Acehan et al., 2009; Dudek et al., 2013a; Moffat et al., 2014). 
The TAZ-KO C2C12 cell line generated in the current study represents the first tafazzin-
deficient mammalian cell culture model system established in an immortalized skeletal 
myoblast cell line. Skeletal myopathy associated with BTHS is presumed to result 
primarily from impaired ATP production owing to alterations in mitochondrial oxidative 
phosphorylation. In the present study, we provide evidence for an additional link 
between dysfunctional CL remodeling and disturbed myocyte ontogenesis. Our findings 
suggest that myocyte differentiation may be affected in BTHS and may contribute to the 
skeletal myopathy observed in these patients. The current study has generated a new 
BTHS model for the study of skeletal myopathy. The TAZ-KO C2C12 cells provide an 
isogenic model system for exploring the muscle-specific effects of tafazzin-deficiency. 
C2C12 cells are widely used for biochemical and metabolic studies of skeletal myocytes, 
and are relatively easy and inexpensive to manipulate. TAZ-KO C2C12 myoblast cells 
display a mitochondrial phenotype similar to that of BTHS patient tissues and other 
mammalian models of BTHS. Loss of tafazzin was associated with a significant 
increase in the MLCL/CL ratio, and a reduction in the number of unsaturated fatty acyl 
chains incorporated into CL. Furthermore, TAZ-KO myoblast cells display decreased 
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membrane potential, decreased mitochondrial respiratory capacity, and increased 
mitochondrial ROS production.  
Although we found that loss of CL remodeling leads to defective skeletal myocyte 
differentiation, the mechanism by which myocyte differentiation is affected remains to be 
elucidated. CL content is an important determinant of mitochondrial membrane structure 
and cristae density (Schlame, 2013), and structural changes resulting from the loss of 
remodeled CL or from the accumulation of monolyso-CL may physically interfere with 
normal mitochondrial network fusion status. In BTHS patient-derived lymphoblast cells, 
mitochondrial hyperproliferation and increased mitochondrial network fragmentation are 
observed (Acehan et al., 2007; Xu et al., 2005). Currently, little is known regarding the 
role of mitochondrial network dynamics in controlling cellular differentiation. However, 
actively dividing blast cells have highly fragmented mitochondrial networks that 
progressively fuse during terminal differentiation, which is associated with increased 
respiratory capacity (Zhang, 2011). In general, highly fused mitochondrial networks are 
associated with maximal respiratory capacity (Chen et al., 2005a; Chen et al., 2003; Yu 
et al., 2006). Thus, it is tempting to speculate that loss of tafazzin may interfere with 
normal differentiation owing to a reduced ability to form highly fused mitochondrial 
networks. Consistent with this notion, increased mitochondrial network fragmentation 
and hyperproliferation have been linked to IKK/NF-κB signaling, which partially inhibits 
myocyte differentiation (34). 
What is the relationship between tafazzin deficiency, cellular energy metabolism, 
and myocyte differentiation? To meet the anabolic demands of proliferation, actively 
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dividing blast cells limit mitochondrial oxidative metabolism to increase cellular biomass 
via anabolic pathways.  Consequently, differentiation requires remodeling of 
mitochondrial oxidative metabolism to support oxidation of glycolysis-derived pyruvate 
to CO2.  Differentiation is associated with a spectrum of changes in mitochondrial 
metabolic machinery, including upregulation of enzymes of the tricarboxylic acid (TCA) 
cycle and subunits of the mitochondrial respiratory chain, and downregulation of 
glycolytic enzymes (Armstrong et al., 2010; Chung et al., 2007; Prigione et al., 2010; 
Tormos et al., 2011). This metabolic transition from glycolysis to mitochondrial oxidative 
metabolism is necessary for cellular differentiation. Studies of pluripotent stem cell 
differentiation confirm that inhibition of key glycolytic enzymes promotes differentiation, 
while impairment of mitochondrial function with respiratory inhibitors improves 
pluripotency and inhibits differentiation (Chung et al., 2007; Mandal et al., 2011). 
Accordingly, it is plausible that defective mitochondrial oxidative metabolism contributes 
to the observed differentiation defect in tafazzin deficient C2C12 myoblast cells.  
Given their roles as energy and redox sensors, AMP-activated kinase (AMPK), 
and the sirtuin family of NAD-dependent deacetylases have been implicated in 
regulating skeletal muscle differentiation in response to metabolic status (Ryall, 2013). 
Although very little is known about the role of these proteins in the development of 
skeletal myopathy, increased AMPK and sirtuin activity have been proposed to inhibit 
differentiation (Fulco et al., 2003; Williamson et al., 2009). It it possible that metabolic 
and/or redox signaling pathways that regulate myoblast differentation are affected in 
tafazzin-dificient cells. Future studies will determine what effect tafazzin-deficiency has 
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on cellular metabolism and redox in order to further elucidate the molecular 
mechanisms regulating myogenic determination in the TAZ-KO C2C12 cells. 
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CHAPTER 7 UNFINISHED PROJECTS AND FUTURE DIRECTIONS 
The studies described in this thesis elucidate functions of CLD1 and CL 
remodeling in the yeast S. cerevisiae and murine myoblasts. Our data demonstrated 
that an increased MLCL/CL ratio, but not decreased CL unsaturation, is likely the 
primary cause of growth defects observed in yeast taz1. This suggests that the 
physiological defects in BTHS patients is possibly caused by an increased MLCL/CL 
ratio, and possibly amenable to treatment by attenuation of CL phospholipases. 
Through nutritional and genetic manipulation of yeast CL species, we identified a novel 
role for Cld1 in mitigating the effects of CL peroxidation, suggesting that elucidating the 
role of CL remodeling may shed light on approaches for mitigating oxidative stress. The 
findings from this study will serve as the basis on which we will improve our 
understanding of CL remodeling and its mechanistic roles in mitigating oxidative stress. 
The tafazzin knockout C2C12 cells provides a mammalian model with a congenic 
control for future studies, and the link between CL deficiency to myotube differentiation 
is identified. 
Additionally, an important function of CL remodeling is to accumulate CL with 
unsaturated fatty acyl chains. It is still a mystery why cells need PUFA-containing CL. In 
this chapter, I summarize several interesting projects pertaining to CL remodeling that 
are left unfinished. These projects can be considered for future studies that could lead 
to a better understanding of CL remodeling and potential BTHS treatments. 
1. Identification of human CL phospholipase that is deleterious to tafazzin-
deficient cells 
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My previous study indicated that deletion of CLD1 rescues growth, life span, and 
respiratory defects of the taz1Δ mutant, suggesting that these defects in tafazzin-
deficient cells are caused by increased MLCL/CL (Ye et al., 2014). This led to the 
hypothesis that the deleterious effects of the loss of tafazzin can be alleviated by 
inhibiting the deacylation of CL. A large number of phospholipases complicate the ability 
to test this hypothesis in mammalian cells.  A 50% decrease in MLCL levels was 
observed in mouse cells carrying a deletion in iPLA2Υ, suggesting that phospholipase 
not yet identified deacylate CL (Kiebish et al., 2013a).  Several other phospholipases 
were shown to deacylate CL in vitro, including sPLA2-GIA and iPLA2-GVIA (Hsu et al., 
2013).  Treatment of BTHS lymphoblasts with the iPLA2 inhibitor, BEL, partially restored 
the MLCL/CL ratio (Malhotra et al., 2009).  Taken together, these published studies 
indicate that there are several human CL phospholipases and that inhibition of their 
activities may alleviate deficiencies in BTHS cells. 
I have developed a method utilizing a yeast functional bioassay to identify the 
human phospholipases that deacylate CL in vivo and determine if inhibiting their 
expression alleviates the respiratory defects in BTHS cells. iPLA2 was cloned into the 
yeast high copy expression vector pYPGK18. Expression of iPLA2 leads to decreased 
growth of taz1 cells at elevated temperature (Figure 7-1).  This is a straightforward and 
inexpensive bioassay that can be used as a functional screen for CL phospholipases.  
157 
 
 
 
To identify the human phospholipases that deacylate CL, the previously described PLA2 
phospholipases (Hsu et al., 2013) were cloned into the yeast expression vector 
pYPGK18. The yeast bioassay was utilized to identify those that exacerbate yeast taz1 
growth defects, which may be deleterious to BTHS cells. This can be tested by inhibiting 
their expression. To do so, BTHS lymphoblasts and TAZ-KO C2C12 cells can be 
transfected with lentivirus-derived small hairpin RNA (shRNA) against specific CL 
phospholipase genes. The effects of knocking down these phospholipases on 
parameters that are defective in BTHS lymphoblasts, including MLCL/CL ratio, CL acyl 
composition, respiration, and mitochondrial membrane potential can be assayed (Xu et 
taz1 
EV 
CLD1 
iPLA2 
iPLA2 
pYPGK18 
Figure 7-1. Expression of iPLA2 leads to decreased growth of taz1Δ at 
elevated temperature 
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al., 2005). The identification of new CL phospholipases will facilitate the understanding 
of CL remodeling pathways in mammalian cells, possibly leading to new strategies for 
BTHS treatment. 
2. Does loss of PGS1 function correlate with low HDL-C level? 
High-Density Lipoprotein-Cholesterol (HDL-C) alleviates plaque build up in 
arteries, while low HDL-C levels correlate with heart disease (Ahmed et al., 2016; 
Hashemi Nazari et al., 2015). A study from the laboratory of Dr. E Shyong Tai in the 
Department of Medicine at the National University of Singapore identified 250 people 
with the highest HDL levels and 250 with the lowest HDL from a population of 3000. The 
PGS1 gene was sequenced, and four rare PGS1 variants were found in patients with 
low HDL. These variants had amino acid substitutions A2E, I114V, A302V, and R343H. 
Due to the decreased levels of HDL in these patients, these variants were predicted to 
be harmful to humans. Based on the above finding, it was hypothesized that loss of 
PGS1 function correlates with low HDL-C level.  
To test the hypothesis, Pgs1 activity and CL levels were assayed in pgs1Δ yeast 
cells expressing human PGS1 variants. To determine if the yeast model is appropriate 
for testing this hypothesis, we first compared the mammalian and yeast PGS1 
sequence. 33% of the human PGS1 amino acid sequence is identical to yeast Pgs1. 
The conserved sequences include the 96 – 269 amino acid and 349 - 534 amino acid 
catalytic domains. Overexpression of human PGS1 rescues yeast pgs1Δ growth defects, 
showing that human PGS1 is functional in yeast (Figure 7-2A). Furthermore, results 
from thin layer chromatography (TLC) demonstrated that yeast pgs1Δ cells do not 
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WT+EV 
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pgs1Δ +yPGS1 
pgs1Δ +hPGS1 
A 
B 
Figure 7-2. Overexpression of human PGS1 rescues yeast pgs1Δ growth 
defects 
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Figure 7-3. Overexpression of human PGS1 variants rescues yeast pgs1Δ 
growth defects  
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synthesize CL; however, expression of human PGS1 leads to CL synthesis in yeast 
(Figure 7-2B). The difference between wild type human PGS1 and the four variants 
(A2E, I114V, A302V, and R343H) in complementing yeast pgs1Δ was determined. All 4 
variants were successfully expressed in yeast pgs1Δ (qRT-PCR) (Figure 7-3A). 
However, overexpression of all four variants rescued yeast pgs1Δ growth defects 
(Figure 7-3B). Although the overexpression of all four hPGS1 variants rescued pgs1Δ, 
the possibility of defective enzymatic activity of Pgs1 variants, expressed at 
endogenous levels, cannot be excluded. In addition, suppressors frequently arising in 
the pgs1Δ mutant can easily affect growth. As a result, growth phenotype is not an 
effective indicator for determining the functionality of human PGS1 variants. In order to 
continue with this project, the CL profile in strains expressing variant human PGS1 
should be measured. An alternative strategy is to complement a diploid heterozygous 
pgs1Δ mutant with a human PGS1 variant. Tetrad analysis can be performed with the 
diploid cells carrying the PGS1 variant in a low copy expression vector followed by 
observing colony growth. A decrease in colony growth (of haploid pgs1Δ expressing the 
PGS1 variant) can identify variants that leads to defective Pgs1 activity.  
Pgs1 ablation eliminates de novo synthesis of PG, the CL precursor, and 
decreased CL is correlated with decreased HDL level (Chang et al., 1998a; Hauff and 
Hatch, 2010). Therefore, identification of human PGS1 variants that have decreased 
Pgs1 activity may provide a molecular marker for decreased HDL level. People who 
carry the defective PGS1 variant can then be diagnosed using these molecular markers 
and receive corresponding treatment. 
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3. Does ferroptosis exist in yeast? 
Ferroptosis is a unique iron-dependent form of nonapoptotic cell death that is 
dependent on intracellular iron but is not affected by other metals. It is morphologically, 
biochemically, and genetically distinct from apoptosis, necrosis, and autophagy (Cao 
and Dixon, 2016; Dixon et al., 2012). Ferroptosis was initially identified in cancer cells. 
In these cells, classic features of apoptosis, including cytochrome c release, caspase 
activation, and chromatin fragmentation, were not observed. Ferroptosis is prevented by 
iron chelation or genetic inhibition of cellular iron uptake (Dixon et al., 2012). The 
manipulation of ferroptosis could be exploited to selectively destroy tumor cells. 
Additionally, inhibition of ferroptosis could be utilized to preserve neuronal cells exposed 
to specific oxidative conditions. The mechanism of ferroptosis regulation is not fully 
understood. Yeast can serve as a powerful model in studying ferroptosis because most 
essential cellular functions are conserved from yeast to humans. Additionally, lipid 
species and intracellular iron can be readily manipulated in yeast. However, it is not 
known if ferroptosis exists in yeast cells.  
Previous studies identified mammalian Gpx4 as a key regulator in ferroptotic cell 
death. Depletion of Gpx4 leads to peroxidation of arachidonic acid (AA) and ferroptosis 
in mammalian cells (2017; Conrad and Friedmann Angeli, 2015; Imai et al., 2017; 
Maiorino et al., 2017; Sakai et al., 2017; Yang et al., 2014). Yeast Gpx3 is the homolog 
of mammalian Gpx4. To determine if ferroptosis exists in yeast, spotting experiments 
were 
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performed to test if Gpx3 deficient yeast exhibit growth retardation when supplemented 
with AA. Briefly, cell cultures were grown to stationary phase. Serial dilutions of the 
culture were plated on YPD plates in the presence or absence of AA or FeSO4. Cells 
were incubated at 30 ℃ or 37 ℃ for 2 days. The results showed that deletion of GPX3 
increased the sensitivity of cells to AA. Sensitivity was more pronounced at the elevated 
temperature. Supplementation with 5 mM FeSO4 was lethal in the presence of AA 
(Figure 7-4).  These data suggest that deletion of GPX3 possibly leads to ferroptosis of 
yeast cells supplementated with AA.   
To confirm that GPX3 deletion in yeast leads to ferroptosis in the presence of AA, 
cells should be grown with an iron chelator that has been shown to inhibit ferroptosis. A 
finding that growth of gpx3 in medium containing AA is restored when an iron chelator 
is supplemented would support the hypothesis that ferroptosis exists in yeast, which can 
then serve as a potent model to study the mechanism and regulation of this death 
pathway.  
4. Does Drosophila ABHD5 have CL phospholipase activity? 
Alpha beta hydrolase domain-containing 5 (ABHD5), also known as comparative 
gene identification 58 (CGI-58), belongs to the AB hydrolase superfamily, which is 
composed of hydrolytic enzymes of widely differing phylogenetic origin and catalytic 
functions (Brown and Mark Brown, 2017; Ollis et al., 1992). Mutations in ABHD5 have 
been associated with Chanarin-Dorfman syndrome, a triglyceride storage disease with 
impaired long-chain fatty acid oxidation (Lefevre et al., 2001) and neutral lipid storage 
disease (Schweiger et al., 2009). Understanding functions and regulation of ABHD5 
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Figure 7-5. Overexpression of B-isoform of the ABHD5 ortholog exhibits a 
growth defect like overexpression of CLD1 and iPLA2γ in taz1  
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may provide clues for deciphering physiological defects caused by ABHD5 mutations. 
Dr. James G. Granneman (Center for Molecular Medicine and Genetics, Wayne State 
University School of Medicine) recently identified a Drosophila AB hydrolase (CG1882) 
that is likely an ortholog of human ABHD5. Interestingly, the yeast mitochondrial 
phospholipase Cld1 is more closely related to ABHD5 than any other protein in the 
database. ABHD5, however, is not considered a mitochondrial lipase (deacylase) 
because it lacks a nucleophilic serine and is not targeted to mitochondria. Unlike 
ABHD5 CG1882 has the nucleophilic serine and a splice variant that is specifically 
targeted to mitochondria. Given the evolution of this gene and the targeting of a specific 
splice variant to mitochondria, it might function as a CL lipase.   
              Our previous study showed that expression of yeast CLD1 or human iPLA2γ in 
yeast taz1 leads to decreased growth (unpublished). In collaboration with Dr. 
Granneman, we determined if expression of CG1882 in taz1 leads to decreased 
growth There are two isoforms of CG1882, A and B, which have the same sequence 
except that isoform B has a mitochondrial targeting sequence. CLD1, iPLA2γ, and 
CG1882 (isoforms A and B, with a RFP tag) were expressed on pYPGK18. Both 
CG1882 isoforms were expressed in taz1 cells and the B isoform localized to 
mitochondria. Cells were spotted on solid synthetic complete Leu- medium with either 
glucose or glycerol/ethanol as a carbon source and incubated at 30 ℃, 37 ℃, and 39℃. 
The results showed that overexpression of the B-isoform exhibits a growth defect similar 
to overexpression of CLD1 and iPLA2γ in taz1Figure 7-5This suggests that 
CG1882 and yeast Cld1 may have similar functions. 
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Future experiments using confocal microscopy could be performed to confirm 
mitochondrial targeting. In addition, CG1882 enzymatic activity could be determined by 
targeted mutation of the catalytic domain. Enzymatic activity can be verified by in vitro 
studies followed by assaying phospholipase activity in vivo. The CG1882B CL 
phospholipase activity could be confirmed in Drosophila cell lines followed by 
characterization of CG1882-null Drosophila. The outcome of this study may provide 
insight for deciphering physiological defects of Chanarin-Dorfman syndrome and neutral 
lipid storage disease to develop potential therapeutic treatment. 
5. Using genetically-modified yeast cells to screen for iPLA2γ inhibitors 
We have shown that a high level of expression of CL phospholipase (CLD1 or 
iPLA2γis lethal to TAZ1 deficient cells. To identify iPLA2γ inhibitors, a yeast bioassay 
strain was genetically manipulated to express the H. brasiliensis Δ12-desaturase gene. 
My colleague Wenxi Yu engineered the pBEVY-L plasmid, which contains a bi-
directional promoter, to constitutively express the human iPLA2γand the H. brasiliensis 
Δ12-desaturase genes in the cld1∆taz1∆ double mutant. The Δ12-desaturase expressing 
strain exhibited decreased growth on non-fermentable carbon sources in the presence 
of tert-butyl-hydroperoxide (TBHP), a mitochondrial oxidant (Figure 7-6). It was 
especially interesting to discover that dose-dependent sensitivity to TBHP was observed 
only on non-fermentable growth medium, suggesting that the lipid mediators generated 
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by iPLA2γ impact cell metabolism only during respiratory conditions.  
The laboratory of Dr. Valerian Kagan (University of Pittsburg) demonstrated that 
R-BEL, an inhibitor of iPLA2γ, suppressed hydrolysis of peroxidized CL and the 
production of peroxidized free fatty acids in a radiation-induced injury mouse model 
(Buland et al., 2016). To test the hypothesis that inhibitors of iPLA2γ protect against cell 
damage caused by CL peroxidation, we examined whether the sensitivity of the Δ12-
desaturase expressing strain to TBHP is affected by supplementation of R-BEL. In 
Figure 7-6. Humanized yeast bioassay strain displays sensitivity to 
mitochondrial oxidative stress.  
Serial dilutions of cld1∆taz1∆ double mutant yeast cells expressing the H. 
brasiliensis Δ12-fatty acid desaturase gene (desa), the human iPLA2γ gene (iPLA2γ), 
or both genes (desa + iPLA2γ) were spotted on synthetic complete media containing 
either 2% glucose or 2% glycerol and lactate. cld1∆taz1∆ double mutant yeast cells 
containing the empty pBEVY-L plasmid (EV) served as a control. Plates were treated 
with either 50 µM TBHP or vehicle control and immediately spotted. Following 5 days 
of incubation at 30C, plates were imaged for subsequent analysis.  
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accordance with our hypothesis, we found that the sensitivity of the Δ12-desaturase 
expressing strain to TBHP on non-fermentable medium was rescued by R-BEL 
supplementation (Figure 7-7). These experiments highlight the utility of this powerful 
yeast model. Future experiments will seek to screen other potential inhibitors of iPLA2γ 
using this strain. 
Pathways that negatively regulate iPLA2γ activity can be identified by 
transforming the bioassay strain with a mammalian cDNA library and screening for 
suppressors of the iPLA2γ-mediated lethality phenotype.  
It is possible to identify activators of iPLA2γ through assessing mutants that 
rescue cells from iPLA2γ-mediated growth inhibition by synthetic genetic array (SGA) 
analysis. Genes and associated pathways that are identified in the yeast screens can 
Figure 7-7. Humanized yeast bioassay strain displays sensitivity to 
mitochondrial oxidative stress.  
Serial dilutions of cld1∆taz1∆ double mutant yeast cells expressing the H. 
brasiliensis Δ12-fatty acid desaturase gene (desa), the human iPLA2γ gene (iPLA2γ), 
or both genes (desa + iPLA2γ) were spotted on synthetic complete media containing 
2% glycerol and lactate. cld1∆taz1∆ double mutant yeast cells containing the empty 
pBEVY-L plasmid (EV) served as a control. Plates were treated with either 50 µM 
TBHP, 50 µM TBHP + R-BEL, or vehicle control and immediately spotted. Following 
5 days of incubation at 30C, plates were imaged for subsequent analysis.  
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Figure 7-8. MLCL species in ∆
12
-desaturase-expressing cells.  
(A) Heat map of MLCL. (B) Quantitative assessment of total MLCL. 
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be further characterized. Subsequent studies testing the suppressive effects of human 
homologs on the iPLA2γ phenotype would help identify regulatory pathways of iPLA2γ 
present in human cells.   
The yeast bioassay can also be utilized to identify new inhibitors of iPLA2γ that 
protect against oxidative damage of CL. Furthermore, a possible outcome of this study 
is the identification of new pathways that regulate iPLA2γ, which will contribute broadly 
to our understanding of lipid mediators. These inhibitors and regulators could be 
examined in animal models to elucidate their role in radiation-induced injury. 
6. Is there a novel CL phospholipase in yeast? 
Cld1 is the only known CL phospholipase that deacylates CL to form MLCL in 
yeast. Although cld1 has decreased levels of MLCL, MLCL is still detectable (Figure 7-
8). Interestingly, the expression of 12-desaturase increased levels of MLCL (Figure 7-8) 
suggesting that there is an unidentified CL phospholipase that prefers to deacylate CL 
with polyunsaturated fatty acyl chains. Future studies to identify this novel CL 
phospholipase will understand functions and regulations of CL remodeling, possibly 
leading to treatment for BTHS. 
7. Novel roles of CL and CL remodeling 
Although roles of CL remodeling have been shown in removal of damaged CL 
acyl chains and in cell differentiation in this dissertation, the functions of CL，CLox and 
CL remodeling in cellular signaling pathways are still unclear. My lab colleagues, Cunqi 
Ye and Jiajia Ji, determined that Cld1 is required for activation of the PKC pathway by 
SGA analysis. Additional genetic interactions of CLD1 have yet to be uncovered and 
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further analysis of the SGA data can be used to identify functions of CL and CL 
remodeling.  
Although we are at the end of this dissertation, people in our lab will not stop 
studying functions and regulation of CL and CL remodeling. I will be excited if future 
researchers are interested in joining in the world of CL research because of my studies. 
It will be a great pleasure if my findings stimulate creative ideas in the minds of fellow 
researchers. 
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ABSTRACT 
NOVEL FUNCTIONS OF CARDIOLIPIN REMODELING IN SACCHAROMYCES 
CEREVISIAE AND MAMMALIAN CELLS IMPLACATIONS FOR BARTH SYNDROME 
by 
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December 2017 
Advisor: Dr. Miriam L. Greenberg 
Major: Biological Sciences 
Degree: Doctor of Philosophy 
Cardiolipin (CL) is a unique phospholipid that is primarily localized within the 
inner mitochondrial membrane. Newly synthesized CL undergoes acyl remodeling to 
produce CL species enriched with unsaturated acyl groups. The tafazzin gene (TAZ) 
encodes a transacylase that remodels CL. Deficiencies in CL remodeling cause Barth 
syndrome (BTHS), an X-linked genetic disorder resulting from TAZ mutations that lead 
to reduced total CL content and an accumulation of monolysocardiolipin (MLCL), an 
intermediate of the CL remodeling pathway. However, which of these biochemical 
outcomes contributes to the physiological defects is not fully understood.  
Deletion of yeast CL phospholipase rescues the taz1growth phenotype. We 
concluded that an increased MLCL/CL, but not decreased CL unsaturation, is likely the 
primary cause of decreased respiratory growth and chronological life span observed in 
taz1. This suggests that the physiological defects of BTHS patients is possibly due to 
increased MLCL/CL ratio instead of decreased unsaturated CL, and that attenuation of 
CL phospholipases may potentially treat BTHS. 
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Furthermore, our findings suggested a possibility that CLD1 expression is 
upregulated in response to oxidative stress. CL peroxidation, resulting from oxidative 
stress, has been described in mammalian cells. Based on this, one of the physiological 
roles of CL remodeling is to remove peroxidized CL. Liquid chromatography−mass-
spectrometry-based phospholipidomics was combined with genetic and nutritional 
manipulations to assay CL incorporation of PUFA during the CL biosynthetic and post-
synthetic remodeling processes in yeast. Our results demonstrated that yeast readily 
incorporate PUFA to synthesize oxidizable CL. Although multiple CL-hydroperoxides 
and CL-dihydroperoxides were readily detected in these cells, cell growth and life span 
were not impacted. cld1Δ cells expressing ∆12-desaturase were utilized to determine the 
effect of peroxidation on CL remodeling. Using this novel yeast model, in which cells 
expressed ∆12-desaturase, the specificity of Cld1 to peroxidized CL, and its role in 
deacylating peroxidized CL, was determined. In cells expressing desaturase, loss of 
CLD1 led to increased peroxidized CL species, as well as decreased cell growth and life 
span. The findings from this study may contribute to our understanding of CL 
remodeling and its mechanistic roles in mitigating oxidative stress. 
To probe defects resulting from CL deficiency in mammalian cells, I constructed 
a tafazzin knockout C2C12 cell line, which exhibits an increased MLCL/CL ratio, 
decreased respiration capacity, increased ROS generation and decreased membrane 
potential. Although WT and TAZ-KO C2C12 cells can differentiate into myotubes, 
differentiation was significantly decreased in TAZ-KO C2C12 cells under certain 
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conditions. Taken together, these findings indicate that CL remodeling plays a role in 
myotube differentiation. 
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